Compare,PMID,Parameter,Sentece,Title,Type,URL,Units,Value,id,Drugbank_id,Name
,2368893,steady-state peak plasma concentration,"The mean steady-state peak plasma concentration was 2.3 mg/l (range 1.2-3.1 mg/l); however, in three of the eight patients peak plasma concentrations were greater than 3 mg/l.",Steady-state pharmacokinetics of interpleural bupivacaine in patients after cholecystectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2368893/),[mg] / [l],2.3,4612,DB00297,Bupivacaine
greater,2368893,peak plasma concentrations,"The mean steady-state peak plasma concentration was 2.3 mg/l (range 1.2-3.1 mg/l); however, in three of the eight patients peak plasma concentrations were greater than 3 mg/l.",Steady-state pharmacokinetics of interpleural bupivacaine in patients after cholecystectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2368893/),[mg] / [l],3,4613,DB00297,Bupivacaine
,2368893,accumulation ratio,"The mean accumulation ratio was found to be 1.6 (range 0.99-2.49), with steady-state occurring within the first 24 hours of drug administration.",Steady-state pharmacokinetics of interpleural bupivacaine in patients after cholecystectomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2368893/),,1.6,4614,DB00297,Bupivacaine
,2368893,apparent systemic plasma clearance,"Mean apparent systemic plasma clearance was 0.16 +/- 0.07 l/kg/h with a mean terminal half-life of 5.8 +/- 2.3 hours measured at steady-state, values which were not significantly different (P greater than 0.05) from those values obtained following single interpleural bolus dose administration.",Steady-state pharmacokinetics of interpleural bupivacaine in patients after cholecystectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2368893/),[l] / [h·kg],0.16,4615,DB00297,Bupivacaine
,2368893,terminal half-life,"Mean apparent systemic plasma clearance was 0.16 +/- 0.07 l/kg/h with a mean terminal half-life of 5.8 +/- 2.3 hours measured at steady-state, values which were not significantly different (P greater than 0.05) from those values obtained following single interpleural bolus dose administration.",Steady-state pharmacokinetics of interpleural bupivacaine in patients after cholecystectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2368893/),h,5.8,4616,DB00297,Bupivacaine
,26612706,population,"In the basic model, the estimated population Ce50 values for adequate and deep sedation were 0.94 and 1.52 μg/ml, respectively.",Modelling of the Sedative Effects of Propofol in Patients undergoing Spinal Anaesthesia: A Pharmacodynamic Analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612706/),[μg] / [ml],0.94,5071,DB00297,Bupivacaine
,26612706,Ce50,"In the basic model, the estimated population Ce50 values for adequate and deep sedation were 0.94 and 1.52 μg/ml, respectively.",Modelling of the Sedative Effects of Propofol in Patients undergoing Spinal Anaesthesia: A Pharmacodynamic Analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612706/),[μg] / [ml],0.94,5072,DB00297,Bupivacaine
,26612706,Ce50,"In the basic model, the estimated population Ce50 values for adequate and deep sedation were 0.94 and 1.52 μg/ml, respectively.",Modelling of the Sedative Effects of Propofol in Patients undergoing Spinal Anaesthesia: A Pharmacodynamic Analysis. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612706/),[μg] / [ml],1.52,5073,DB00297,Bupivacaine
,26612706,Ce50,"The simulated Ce50 values for adequate sedation in 20-year-old patients with a T12 sensory level and in 80-year-old patients with a T4 level were 1.63 and 0.53 μg/ml, respectively.",Modelling of the Sedative Effects of Propofol in Patients undergoing Spinal Anaesthesia: A Pharmacodynamic Analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612706/),[μg] / [ml],1.63,5074,DB00297,Bupivacaine
,26612706,Ce50,"The simulated Ce50 values for adequate sedation in 20-year-old patients with a T12 sensory level and in 80-year-old patients with a T4 level were 1.63 and 0.53 μg/ml, respectively.",Modelling of the Sedative Effects of Propofol in Patients undergoing Spinal Anaesthesia: A Pharmacodynamic Analysis. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26612706/),[μg] / [ml],0.53,5075,DB00297,Bupivacaine
,10319782,duration of analgesia,"A significantly longer (P < 0.0001) duration of analgesia (median [range]) was observed in the R0.5 group (1,440 [335-1,440] min), whereas the R0.25 group (208 [175-340] min) and the B0.25 group (220 [100-390] min) were comparable.",The dose-response of caudal ropivacaine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319782/),min,"1,440",6338,DB00297,Bupivacaine
,10319782,duration of analgesia,"A significantly longer (P < 0.0001) duration of analgesia (median [range]) was observed in the R0.5 group (1,440 [335-1,440] min), whereas the R0.25 group (208 [175-340] min) and the B0.25 group (220 [100-390] min) were comparable.",The dose-response of caudal ropivacaine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319782/),min,208,6339,DB00297,Bupivacaine
,10319782,duration of analgesia,"A significantly longer (P < 0.0001) duration of analgesia (median [range]) was observed in the R0.5 group (1,440 [335-1,440] min), whereas the R0.25 group (208 [175-340] min) and the B0.25 group (220 [100-390] min) were comparable.",The dose-response of caudal ropivacaine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10319782/),min,220,6340,DB00297,Bupivacaine
,25776489,CMAX,"CMAX and TMAX were similar in both groups: 952 ± 346 ng/mL, 0.65 ± 0.5 1h in the needle group; 810 ± 307 ng/mL, 0.43 ± 0.29 h in the catheter group respectively.",Is the pharmacokinetics of bupivacaine equivalent after lumbar epidural administration through a needle or a catheter in male and female adults? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776489/),[ng] / [ml],952,6882,DB00297,Bupivacaine
,25776489,CMAX,"CMAX and TMAX were similar in both groups: 952 ± 346 ng/mL, 0.65 ± 0.5 1h in the needle group; 810 ± 307 ng/mL, 0.43 ± 0.29 h in the catheter group respectively.",Is the pharmacokinetics of bupivacaine equivalent after lumbar epidural administration through a needle or a catheter in male and female adults? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776489/),[ng] / [ml],810,6883,DB00297,Bupivacaine
,25776489,TMAX,"CMAX and TMAX were similar in both groups: 952 ± 346 ng/mL, 0.65 ± 0.5 1h in the needle group; 810 ± 307 ng/mL, 0.43 ± 0.29 h in the catheter group respectively.",Is the pharmacokinetics of bupivacaine equivalent after lumbar epidural administration through a needle or a catheter in male and female adults? ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776489/),h,0.43,6884,DB00297,Bupivacaine
,25776489,Plasma AUC₀→∞,Plasma AUC₀→∞ was also similar in both groups: 3868 ± 1687 ngh/mL for needle versus 4096 ± 1748 ngh/mL using catheter.,Is the pharmacokinetics of bupivacaine equivalent after lumbar epidural administration through a needle or a catheter in male and female adults? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776489/),[ngh] / [ml],3868,6885,DB00297,Bupivacaine
,25776489,Plasma AUC₀→∞,Plasma AUC₀→∞ was also similar in both groups: 3868 ± 1687 ngh/mL for needle versus 4096 ± 1748 ngh/mL using catheter.,Is the pharmacokinetics of bupivacaine equivalent after lumbar epidural administration through a needle or a catheter in male and female adults? ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776489/),[ngh] / [ml],4096,6886,DB00297,Bupivacaine
,25776489,t₁/₂,"The catheter group showed slower disposition than the needle group: t₁/₂=3.9 ± 2.3 h, MRT=6.0 ± 3.1 h versus 2.7 ± 1.03 h and 4.5 ± 1.2 h with needle administration respectively though it did not reach statistical significance, Cl/F and V/F were also similar.",Is the pharmacokinetics of bupivacaine equivalent after lumbar epidural administration through a needle or a catheter in male and female adults? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776489/),h,3.9,6887,DB00297,Bupivacaine
,25776489,MRT,"The catheter group showed slower disposition than the needle group: t₁/₂=3.9 ± 2.3 h, MRT=6.0 ± 3.1 h versus 2.7 ± 1.03 h and 4.5 ± 1.2 h with needle administration respectively though it did not reach statistical significance, Cl/F and V/F were also similar.",Is the pharmacokinetics of bupivacaine equivalent after lumbar epidural administration through a needle or a catheter in male and female adults? ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776489/),h,6.0,6888,DB00297,Bupivacaine
,25776489,MRT,"The catheter group showed slower disposition than the needle group: t₁/₂=3.9 ± 2.3 h, MRT=6.0 ± 3.1 h versus 2.7 ± 1.03 h and 4.5 ± 1.2 h with needle administration respectively though it did not reach statistical significance, Cl/F and V/F were also similar.",Is the pharmacokinetics of bupivacaine equivalent after lumbar epidural administration through a needle or a catheter in male and female adults? ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776489/),h,2.7,6889,DB00297,Bupivacaine
,25776489,MRT,"The catheter group showed slower disposition than the needle group: t₁/₂=3.9 ± 2.3 h, MRT=6.0 ± 3.1 h versus 2.7 ± 1.03 h and 4.5 ± 1.2 h with needle administration respectively though it did not reach statistical significance, Cl/F and V/F were also similar.",Is the pharmacokinetics of bupivacaine equivalent after lumbar epidural administration through a needle or a catheter in male and female adults? ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776489/),h,4.5,6890,DB00297,Bupivacaine
,25776489,t1/2,"Lastly, female patients showed significant longer t1/2 after administration through catheter (5.7 ± 2.0 h) than needle (2.7 ± 0.6 h) group (P=0.0279).",Is the pharmacokinetics of bupivacaine equivalent after lumbar epidural administration through a needle or a catheter in male and female adults? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776489/),h,5.7,6891,DB00297,Bupivacaine
,25776489,t1/2,"Lastly, female patients showed significant longer t1/2 after administration through catheter (5.7 ± 2.0 h) than needle (2.7 ± 0.6 h) group (P=0.0279).",Is the pharmacokinetics of bupivacaine equivalent after lumbar epidural administration through a needle or a catheter in male and female adults? ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25776489/),h,2.7,6892,DB00297,Bupivacaine
,9338908,terminal elimination half-life,"The terminal elimination half-life in serum was about 3.5-4.0 hours and 6 hours for ropivacaine and bupivacaine, respectively.",Comparative local anesthetic efficacy and pharmacokinetics of epidurally administered ropivacaine and bupivacaine in the sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9338908/),h,3.5-4.0,8044,DB00297,Bupivacaine
,9338908,terminal elimination half-life,"The terminal elimination half-life in serum was about 3.5-4.0 hours and 6 hours for ropivacaine and bupivacaine, respectively.",Comparative local anesthetic efficacy and pharmacokinetics of epidurally administered ropivacaine and bupivacaine in the sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9338908/),h,6,8045,DB00297,Bupivacaine
,32833710,Tmax,"Median (interquartile range [IQR]) Tmax was 24 (12) hours (confidence interval [CI], 19.5-28.5 hours) with a range of 15 minutes to 48 hours.",An Observational Study of the Pharmacokinetics of Surgeon-Performed Intercostal Nerve Blockade With Liposomal Bupivacaine for Posterior-Lateral Thoracotomy Analgesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32833710/),h,24,8939,DB00297,Bupivacaine
,32833710,peak plasma concentration (Cmax),"The median (IQR) peak plasma concentration (Cmax) was 0.6 (0.3) μg/mL (CI, 00.45-0.74 μg/mL) in a range of 0.3-1.2.",An Observational Study of the Pharmacokinetics of Surgeon-Performed Intercostal Nerve Blockade With Liposomal Bupivacaine for Posterior-Lateral Thoracotomy Analgesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32833710/),[μg] / [ml],0.6,8940,DB00297,Bupivacaine
,24853314,time to first morphine dose,"When required, median time to first morphine dose was longer in the USGRSB group (65.5 min vs. 47.5 min, P = 0.049).",Ultrasound-guided rectus sheath block or wound infiltration in children: a randomized blinded study of analgesia and bupivacaine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24853314/),min,65.5,10379,DB00297,Bupivacaine
,24853314,time to first morphine dose,"When required, median time to first morphine dose was longer in the USGRSB group (65.5 min vs. 47.5 min, P = 0.049).",Ultrasound-guided rectus sheath block or wound infiltration in children: a randomized blinded study of analgesia and bupivacaine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24853314/),min,47.5,10380,DB00297,Bupivacaine
,24853314,Peak plasma bupivacaine concentration,"Peak plasma bupivacaine concentration was higher following USGRSB than WI (median: 631.9 ng·ml(-1) IQR: 553.9-784.1 vs. 389.7 ng·ml(-1) IQR: 250.5-502.7, P = 0.002).",Ultrasound-guided rectus sheath block or wound infiltration in children: a randomized blinded study of analgesia and bupivacaine absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24853314/),[ng] / [ml],631.9,10381,DB00297,Bupivacaine
,24853314,Peak plasma bupivacaine concentration,"Peak plasma bupivacaine concentration was higher following USGRSB than WI (median: 631.9 ng·ml(-1) IQR: 553.9-784.1 vs. 389.7 ng·ml(-1) IQR: 250.5-502.7, P = 0.002).",Ultrasound-guided rectus sheath block or wound infiltration in children: a randomized blinded study of analgesia and bupivacaine absorption. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24853314/),[ng] / [ml],389.7,10382,DB00297,Bupivacaine
,24853314,Tmax,"Tmax was longer in the USGRSB group (median 45 min IQR: 30-60 vs. 20 min IQR: 20-45, P = 0.006).",Ultrasound-guided rectus sheath block or wound infiltration in children: a randomized blinded study of analgesia and bupivacaine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24853314/),min,45,10383,DB00297,Bupivacaine
,24853314,Tmax,"Tmax was longer in the USGRSB group (median 45 min IQR: 30-60 vs. 20 min IQR: 20-45, P = 0.006).",Ultrasound-guided rectus sheath block or wound infiltration in children: a randomized blinded study of analgesia and bupivacaine absorption. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24853314/),min,20,10384,DB00297,Bupivacaine
,2907021,tmax,"Our data showed significant 24 h variations in the following parameters: Highest tmax value = 0.366 +/- 0.073 h at 1000 h (P less than 0.005, amplitude, maximum-minimum/mean x 100, = 184%), highest Cmax/tmax ratio = 177.17 +/- 9.49 at 2200 h (P less than 0.005, amplitude = 192%), highest Vd = 0.842 +/- 0.23 L kg-1 at 2200 h (P less than 0.005, amplitude = 158%) and highest beta phase elimination half-life = 5.408 +/- 1.36 h at 2200 h (P less than 0.025, amplitude = 145%).",Circadian phase-dependent pharmacokinetics and acute toxicity of mepivacaine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907021/),h,0.366,10726,DB00297,Bupivacaine
,2907021,Cmax/tmax ratio,"Our data showed significant 24 h variations in the following parameters: Highest tmax value = 0.366 +/- 0.073 h at 1000 h (P less than 0.005, amplitude, maximum-minimum/mean x 100, = 184%), highest Cmax/tmax ratio = 177.17 +/- 9.49 at 2200 h (P less than 0.005, amplitude = 192%), highest Vd = 0.842 +/- 0.23 L kg-1 at 2200 h (P less than 0.005, amplitude = 158%) and highest beta phase elimination half-life = 5.408 +/- 1.36 h at 2200 h (P less than 0.025, amplitude = 145%).",Circadian phase-dependent pharmacokinetics and acute toxicity of mepivacaine. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907021/),,177.17,10727,DB00297,Bupivacaine
,2907021,Vd,"Our data showed significant 24 h variations in the following parameters: Highest tmax value = 0.366 +/- 0.073 h at 1000 h (P less than 0.005, amplitude, maximum-minimum/mean x 100, = 184%), highest Cmax/tmax ratio = 177.17 +/- 9.49 at 2200 h (P less than 0.005, amplitude = 192%), highest Vd = 0.842 +/- 0.23 L kg-1 at 2200 h (P less than 0.005, amplitude = 158%) and highest beta phase elimination half-life = 5.408 +/- 1.36 h at 2200 h (P less than 0.025, amplitude = 145%).",Circadian phase-dependent pharmacokinetics and acute toxicity of mepivacaine. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907021/),[l] / [kg],0.842,10728,DB00297,Bupivacaine
,2907021,beta phase elimination half-life,"Our data showed significant 24 h variations in the following parameters: Highest tmax value = 0.366 +/- 0.073 h at 1000 h (P less than 0.005, amplitude, maximum-minimum/mean x 100, = 184%), highest Cmax/tmax ratio = 177.17 +/- 9.49 at 2200 h (P less than 0.005, amplitude = 192%), highest Vd = 0.842 +/- 0.23 L kg-1 at 2200 h (P less than 0.005, amplitude = 158%) and highest beta phase elimination half-life = 5.408 +/- 1.36 h at 2200 h (P less than 0.025, amplitude = 145%).",Circadian phase-dependent pharmacokinetics and acute toxicity of mepivacaine. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2907021/),h,5.408,10729,DB00297,Bupivacaine
,11020763,elimination half-life,The elimination half-life of bupivacaine was 37.7 min.,"Disposition of bupivacaine and its metabolites in the maternal, placental, and fetal compartments in rats. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020763/),min,37.7,11258,DB00297,Bupivacaine
,11020763,concentration ratio,"The fetal to maternal concentration ratio of bupivacaine in plasma was 0.29, and in the placenta was 0.63.","Disposition of bupivacaine and its metabolites in the maternal, placental, and fetal compartments in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020763/),,0.29,11259,DB00297,Bupivacaine
,11020763,concentration ratio,"The fetal to maternal concentration ratio of bupivacaine in plasma was 0.29, and in the placenta was 0.63.","Disposition of bupivacaine and its metabolites in the maternal, placental, and fetal compartments in rats. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11020763/),,0,11260,DB00297,Bupivacaine
,31094793,peak concentrations,"The pharmacokinetic profile of levobupivacaine was comparable in the 2 groups: the mean total and free levobupivacaine peak concentrations were 379 ± 248 and 3.95 ± 3.16 ng·mL, respectively, occurring 22.5 ± 11 minutes after injection.",Transversus Abdominal Plane Block in Children: Efficacy and Safety: A Randomized Clinical Study and Pharmacokinetic Profile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094793/),ml·ng,379,14599,DB00297,Bupivacaine
,31094793,peak concentrations,"The pharmacokinetic profile of levobupivacaine was comparable in the 2 groups: the mean total and free levobupivacaine peak concentrations were 379 ± 248 and 3.95 ± 3.16 ng·mL, respectively, occurring 22.5 ± 11 minutes after injection.",Transversus Abdominal Plane Block in Children: Efficacy and Safety: A Randomized Clinical Study and Pharmacokinetic Profile. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31094793/),ml·ng,3.95,14600,DB00297,Bupivacaine
,30399533,protein binding,Changes in bupivacaine plasma protein binding is of clinical relevance considering its high protein binding (approximately 95%) and its classification as an intermediate hepatic extraction ratio drug (E = 0.38).,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),%,95,16533,DB00297,Bupivacaine
,30399533,flow rate,"The separation of bupivacaine enantiomers was obtained on a Chirex® 3020 chiral stationary phase column using as a mobile phase a mixture of 95% n-hexane:ethanol (80:20, v/v) at a flow rate of 0.8 mL/min.",Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),[ml] / [min],0.8,16534,DB00297,Bupivacaine
,30399533,unbound concentration,The lower limit of quantification was 0.25 ng of each enantiomer/mL of plasma as the total concentration and 0.125 ng of each enantiomer/mL of plasma as the unbound concentration.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),ng,0.125,16535,DB00297,Bupivacaine
,30399533,AUC0-∞,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),[h·ng] / [ml],25.42,16536,DB00297,Bupivacaine
,30399533,AUC0-∞,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),[h·ng] / [ml],30.57,16537,DB00297,Bupivacaine
,30399533,volume of distribution,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),l,841.96,16538,DB00297,Bupivacaine
,30399533,volume of distribution,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),l,655.05,16539,DB00297,Bupivacaine
,30399533,total clearance,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),[l] / [h],98.34,16540,DB00297,Bupivacaine
,30399533,total clearance,The parturient showed lower AUC0-∞ (25.42 vs. 30.57 ng.h/mL) and higher volume of distribution (841.96 vs 655.05 L) and total clearance (98.34 vs 81.79 L/h) for the R-bupivacaine enantiomer.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),[l] / [h],81.79,16541,DB00297,Bupivacaine
,30399533,AUC(R)/(S) ratio,The pharmacokinetics of bupivacaine were enantioselective displaying a lower plasma proportion of the enantiomer R-bupivacaine (AUC(R)/(S) ratio equal to 0.83).,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),,0.83,16542,DB00297,Bupivacaine
,30399533,placental transfer,The placental transfer was approximately 60% for both bupivacaine enantiomers.,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),%,60,16543,DB00297,Bupivacaine
,30399533,unbound fraction (Fu),The unbound fraction (Fu) for the R-bupivacaine enantiomer was higher (10.84%) than the eutomer S-bupivacaine (6.29%).,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),%,10.84,16544,DB00297,Bupivacaine
,30399533,unbound fraction (Fu),The unbound fraction (Fu) for the R-bupivacaine enantiomer was higher (10.84%) than the eutomer S-bupivacaine (6.29%).,Analysis of bupivacaine enantiomers in plasma as total and unbound concentrations using LC-MS/MS: Application in a pharmacokinetic study of a parturient with placental transfer. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30399533/),%,6.29,16545,DB00297,Bupivacaine
,9459249,Peak plasma concentrations,"Peak plasma concentrations of R(+)-bupivacaine (389 +/- 93 ng/mL) and R(-)-mepivacaine (1350 +/- 430 ng/mL) were smaller than those of S(-)-bupivacaine (449 +/- 109 ng/mL, P < 0.0001) and S(+)-mepivacaine (1740 +/- 490 ng/mL, P < 0.002), respectively.",Pharmacokinetics of the enantiomers of bupivacaine and mepivacaine after epidural administration of the racemates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459249/),[ng] / [ml],389,16732,DB00297,Bupivacaine
,9459249,Peak plasma concentrations,"Peak plasma concentrations of R(+)-bupivacaine (389 +/- 93 ng/mL) and R(-)-mepivacaine (1350 +/- 430 ng/mL) were smaller than those of S(-)-bupivacaine (449 +/- 109 ng/mL, P < 0.0001) and S(+)-mepivacaine (1740 +/- 490 ng/mL, P < 0.002), respectively.",Pharmacokinetics of the enantiomers of bupivacaine and mepivacaine after epidural administration of the racemates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459249/),[ng] / [ml],1350,16733,DB00297,Bupivacaine
,9459249,Peak plasma concentrations,"Peak plasma concentrations of R(+)-bupivacaine (389 +/- 93 ng/mL) and R(-)-mepivacaine (1350 +/- 430 ng/mL) were smaller than those of S(-)-bupivacaine (449 +/- 109 ng/mL, P < 0.0001) and S(+)-mepivacaine (1740 +/- 490 ng/mL, P < 0.002), respectively.",Pharmacokinetics of the enantiomers of bupivacaine and mepivacaine after epidural administration of the racemates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459249/),[ng] / [ml],449,16734,DB00297,Bupivacaine
,9459249,Peak plasma concentrations,"Peak plasma concentrations of R(+)-bupivacaine (389 +/- 93 ng/mL) and R(-)-mepivacaine (1350 +/- 430 ng/mL) were smaller than those of S(-)-bupivacaine (449 +/- 109 ng/mL, P < 0.0001) and S(+)-mepivacaine (1740 +/- 490 ng/mL, P < 0.002), respectively.",Pharmacokinetics of the enantiomers of bupivacaine and mepivacaine after epidural administration of the racemates. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459249/),[ng] / [ml],1740,16735,DB00297,Bupivacaine
,9459249,unbound peak concentrations,"However, the unbound peak concentrations of R(+)-bupivacaine (20 +/- 11 ng/mL) were larger than those of S(-)-bupivacaine (15 +/- 9 ng/mL, P < 0.005); unbound peak concentrations of R(-)-mepivacaine (485 +/- 158 ng/mL) and S(+)-mepivacaine (460 +/- 139 ng/mL) did not differ.",Pharmacokinetics of the enantiomers of bupivacaine and mepivacaine after epidural administration of the racemates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459249/),[ng] / [ml],20,16736,DB00297,Bupivacaine
,9459249,unbound peak concentrations,"However, the unbound peak concentrations of R(+)-bupivacaine (20 +/- 11 ng/mL) were larger than those of S(-)-bupivacaine (15 +/- 9 ng/mL, P < 0.005); unbound peak concentrations of R(-)-mepivacaine (485 +/- 158 ng/mL) and S(+)-mepivacaine (460 +/- 139 ng/mL) did not differ.",Pharmacokinetics of the enantiomers of bupivacaine and mepivacaine after epidural administration of the racemates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459249/),[ng] / [ml],15,16737,DB00297,Bupivacaine
,9459249,unbound peak concentrations,"However, the unbound peak concentrations of R(+)-bupivacaine (20 +/- 11 ng/mL) were larger than those of S(-)-bupivacaine (15 +/- 9 ng/mL, P < 0.005); unbound peak concentrations of R(-)-mepivacaine (485 +/- 158 ng/mL) and S(+)-mepivacaine (460 +/- 139 ng/mL) did not differ.",Pharmacokinetics of the enantiomers of bupivacaine and mepivacaine after epidural administration of the racemates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459249/),[ng] / [ml],485,16738,DB00297,Bupivacaine
,9459249,unbound peak concentrations,"However, the unbound peak concentrations of R(+)-bupivacaine (20 +/- 11 ng/mL) were larger than those of S(-)-bupivacaine (15 +/- 9 ng/mL, P < 0.005); unbound peak concentrations of R(-)-mepivacaine (485 +/- 158 ng/mL) and S(+)-mepivacaine (460 +/- 139 ng/mL) did not differ.",Pharmacokinetics of the enantiomers of bupivacaine and mepivacaine after epidural administration of the racemates. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9459249/),[ng] / [ml],460,16739,DB00297,Bupivacaine
,8187262,clearance,"Our data have demonstrated a decrease in clearance of bupivacaine (5.85 +/- 0.23 ml.hr-1 and 4.59 +/- 0.35 ml.hr-1 for groups A and B, respectively, P < 0.05, and, Tmax of PPX during hyperthermia (0.24 +/- 0.03 hr and 0.15 +/- 0.0 hr for Groups A and B, respectively, P < 0.05).",Bupivacaine kinetics during hyperthermia in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8187262/),[ml] / [h],5.85,17035,DB00297,Bupivacaine
,8187262,clearance,"Our data have demonstrated a decrease in clearance of bupivacaine (5.85 +/- 0.23 ml.hr-1 and 4.59 +/- 0.35 ml.hr-1 for groups A and B, respectively, P < 0.05, and, Tmax of PPX during hyperthermia (0.24 +/- 0.03 hr and 0.15 +/- 0.0 hr for Groups A and B, respectively, P < 0.05).",Bupivacaine kinetics during hyperthermia in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8187262/),[ml] / [h],4.59,17036,DB00297,Bupivacaine
,8187262,Tmax,"Our data have demonstrated a decrease in clearance of bupivacaine (5.85 +/- 0.23 ml.hr-1 and 4.59 +/- 0.35 ml.hr-1 for groups A and B, respectively, P < 0.05, and, Tmax of PPX during hyperthermia (0.24 +/- 0.03 hr and 0.15 +/- 0.0 hr for Groups A and B, respectively, P < 0.05).",Bupivacaine kinetics during hyperthermia in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8187262/),h,0.24,17037,DB00297,Bupivacaine
,8187262,Tmax,"Our data have demonstrated a decrease in clearance of bupivacaine (5.85 +/- 0.23 ml.hr-1 and 4.59 +/- 0.35 ml.hr-1 for groups A and B, respectively, P < 0.05, and, Tmax of PPX during hyperthermia (0.24 +/- 0.03 hr and 0.15 +/- 0.0 hr for Groups A and B, respectively, P < 0.05).",Bupivacaine kinetics during hyperthermia in rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8187262/),h,0.15,17038,DB00297,Bupivacaine
,12665159,peak plasma concentrations,The mean of the individual peak plasma concentrations of bupivacaine (C(max) was 0.74+/- 0.64 microg/ml.,"Steady state bupivacaine plasma concentrations and safety of a femoral ""3-in-1"" nerve block with bupivacaine in patients over 80 years of age. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12665159/),[μg] / [ml],0.74,17288,DB00297,Bupivacaine
,12665159,highest plasma concentration,The highest plasma concentration was 1.83 microg/ml.,"Steady state bupivacaine plasma concentrations and safety of a femoral ""3-in-1"" nerve block with bupivacaine in patients over 80 years of age. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12665159/),[μg] / [ml],1.83,17289,DB00297,Bupivacaine
,28844768,peak level (Cmax),"The mean peak level (Cmax) was 0.8 μg/mL (range, 0.4-1.2 μg/mL).",Systemic Safety of Liposomal Bupivacaine in Simultaneous Bilateral Total Knee Arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28844768/),[μg] / [ml],0.8,19826,DB00297,Bupivacaine
,2331063,time intervals,"The mean time intervals from the injection to two-dermatome regression and to first need for additional pain medication were 4 h (IP) and 5.5 h (IC) (P less than 0.02) and 5.3 h (IP) and 9.8 h (IC) (P = 0.002), respectively.",Single-dose interpleural versus intercostal blockade: nerve block characteristics and plasma concentration profiles after administration of 0.5% bupivacaine with epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331063/),h,4,19904,DB00297,Bupivacaine
,2331063,time intervals,"The mean time intervals from the injection to two-dermatome regression and to first need for additional pain medication were 4 h (IP) and 5.5 h (IC) (P less than 0.02) and 5.3 h (IP) and 9.8 h (IC) (P = 0.002), respectively.",Single-dose interpleural versus intercostal blockade: nerve block characteristics and plasma concentration profiles after administration of 0.5% bupivacaine with epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331063/),h,5.5,19905,DB00297,Bupivacaine
,2331063,time intervals,"The mean time intervals from the injection to two-dermatome regression and to first need for additional pain medication were 4 h (IP) and 5.5 h (IC) (P less than 0.02) and 5.3 h (IP) and 9.8 h (IC) (P = 0.002), respectively.",Single-dose interpleural versus intercostal blockade: nerve block characteristics and plasma concentration profiles after administration of 0.5% bupivacaine with epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331063/),h,5.3,19906,DB00297,Bupivacaine
,2331063,time intervals,"The mean time intervals from the injection to two-dermatome regression and to first need for additional pain medication were 4 h (IP) and 5.5 h (IC) (P less than 0.02) and 5.3 h (IP) and 9.8 h (IC) (P = 0.002), respectively.",Single-dose interpleural versus intercostal blockade: nerve block characteristics and plasma concentration profiles after administration of 0.5% bupivacaine with epinephrine. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331063/),h,9.8,19907,DB00297,Bupivacaine
,2331063,Peak arterial plasma concentrations,Peak arterial plasma concentrations after IP injection (2.07 +/- 0.53 micrograms/mL) were significantly higher (P less than 0.005) than those after IC administration (1.36 +/- 0.48 micrograms/mL).,Single-dose interpleural versus intercostal blockade: nerve block characteristics and plasma concentration profiles after administration of 0.5% bupivacaine with epinephrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331063/),[μg] / [ml],2.07,19908,DB00297,Bupivacaine
,2331063,Peak arterial plasma concentrations,Peak arterial plasma concentrations after IP injection (2.07 +/- 0.53 micrograms/mL) were significantly higher (P less than 0.005) than those after IC administration (1.36 +/- 0.48 micrograms/mL).,Single-dose interpleural versus intercostal blockade: nerve block characteristics and plasma concentration profiles after administration of 0.5% bupivacaine with epinephrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331063/),[μg] / [ml],1.36,19909,DB00297,Bupivacaine
,2331063,Peak venous plasma concentrations,Peak venous plasma concentrations showed a similar difference (IP: 1.86 +/- 0.45 micrograms/mL; IC: 1.21 +/- 0.48 micrograms/mL; P less than 0.005).,Single-dose interpleural versus intercostal blockade: nerve block characteristics and plasma concentration profiles after administration of 0.5% bupivacaine with epinephrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331063/),[μg] / [ml],1.86,19910,DB00297,Bupivacaine
,2331063,Peak venous plasma concentrations,Peak venous plasma concentrations showed a similar difference (IP: 1.86 +/- 0.45 micrograms/mL; IC: 1.21 +/- 0.48 micrograms/mL; P less than 0.005).,Single-dose interpleural versus intercostal blockade: nerve block characteristics and plasma concentration profiles after administration of 0.5% bupivacaine with epinephrine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2331063/),[μg] / [ml],1.21,19911,DB00297,Bupivacaine
,27417947,absorption half-life,Epinephrine prolonged the levobupivacaine absorption half-life {4.22 [95 % confidence interval (CI) 2.53-6.50] vs. 7.02 [95 % CI 3.74-14.1]; p < 0.05} and reduced its relative bioavailability (0.84; 95 % CI 0.72-0.97; p < 0.05) The derived model predicts that levobupivacaine dose schemes should be halved from 3 mg kg(-1) body weight with epinephrine to 1.5 mg kg(-1) without epinephrine to obtain a comparable risk of anaesthetic toxicity symptoms of approximately 0.1 %.,Levobupivacaine absorption pharmacokinetics with and without epinephrine during TAP block: analysis of doses based on the associated risk of local anaesthetic toxicity. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27417947/),,4.22,21818,DB00297,Bupivacaine
,27417947,absorption half-life,Epinephrine prolonged the levobupivacaine absorption half-life {4.22 [95 % confidence interval (CI) 2.53-6.50] vs. 7.02 [95 % CI 3.74-14.1]; p < 0.05} and reduced its relative bioavailability (0.84; 95 % CI 0.72-0.97; p < 0.05) The derived model predicts that levobupivacaine dose schemes should be halved from 3 mg kg(-1) body weight with epinephrine to 1.5 mg kg(-1) without epinephrine to obtain a comparable risk of anaesthetic toxicity symptoms of approximately 0.1 %.,Levobupivacaine absorption pharmacokinetics with and without epinephrine during TAP block: analysis of doses based on the associated risk of local anaesthetic toxicity. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27417947/),,7.02,21819,DB00297,Bupivacaine
,27417947,relative bioavailability,Epinephrine prolonged the levobupivacaine absorption half-life {4.22 [95 % confidence interval (CI) 2.53-6.50] vs. 7.02 [95 % CI 3.74-14.1]; p < 0.05} and reduced its relative bioavailability (0.84; 95 % CI 0.72-0.97; p < 0.05) The derived model predicts that levobupivacaine dose schemes should be halved from 3 mg kg(-1) body weight with epinephrine to 1.5 mg kg(-1) without epinephrine to obtain a comparable risk of anaesthetic toxicity symptoms of approximately 0.1 %.,Levobupivacaine absorption pharmacokinetics with and without epinephrine during TAP block: analysis of doses based on the associated risk of local anaesthetic toxicity. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27417947/),,0.,21820,DB00297,Bupivacaine
,3777457,peak plasma concentrations,"Addition of epinephrine to the local anesthetic solutions reduced the mean peak plasma concentrations of lidocaine and bupivacaine from 2.2 to 1.7 micrograms/ml (23%) and from 0.73 to 0.53 microgram/ml (28%), respectively, but did not alter the times at which the peak concentrations were reached.",Epidural anesthesia with lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777457/),[μg] / [ml],2.2 to 1.7,23243,DB00297,Bupivacaine
,3777457,peak plasma concentrations,"Addition of epinephrine to the local anesthetic solutions reduced the mean peak plasma concentrations of lidocaine and bupivacaine from 2.2 to 1.7 micrograms/ml (23%) and from 0.73 to 0.53 microgram/ml (28%), respectively, but did not alter the times at which the peak concentrations were reached.",Epidural anesthesia with lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3777457/),[μg] / [ml],0.73 to 0.53,23244,DB00297,Bupivacaine
,17619868,AUC(CSF)/AUC(serum) (0-120 min) concentration ratios,"The mean AUC(CSF)/AUC(serum) (0-120 min) concentration ratios were 0.18 and 0.09 after IV and IM, respectively.",Serum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17619868/),,0.18,24202,DB00297,Bupivacaine
,17619868,AUC(CSF)/AUC(serum) (0-120 min) concentration ratios,"The mean AUC(CSF)/AUC(serum) (0-120 min) concentration ratios were 0.18 and 0.09 after IV and IM, respectively.",Serum and cerebrospinal fluid morphine pharmacokinetics after single doses of intravenous and intramuscular morphine after hip replacement surgery. ,AUCR-Q21,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17619868/),,0.09,24203,DB00297,Bupivacaine
,7486098,C5-10h,"The C5-10h values were proportional to the dose of ropivacaine and were estimated as 0.3, 0.6, and 0.9 mg/L, and for bupivacaine as 0.7 mg/L.",Pharmacokinetics of ropivacaine and bupivacaine during 21 hours of continuous epidural infusion in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486098/),[mg] / [l],0.3,24610,DB00297,Bupivacaine
,7486098,C5-10h,"The C5-10h values were proportional to the dose of ropivacaine and were estimated as 0.3, 0.6, and 0.9 mg/L, and for bupivacaine as 0.7 mg/L.",Pharmacokinetics of ropivacaine and bupivacaine during 21 hours of continuous epidural infusion in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486098/),[mg] / [l],0.6,24611,DB00297,Bupivacaine
,7486098,C5-10h,"The C5-10h values were proportional to the dose of ropivacaine and were estimated as 0.3, 0.6, and 0.9 mg/L, and for bupivacaine as 0.7 mg/L.",Pharmacokinetics of ropivacaine and bupivacaine during 21 hours of continuous epidural infusion in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486098/),[mg] / [l],0.9,24612,DB00297,Bupivacaine
,7486098,C5-10h,"The C5-10h values were proportional to the dose of ropivacaine and were estimated as 0.3, 0.6, and 0.9 mg/L, and for bupivacaine as 0.7 mg/L.",Pharmacokinetics of ropivacaine and bupivacaine during 21 hours of continuous epidural infusion in healthy male volunteers. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486098/),[mg] / [l],0.7,24613,DB00297,Bupivacaine
,7486098,individual plasma concentration,"The highest individual plasma concentration was 1.7 mg/L (20 mg/h), and no patient showed signs of toxic systemic plasma levels.",Pharmacokinetics of ropivacaine and bupivacaine during 21 hours of continuous epidural infusion in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486098/),[mg] / [l],1.7,24614,DB00297,Bupivacaine
,7486098,free fraction,The free fraction was independent of the dose (6.1% for ropivacaine and 4.8% for bupivacaine).,Pharmacokinetics of ropivacaine and bupivacaine during 21 hours of continuous epidural infusion in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486098/),%,6.1,24615,DB00297,Bupivacaine
,7486098,free fraction,The free fraction was independent of the dose (6.1% for ropivacaine and 4.8% for bupivacaine).,Pharmacokinetics of ropivacaine and bupivacaine during 21 hours of continuous epidural infusion in healthy male volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486098/),%,4.8,24616,DB00297,Bupivacaine
,3800032,peak venous plasma concentrations,"All subjects experienced mild CNS toxicity, consisting of tinnitus, facial tingling, or subtle visual disturbances, associated with peak venous plasma concentrations of 0.81 to 2.7 micrograms/ml.",Propranolol reduces bupivacaine clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),[μg] / [ml],0.81 to 2.7,25303,DB00297,Bupivacaine
,3800032,clearance,"Mean bupivacaine clearance was 0.33 +/- 0.12 l/min for the control session and 0.21 +/- 0.12 l/min during propranolol use, a significant 35% reduction (P less than 0.01).",Propranolol reduces bupivacaine clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),[l] / [min],0.33,25304,DB00297,Bupivacaine
,3800032,clearance,"Mean bupivacaine clearance was 0.33 +/- 0.12 l/min for the control session and 0.21 +/- 0.12 l/min during propranolol use, a significant 35% reduction (P less than 0.01).",Propranolol reduces bupivacaine clearance. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),[l] / [min],0.21,25305,DB00297,Bupivacaine
,3800032,terminal elimination rate constant (beta),"The terminal elimination rate constant (beta) was 0.27 +/- 0.16 h-1 for the control session and 0.14 +/- 0.069 h-1 with propranolol (P less than 0.05); terminal elimination half-lives were 2.6 and 4.9 h, respectively.",Propranolol reduces bupivacaine clearance. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),1/[h],0.27,25306,DB00297,Bupivacaine
,3800032,terminal elimination rate constant (beta),"The terminal elimination rate constant (beta) was 0.27 +/- 0.16 h-1 for the control session and 0.14 +/- 0.069 h-1 with propranolol (P less than 0.05); terminal elimination half-lives were 2.6 and 4.9 h, respectively.",Propranolol reduces bupivacaine clearance. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),1/[h],0.14,25307,DB00297,Bupivacaine
,3800032,terminal elimination half-lives,"The terminal elimination rate constant (beta) was 0.27 +/- 0.16 h-1 for the control session and 0.14 +/- 0.069 h-1 with propranolol (P less than 0.05); terminal elimination half-lives were 2.6 and 4.9 h, respectively.",Propranolol reduces bupivacaine clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),h,2.6,25308,DB00297,Bupivacaine
,3800032,terminal elimination half-lives,"The terminal elimination rate constant (beta) was 0.27 +/- 0.16 h-1 for the control session and 0.14 +/- 0.069 h-1 with propranolol (P less than 0.05); terminal elimination half-lives were 2.6 and 4.9 h, respectively.",Propranolol reduces bupivacaine clearance. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3800032/),h,4.9,25309,DB00297,Bupivacaine
,2354094,time,"We found a similar time (about 0.4 h) to maximum serum concentration after extradural administration of bupivacaine 1.78 (SD 0.27) mg kg-1 to six pregnant patients at term, 1.58 (0.13) mg kg-1 to six women younger than 65 yr and 1.50 mg kg-1 to six women older than 65 yr.",Extradural administration of bupivacaine: pharmacokinetics and metabolism in pregnant and non-pregnant women. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354094/),h,0.4,27609,DB00297,Bupivacaine
,2354094,total urinary excretion,"The mean total urinary excretion of bupivacaine and its metabolites and their conjugates varied between 2.46 and 3.22% of the total dose administered in the three patient groups, indicating that both 4'-hydroxylation and N-dealkylation are minor metabolic pathways in man.",Extradural administration of bupivacaine: pharmacokinetics and metabolism in pregnant and non-pregnant women. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354094/),%,2.46,27610,DB00297,Bupivacaine
,2354094,total urinary excretion,"The mean total urinary excretion of bupivacaine and its metabolites and their conjugates varied between 2.46 and 3.22% of the total dose administered in the three patient groups, indicating that both 4'-hydroxylation and N-dealkylation are minor metabolic pathways in man.",Extradural administration of bupivacaine: pharmacokinetics and metabolism in pregnant and non-pregnant women. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2354094/),%,3,27611,DB00297,Bupivacaine
,3706800,peak whole blood arterial bupivacaine,"Doses of 2 mg/kg, 3 mg/kg, and 4 mg/kg resulted in peak whole blood arterial bupivacaine (base) concentrations (mean +/- SD) of 0.77 +/- 0.25 microgram/ml, 1.37 +/- 0.23 microgram/ml, and 1.87 +/- 0.53 microgram/ml, respectively.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),[μg] / [ml],0.77,29433,DB00297,Bupivacaine
,3706800,peak whole blood arterial bupivacaine,"Doses of 2 mg/kg, 3 mg/kg, and 4 mg/kg resulted in peak whole blood arterial bupivacaine (base) concentrations (mean +/- SD) of 0.77 +/- 0.25 microgram/ml, 1.37 +/- 0.23 microgram/ml, and 1.87 +/- 0.53 microgram/ml, respectively.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),[μg] / [ml],1.37,29434,DB00297,Bupivacaine
,3706800,peak whole blood arterial bupivacaine,"Doses of 2 mg/kg, 3 mg/kg, and 4 mg/kg resulted in peak whole blood arterial bupivacaine (base) concentrations (mean +/- SD) of 0.77 +/- 0.25 microgram/ml, 1.37 +/- 0.23 microgram/ml, and 1.87 +/- 0.53 microgram/ml, respectively.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),[μg] / [ml],1.87,29435,DB00297,Bupivacaine
,3706800,apparent volume of distribution (VD beta),"Calculated pharmacokinetic parameters (mean +/- SD) were the following: apparent volume of distribution (VD beta), 2.8 +/- 0.8 L/kg; steady-state volume of distribution (VDss), 2.7 +/- 0.7 L/kg; elimination half-life (t1/2 beta), 147 +/- 80 min; and total body clearance (Cl), 16.0 +/- 7.4 ml X min-1 X kg-1, or 382 +/- 201 ml X min-1 X m-2.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),[l] / [kg],2.8,29436,DB00297,Bupivacaine
,3706800,steady-state volume of distribution (VDss),"Calculated pharmacokinetic parameters (mean +/- SD) were the following: apparent volume of distribution (VD beta), 2.8 +/- 0.8 L/kg; steady-state volume of distribution (VDss), 2.7 +/- 0.7 L/kg; elimination half-life (t1/2 beta), 147 +/- 80 min; and total body clearance (Cl), 16.0 +/- 7.4 ml X min-1 X kg-1, or 382 +/- 201 ml X min-1 X m-2.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),[l] / [kg],2.7,29437,DB00297,Bupivacaine
,3706800,elimination half-life (t1/2 beta),"Calculated pharmacokinetic parameters (mean +/- SD) were the following: apparent volume of distribution (VD beta), 2.8 +/- 0.8 L/kg; steady-state volume of distribution (VDss), 2.7 +/- 0.7 L/kg; elimination half-life (t1/2 beta), 147 +/- 80 min; and total body clearance (Cl), 16.0 +/- 7.4 ml X min-1 X kg-1, or 382 +/- 201 ml X min-1 X m-2.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),min,147,29438,DB00297,Bupivacaine
,3706800,total body clearance (Cl),"Calculated pharmacokinetic parameters (mean +/- SD) were the following: apparent volume of distribution (VD beta), 2.8 +/- 0.8 L/kg; steady-state volume of distribution (VDss), 2.7 +/- 0.7 L/kg; elimination half-life (t1/2 beta), 147 +/- 80 min; and total body clearance (Cl), 16.0 +/- 7.4 ml X min-1 X kg-1, or 382 +/- 201 ml X min-1 X m-2.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),[ml] / [kg·min],16.0,29439,DB00297,Bupivacaine
,3706800,total body clearance (Cl),"Calculated pharmacokinetic parameters (mean +/- SD) were the following: apparent volume of distribution (VD beta), 2.8 +/- 0.8 L/kg; steady-state volume of distribution (VDss), 2.7 +/- 0.7 L/kg; elimination half-life (t1/2 beta), 147 +/- 80 min; and total body clearance (Cl), 16.0 +/- 7.4 ml X min-1 X kg-1, or 382 +/- 201 ml X min-1 X m-2.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),[ml] / [(m)^2·min],382,29440,DB00297,Bupivacaine
,3706800,lambda,"Hematocrit in this group ranged from 30 to 59, and lambda varied from 0.47 to 0.82.",Bupivacaine for intercostal nerve blocks in children: blood concentrations and pharmacokinetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3706800/),,0.47 to 0.82,29441,DB00297,Bupivacaine
,18067620,maximum concentration (C(max),"For SI, mean maximum concentration (C(max), 1.33+/-0.954 microg/mL) occurred at 11.37+/-4.546 minutes.",Estimated plasma bupivacaine concentration after single dose and eight-hour continuous intra-articular infusion of bupivacaine in normal dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18067620/),[μg] / [ml],1.33,30437,DB00297,Bupivacaine
,18067620,C(max),"For CI, mean C(max) (1.13+/-0.509 microg/mL) occurred at 10.37+/-4.109 minutes.",Estimated plasma bupivacaine concentration after single dose and eight-hour continuous intra-articular infusion of bupivacaine in normal dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18067620/),[μg] / [ml],1.13,30438,DB00297,Bupivacaine
,18067620,area under the concentration-time curve,"The area under the concentration-time curve was smaller for SI (143.59+/-118.390 microg/mL x min) than for CI (626.502+/-423.653 microg/mL x min, P=.02) and half-life was shorter for SI (61.33+/-77.706 minutes) than for CI (245.363+/-104.415 minutes, P=.01).",Estimated plasma bupivacaine concentration after single dose and eight-hour continuous intra-articular infusion of bupivacaine in normal dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18067620/),[μg] / [min·ml],143.59,30439,DB00297,Bupivacaine
,18067620,area under the concentration-time curve,"The area under the concentration-time curve was smaller for SI (143.59+/-118.390 microg/mL x min) than for CI (626.502+/-423.653 microg/mL x min, P=.02) and half-life was shorter for SI (61.33+/-77.706 minutes) than for CI (245.363+/-104.415 minutes, P=.01).",Estimated plasma bupivacaine concentration after single dose and eight-hour continuous intra-articular infusion of bupivacaine in normal dogs. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18067620/),[μg] / [min·ml],626.502,30440,DB00297,Bupivacaine
,18067620,half-life,"The area under the concentration-time curve was smaller for SI (143.59+/-118.390 microg/mL x min) than for CI (626.502+/-423.653 microg/mL x min, P=.02) and half-life was shorter for SI (61.33+/-77.706 minutes) than for CI (245.363+/-104.415 minutes, P=.01).",Estimated plasma bupivacaine concentration after single dose and eight-hour continuous intra-articular infusion of bupivacaine in normal dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18067620/),min,61.33,30441,DB00297,Bupivacaine
,18067620,half-life,"The area under the concentration-time curve was smaller for SI (143.59+/-118.390 microg/mL x min) than for CI (626.502+/-423.653 microg/mL x min, P=.02) and half-life was shorter for SI (61.33+/-77.706 minutes) than for CI (245.363+/-104.415 minutes, P=.01).",Estimated plasma bupivacaine concentration after single dose and eight-hour continuous intra-articular infusion of bupivacaine in normal dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18067620/),min,245.363,30442,DB00297,Bupivacaine
,8744668,Arterial plasma concentrations,"Arterial plasma concentrations of bupivacaine 5 minutes after the start of bupivacaine infusion were significantly higher in the L-NAME than in the saline group (22.3 +/- 2.9 vs 12.8 +/- 1.5 micrograms/mL, P < .05).",Nitric oxide synthesis inhibition enhances bupivacaine cardiotoxicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8744668/),[μg] / [ml],22.3,30592,DB00297,Bupivacaine
,8744668,Arterial plasma concentrations,"Arterial plasma concentrations of bupivacaine 5 minutes after the start of bupivacaine infusion were significantly higher in the L-NAME than in the saline group (22.3 +/- 2.9 vs 12.8 +/- 1.5 micrograms/mL, P < .05).",Nitric oxide synthesis inhibition enhances bupivacaine cardiotoxicity. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8744668/),[μg] / [ml],12.8,30593,DB00297,Bupivacaine
,3188822,elimination half-life,"Increases in elimination half-life only achieved statistical significance in mepivacaine-treated animals (non-convulsing 45.2 min, convulsing 105.4 min, P less than 0.01).",Alterations in the pharmacokinetic properties of amide local anaesthetics following local anaesthetic induced convulsions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3188822/),min,45.2,30834,DB00297,Bupivacaine
,3188822,elimination half-life,"Increases in elimination half-life only achieved statistical significance in mepivacaine-treated animals (non-convulsing 45.2 min, convulsing 105.4 min, P less than 0.01).",Alterations in the pharmacokinetic properties of amide local anaesthetics following local anaesthetic induced convulsions. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3188822/),min,105.4,30835,DB00297,Bupivacaine
,30447167,serum concentration,The observed median total levobupivacaine serum concentration was 0.30 mg/L (range: 0.20-0.70 mg/L) at 1 hour after the loading dose of 2 mg/kg.,A study of the dosage and duration for levobupivacaine infusion by the caudal-epidural route in infants aged 3-6 months. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30447167/),[mg] / [l],0.30,31316,DB00297,Bupivacaine
,30447167,total levobupivacaine concentration,"The median total levobupivacaine concentration after 47 hours of infusion, at 0.2 mg/kg/h, was 1.21 mg/L (0.07-1.85 mg/L).",A study of the dosage and duration for levobupivacaine infusion by the caudal-epidural route in infants aged 3-6 months. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30447167/),[mg] / [l],1.21,31317,DB00297,Bupivacaine
,2961361,peak plasma venous concentration,"Mean peak plasma venous concentration achieved following 0.5% plain bupivacaine was 2.23 +/- 0.24 micrograms ml-1 (mean +/- SEM), while the mean peak concentration following 0.5% bupivacaine with adrenaline was 0.98 +/- 0.10 micrograms ml-1 (mean +/- SEM).",Venous plasma (total) bupivacaine concentrations following lower abdominal field block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2961361/),[μg] / [ml],2.23,31938,DB00297,Bupivacaine
,2961361,peak concentration,"Mean peak plasma venous concentration achieved following 0.5% plain bupivacaine was 2.23 +/- 0.24 micrograms ml-1 (mean +/- SEM), while the mean peak concentration following 0.5% bupivacaine with adrenaline was 0.98 +/- 0.10 micrograms ml-1 (mean +/- SEM).",Venous plasma (total) bupivacaine concentrations following lower abdominal field block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2961361/),[μg] / [ml],0.98,31939,DB00297,Bupivacaine
,8734231,plasma peak concentration,The median plasma peak concentration was 0.94 +/- 0.47 microgram.,[Analgesia after laparoscopic cholecystectomy by intraperitoneal administration of bupivacaine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8734231/),μg,0.94,32102,DB00297,Bupivacaine
>,8734231,toxic concentrations,In one patient toxic concentrations (> 1.6 micrograms.,[Analgesia after laparoscopic cholecystectomy by intraperitoneal administration of bupivacaine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8734231/),μg,1.6,32103,DB00297,Bupivacaine
,14715049,Protein binding,"Protein binding ranges from 65% (lidocaine) to more than 95% (bupivacaine, ropivacaine).",Pharmacokinetics of local anaesthetics in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14715049/),%,65,32796,DB00297,Bupivacaine
more,14715049,Protein binding,"Protein binding ranges from 65% (lidocaine) to more than 95% (bupivacaine, ropivacaine).",Pharmacokinetics of local anaesthetics in infants and children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14715049/),%,95,32797,DB00297,Bupivacaine
,14715049,time to C(max),The time to C(max) decreases from 90-120 minutes in infants aged less than 6 months to 30 minutes in children aged more than 8 years.,Pharmacokinetics of local anaesthetics in infants and children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14715049/),min,90-120,32798,DB00297,Bupivacaine
,14715049,time to C(max),The time to C(max) decreases from 90-120 minutes in infants aged less than 6 months to 30 minutes in children aged more than 8 years.,Pharmacokinetics of local anaesthetics in infants and children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14715049/),min,30,32799,DB00297,Bupivacaine
,2012289,peak plasma level,Morphine was absorbed rapidly after caudal injection to reach a peak plasma level of 21.2 (+/- 4.8) ng.,Combined morphine-bupivacaine caudals for reconstructive penile surgery in children: systemic absorption of morphine and postoperative analgesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2012289/),ng,21.2,33111,DB00297,Bupivacaine
,3414999,volume of distribution (Vd beta),"Pharmacokinetic parameters determined were (mean +/- SD): volume of distribution (Vd beta) 206 +/- 88 L, clearance (Cl) 0.816 +/- 0.378 L/min, terminal half-life (T1/2) beta 189 +/- 84 minutes, absorption rate constant (ka) 9.92 +/- 6.79/min, estimated peak plasma concentrations (Cpmax) 0.48 +/- 0.20 micrograms/mL, and time to peak concentration (tmax) 43.4 +/- 23.1 minutes.",The pharmacokinetics of bupivacaine when injected intra-articularly after knee arthroscopy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3414999/),l,206,33926,DB00297,Bupivacaine
,3414999,clearance (Cl),"Pharmacokinetic parameters determined were (mean +/- SD): volume of distribution (Vd beta) 206 +/- 88 L, clearance (Cl) 0.816 +/- 0.378 L/min, terminal half-life (T1/2) beta 189 +/- 84 minutes, absorption rate constant (ka) 9.92 +/- 6.79/min, estimated peak plasma concentrations (Cpmax) 0.48 +/- 0.20 micrograms/mL, and time to peak concentration (tmax) 43.4 +/- 23.1 minutes.",The pharmacokinetics of bupivacaine when injected intra-articularly after knee arthroscopy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3414999/),[l] / [min],0.816,33927,DB00297,Bupivacaine
,3414999,terminal half-life (T1/2) beta,"Pharmacokinetic parameters determined were (mean +/- SD): volume of distribution (Vd beta) 206 +/- 88 L, clearance (Cl) 0.816 +/- 0.378 L/min, terminal half-life (T1/2) beta 189 +/- 84 minutes, absorption rate constant (ka) 9.92 +/- 6.79/min, estimated peak plasma concentrations (Cpmax) 0.48 +/- 0.20 micrograms/mL, and time to peak concentration (tmax) 43.4 +/- 23.1 minutes.",The pharmacokinetics of bupivacaine when injected intra-articularly after knee arthroscopy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3414999/),min,189,33928,DB00297,Bupivacaine
,3414999,absorption rate constant (ka),"Pharmacokinetic parameters determined were (mean +/- SD): volume of distribution (Vd beta) 206 +/- 88 L, clearance (Cl) 0.816 +/- 0.378 L/min, terminal half-life (T1/2) beta 189 +/- 84 minutes, absorption rate constant (ka) 9.92 +/- 6.79/min, estimated peak plasma concentrations (Cpmax) 0.48 +/- 0.20 micrograms/mL, and time to peak concentration (tmax) 43.4 +/- 23.1 minutes.",The pharmacokinetics of bupivacaine when injected intra-articularly after knee arthroscopy. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3414999/),1/[min],9.92,33929,DB00297,Bupivacaine
,3414999,peak plasma concentrations (Cpmax),"Pharmacokinetic parameters determined were (mean +/- SD): volume of distribution (Vd beta) 206 +/- 88 L, clearance (Cl) 0.816 +/- 0.378 L/min, terminal half-life (T1/2) beta 189 +/- 84 minutes, absorption rate constant (ka) 9.92 +/- 6.79/min, estimated peak plasma concentrations (Cpmax) 0.48 +/- 0.20 micrograms/mL, and time to peak concentration (tmax) 43.4 +/- 23.1 minutes.",The pharmacokinetics of bupivacaine when injected intra-articularly after knee arthroscopy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3414999/),[μg] / [ml],0.48,33930,DB00297,Bupivacaine
,3414999,time to peak concentration (tmax),"Pharmacokinetic parameters determined were (mean +/- SD): volume of distribution (Vd beta) 206 +/- 88 L, clearance (Cl) 0.816 +/- 0.378 L/min, terminal half-life (T1/2) beta 189 +/- 84 minutes, absorption rate constant (ka) 9.92 +/- 6.79/min, estimated peak plasma concentrations (Cpmax) 0.48 +/- 0.20 micrograms/mL, and time to peak concentration (tmax) 43.4 +/- 23.1 minutes.",The pharmacokinetics of bupivacaine when injected intra-articularly after knee arthroscopy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3414999/),min,43.4,33931,DB00297,Bupivacaine
,14722171,Time to peak plasma concentration (T(max)),Time to peak plasma concentration (T(max)) ranged between 5 and 60 min (median 30 min) and was reached later in children aged less than 3 months (P<0.005).,Pharmacokinetics of levobupivacaine 0.25% following caudal administration in children under 2 years of age. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722171/),min,30,34250,DB00297,Bupivacaine
,14722171,Peak plasma concentration (C(max)),"Peak plasma concentration (C(max)) ranged between 0.41 and 2.12 micro g ml(-1) (median 0.80, mean (SD) 0.91 (0.40) micro g ml(-1)).",Pharmacokinetics of levobupivacaine 0.25% following caudal administration in children under 2 years of age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722171/),[μg] / [ml],0.80,34251,DB00297,Bupivacaine
,14722171,Peak plasma concentration (C(max)),"Peak plasma concentration (C(max)) ranged between 0.41 and 2.12 micro g ml(-1) (median 0.80, mean (SD) 0.91 (0.40) micro g ml(-1)).",Pharmacokinetics of levobupivacaine 0.25% following caudal administration in children under 2 years of age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14722171/),[μg] / [ml],0.91,34252,DB00297,Bupivacaine
,2729635,Peak blood concentrations,"Peak blood concentrations were attained within 10 min in 18 of 22 subjects, and were 087 micrograms.",Pharmacokinetics of bupivacaine following intraoperative intercostal nerve block in neonates and in infants aged less than 6 months. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729635/),μg,087,36409,DB00297,Bupivacaine
,2729635,elimination half-life (t1/2 beta),Pharmacokinetic variables in the two groups included elimination half-life (t1/2 beta): 132 +/- 59 min and 102 +/- 39 min; steady-state volume of distribution (Vdss): 2.56 +/- 0.76 l.kg-1 and 2.17 +/- 0.17 l.kg-1; and total body clearance (Clt): 16.93 +/- 9.32 ml.min-1.kg-1 and 15.71 +/- 6.99 ml.min-1.kg-1.,Pharmacokinetics of bupivacaine following intraoperative intercostal nerve block in neonates and in infants aged less than 6 months. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729635/),min,132,36410,DB00297,Bupivacaine
,2729635,elimination half-life (t1/2 beta),Pharmacokinetic variables in the two groups included elimination half-life (t1/2 beta): 132 +/- 59 min and 102 +/- 39 min; steady-state volume of distribution (Vdss): 2.56 +/- 0.76 l.kg-1 and 2.17 +/- 0.17 l.kg-1; and total body clearance (Clt): 16.93 +/- 9.32 ml.min-1.kg-1 and 15.71 +/- 6.99 ml.min-1.kg-1.,Pharmacokinetics of bupivacaine following intraoperative intercostal nerve block in neonates and in infants aged less than 6 months. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729635/),min,102,36411,DB00297,Bupivacaine
,2729635,steady-state volume of distribution (Vdss),Pharmacokinetic variables in the two groups included elimination half-life (t1/2 beta): 132 +/- 59 min and 102 +/- 39 min; steady-state volume of distribution (Vdss): 2.56 +/- 0.76 l.kg-1 and 2.17 +/- 0.17 l.kg-1; and total body clearance (Clt): 16.93 +/- 9.32 ml.min-1.kg-1 and 15.71 +/- 6.99 ml.min-1.kg-1.,Pharmacokinetics of bupivacaine following intraoperative intercostal nerve block in neonates and in infants aged less than 6 months. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729635/),[l] / [kg],2.56,36412,DB00297,Bupivacaine
,2729635,steady-state volume of distribution (Vdss),Pharmacokinetic variables in the two groups included elimination half-life (t1/2 beta): 132 +/- 59 min and 102 +/- 39 min; steady-state volume of distribution (Vdss): 2.56 +/- 0.76 l.kg-1 and 2.17 +/- 0.17 l.kg-1; and total body clearance (Clt): 16.93 +/- 9.32 ml.min-1.kg-1 and 15.71 +/- 6.99 ml.min-1.kg-1.,Pharmacokinetics of bupivacaine following intraoperative intercostal nerve block in neonates and in infants aged less than 6 months. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729635/),[l] / [kg],2.17,36413,DB00297,Bupivacaine
,2729635,total body clearance (Clt),Pharmacokinetic variables in the two groups included elimination half-life (t1/2 beta): 132 +/- 59 min and 102 +/- 39 min; steady-state volume of distribution (Vdss): 2.56 +/- 0.76 l.kg-1 and 2.17 +/- 0.17 l.kg-1; and total body clearance (Clt): 16.93 +/- 9.32 ml.min-1.kg-1 and 15.71 +/- 6.99 ml.min-1.kg-1.,Pharmacokinetics of bupivacaine following intraoperative intercostal nerve block in neonates and in infants aged less than 6 months. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729635/),[ml] / [kg·min],16.93,36414,DB00297,Bupivacaine
,2729635,total body clearance (Clt),Pharmacokinetic variables in the two groups included elimination half-life (t1/2 beta): 132 +/- 59 min and 102 +/- 39 min; steady-state volume of distribution (Vdss): 2.56 +/- 0.76 l.kg-1 and 2.17 +/- 0.17 l.kg-1; and total body clearance (Clt): 16.93 +/- 9.32 ml.min-1.kg-1 and 15.71 +/- 6.99 ml.min-1.kg-1.,Pharmacokinetics of bupivacaine following intraoperative intercostal nerve block in neonates and in infants aged less than 6 months. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2729635/),[ml] / [kg·min],15.71,36415,DB00297,Bupivacaine
,8900518,detection limit,The detection limit of this system was 10 ng/ml defined by a signal-to-noise ratio of 3:1.,Direct injection of large volumes of plasma in a column-switching system for the analysis of local anaesthetics. Determination of bupivacaine in human plasma with an alkyldiol silica precolumn. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8900518/),[ng] / [ml],10,36472,DB00297,Bupivacaine
,8900518,signal-to-noise ratio,The detection limit of this system was 10 ng/ml defined by a signal-to-noise ratio of 3:1.,Direct injection of large volumes of plasma in a column-switching system for the analysis of local anaesthetics. Determination of bupivacaine in human plasma with an alkyldiol silica precolumn. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8900518/),,3:1,36473,DB00297,Bupivacaine
,20085546,Peak plasma concentrations,"Peak plasma concentrations differed significantly: RO7.5: 1.4 +/- 0.4 (0.73-2.6) [microg/ml, mean +/- SD (range)] after 33 +/- 14 (10-40) min, RO2.0: 0.6 +/- 0.3 (0.13-1.0) after 22+17 (10-60) and BU2.5: 0.3 +/- 0.16 (0.05-0.62) at 31 +/- 17 (10-60), respectively.",Femoral nerve block with ropivacaine or bupivacaine in day case anterior crucial ligament reconstruction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20085546/),[μg] / [ml],1.4,36604,DB00297,Bupivacaine
,20085546,Peak plasma concentrations,"Peak plasma concentrations differed significantly: RO7.5: 1.4 +/- 0.4 (0.73-2.6) [microg/ml, mean +/- SD (range)] after 33 +/- 14 (10-40) min, RO2.0: 0.6 +/- 0.3 (0.13-1.0) after 22+17 (10-60) and BU2.5: 0.3 +/- 0.16 (0.05-0.62) at 31 +/- 17 (10-60), respectively.",Femoral nerve block with ropivacaine or bupivacaine in day case anterior crucial ligament reconstruction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20085546/),[μg] / [ml],0.6,36605,DB00297,Bupivacaine
,20085546,Peak plasma concentrations,"Peak plasma concentrations differed significantly: RO7.5: 1.4 +/- 0.4 (0.73-2.6) [microg/ml, mean +/- SD (range)] after 33 +/- 14 (10-40) min, RO2.0: 0.6 +/- 0.3 (0.13-1.0) after 22+17 (10-60) and BU2.5: 0.3 +/- 0.16 (0.05-0.62) at 31 +/- 17 (10-60), respectively.",Femoral nerve block with ropivacaine or bupivacaine in day case anterior crucial ligament reconstruction. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20085546/),[μg] / [ml],0.3,36606,DB00297,Bupivacaine
,9869373,limits of detection,"Using 0.6-ml samples, the estimated limits of detection for R-(+)-bupivacaine and S-(-)-bupivacaine were both 15 ng/ml of blood.",High-performance liquid chromatographic separation and nanogram quantitation of bupivacaine enantiomers in blood. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9869373/),[ng] / [ml],15,37668,DB00297,Bupivacaine
,18761239,maximal concentrations,Mean +/- SD of maximal concentrations of levobupivacaine was 0.58 +/- 0.41 mg/L in group superficial and 0.52 +/- 0.28 mg/L in group combined (P = 0.71).,Pharmacokinetics of levobupivacaine 0.5% after superficial or combined (deep and superficial) cervical plexus block in patients undergoing minimally invasive parathyroidectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761239/),[mg] / [l],0.58,37998,DB00297,Bupivacaine
,18761239,maximal concentrations,Mean +/- SD of maximal concentrations of levobupivacaine was 0.58 +/- 0.41 mg/L in group superficial and 0.52 +/- 0.28 mg/L in group combined (P = 0.71).,Pharmacokinetics of levobupivacaine 0.5% after superficial or combined (deep and superficial) cervical plexus block in patients undergoing minimally invasive parathyroidectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761239/),[mg] / [l],0.52,37999,DB00297,Bupivacaine
,18761239,time required to reach the maximal concentrations,The median (range) time required to reach the maximal concentrations was 30 minutes (20-30 min) in group superficial and 20 minutes (15-30 min) in group combined (P = 0.45).,Pharmacokinetics of levobupivacaine 0.5% after superficial or combined (deep and superficial) cervical plexus block in patients undergoing minimally invasive parathyroidectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761239/),min,30,38000,DB00297,Bupivacaine
,18761239,time required to reach the maximal concentrations,The median (range) time required to reach the maximal concentrations was 30 minutes (20-30 min) in group superficial and 20 minutes (15-30 min) in group combined (P = 0.45).,Pharmacokinetics of levobupivacaine 0.5% after superficial or combined (deep and superficial) cervical plexus block in patients undergoing minimally invasive parathyroidectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18761239/),min,20,38001,DB00297,Bupivacaine
,2310448,Vd beta,Pharmacokinetic parameters obtained were (mean +/- SD): Vd beta 206 +/- 88 L; Cle 0.816 +/- 0.378 L/min; t 1/2 beta 189 +/- 84 min; ka 9.92 +/- 6.79 x 10/min; Cpmax 0.48 +/- 0.20 micrograms/ml; and tmax 43.4 +/- 23.1 min.,Bupivacaine use after knee arthroscopy: pharmacokinetics and pain control study. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310448/),l,206,39496,DB00297,Bupivacaine
,2310448,Cle,Pharmacokinetic parameters obtained were (mean +/- SD): Vd beta 206 +/- 88 L; Cle 0.816 +/- 0.378 L/min; t 1/2 beta 189 +/- 84 min; ka 9.92 +/- 6.79 x 10/min; Cpmax 0.48 +/- 0.20 micrograms/ml; and tmax 43.4 +/- 23.1 min.,Bupivacaine use after knee arthroscopy: pharmacokinetics and pain control study. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310448/),[l] / [min],0.816,39497,DB00297,Bupivacaine
,2310448,t 1/2 beta,Pharmacokinetic parameters obtained were (mean +/- SD): Vd beta 206 +/- 88 L; Cle 0.816 +/- 0.378 L/min; t 1/2 beta 189 +/- 84 min; ka 9.92 +/- 6.79 x 10/min; Cpmax 0.48 +/- 0.20 micrograms/ml; and tmax 43.4 +/- 23.1 min.,Bupivacaine use after knee arthroscopy: pharmacokinetics and pain control study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310448/),min,189,39498,DB00297,Bupivacaine
,2310448,ka,Pharmacokinetic parameters obtained were (mean +/- SD): Vd beta 206 +/- 88 L; Cle 0.816 +/- 0.378 L/min; t 1/2 beta 189 +/- 84 min; ka 9.92 +/- 6.79 x 10/min; Cpmax 0.48 +/- 0.20 micrograms/ml; and tmax 43.4 +/- 23.1 min.,Bupivacaine use after knee arthroscopy: pharmacokinetics and pain control study. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310448/),[10] / [min],9.92,39499,DB00297,Bupivacaine
,2310448,Cpmax,Pharmacokinetic parameters obtained were (mean +/- SD): Vd beta 206 +/- 88 L; Cle 0.816 +/- 0.378 L/min; t 1/2 beta 189 +/- 84 min; ka 9.92 +/- 6.79 x 10/min; Cpmax 0.48 +/- 0.20 micrograms/ml; and tmax 43.4 +/- 23.1 min.,Bupivacaine use after knee arthroscopy: pharmacokinetics and pain control study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310448/),[μg] / [ml],0.48,39500,DB00297,Bupivacaine
,2310448,tmax,Pharmacokinetic parameters obtained were (mean +/- SD): Vd beta 206 +/- 88 L; Cle 0.816 +/- 0.378 L/min; t 1/2 beta 189 +/- 84 min; ka 9.92 +/- 6.79 x 10/min; Cpmax 0.48 +/- 0.20 micrograms/ml; and tmax 43.4 +/- 23.1 min.,Bupivacaine use after knee arthroscopy: pharmacokinetics and pain control study. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2310448/),min,43.4,39501,DB00297,Bupivacaine
,27224931,clearance,"In the LCT group, the clearance (15 ± 2 vs 10 ± 1 mL·min·kg, P = .003) was higher; the volume of distribution (0.57 ± 0.10 vs 0.36 ± 0.11 L·kg, P = .007) and K21 (0.0100 ± 0.0018 vs 0.0070 ± 0.0020 min, P = .021, P' = .032) were larger; and the area under the blood concentration-time curve 0 - t; (605 ± 82 vs 867 ± 110 mgL·min, P =.001) and the area under the blood concentration-time curve (0 - ∞) (697 ± 111 vs 991 ± 121 mgL·min, P =.001) were less, when compared with the LCT/MCT group.",The Effect of Lipid Emulsion on Pharmacokinetics of Bupivacaine in Rats: Long-Chain Triglyceride Versus Long- and Medium-Chain Triglyceride. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27224931/),kg·min·ml,15,40494,DB00297,Bupivacaine
,27224931,clearance,"In the LCT group, the clearance (15 ± 2 vs 10 ± 1 mL·min·kg, P = .003) was higher; the volume of distribution (0.57 ± 0.10 vs 0.36 ± 0.11 L·kg, P = .007) and K21 (0.0100 ± 0.0018 vs 0.0070 ± 0.0020 min, P = .021, P' = .032) were larger; and the area under the blood concentration-time curve 0 - t; (605 ± 82 vs 867 ± 110 mgL·min, P =.001) and the area under the blood concentration-time curve (0 - ∞) (697 ± 111 vs 991 ± 121 mgL·min, P =.001) were less, when compared with the LCT/MCT group.",The Effect of Lipid Emulsion on Pharmacokinetics of Bupivacaine in Rats: Long-Chain Triglyceride Versus Long- and Medium-Chain Triglyceride. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27224931/),kg·min·ml,10,40495,DB00297,Bupivacaine
,27224931,volume of distribution,"In the LCT group, the clearance (15 ± 2 vs 10 ± 1 mL·min·kg, P = .003) was higher; the volume of distribution (0.57 ± 0.10 vs 0.36 ± 0.11 L·kg, P = .007) and K21 (0.0100 ± 0.0018 vs 0.0070 ± 0.0020 min, P = .021, P' = .032) were larger; and the area under the blood concentration-time curve 0 - t; (605 ± 82 vs 867 ± 110 mgL·min, P =.001) and the area under the blood concentration-time curve (0 - ∞) (697 ± 111 vs 991 ± 121 mgL·min, P =.001) were less, when compared with the LCT/MCT group.",The Effect of Lipid Emulsion on Pharmacokinetics of Bupivacaine in Rats: Long-Chain Triglyceride Versus Long- and Medium-Chain Triglyceride. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27224931/),kg·l,0.57,40496,DB00297,Bupivacaine
,27224931,volume of distribution,"In the LCT group, the clearance (15 ± 2 vs 10 ± 1 mL·min·kg, P = .003) was higher; the volume of distribution (0.57 ± 0.10 vs 0.36 ± 0.11 L·kg, P = .007) and K21 (0.0100 ± 0.0018 vs 0.0070 ± 0.0020 min, P = .021, P' = .032) were larger; and the area under the blood concentration-time curve 0 - t; (605 ± 82 vs 867 ± 110 mgL·min, P =.001) and the area under the blood concentration-time curve (0 - ∞) (697 ± 111 vs 991 ± 121 mgL·min, P =.001) were less, when compared with the LCT/MCT group.",The Effect of Lipid Emulsion on Pharmacokinetics of Bupivacaine in Rats: Long-Chain Triglyceride Versus Long- and Medium-Chain Triglyceride. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27224931/),kg·l,0.36,40497,DB00297,Bupivacaine
,27224931,K21,"In the LCT group, the clearance (15 ± 2 vs 10 ± 1 mL·min·kg, P = .003) was higher; the volume of distribution (0.57 ± 0.10 vs 0.36 ± 0.11 L·kg, P = .007) and K21 (0.0100 ± 0.0018 vs 0.0070 ± 0.0020 min, P = .021, P' = .032) were larger; and the area under the blood concentration-time curve 0 - t; (605 ± 82 vs 867 ± 110 mgL·min, P =.001) and the area under the blood concentration-time curve (0 - ∞) (697 ± 111 vs 991 ± 121 mgL·min, P =.001) were less, when compared with the LCT/MCT group.",The Effect of Lipid Emulsion on Pharmacokinetics of Bupivacaine in Rats: Long-Chain Triglyceride Versus Long- and Medium-Chain Triglyceride. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27224931/),min,0.0100,40498,DB00297,Bupivacaine
,27224931,K21,"In the LCT group, the clearance (15 ± 2 vs 10 ± 1 mL·min·kg, P = .003) was higher; the volume of distribution (0.57 ± 0.10 vs 0.36 ± 0.11 L·kg, P = .007) and K21 (0.0100 ± 0.0018 vs 0.0070 ± 0.0020 min, P = .021, P' = .032) were larger; and the area under the blood concentration-time curve 0 - t; (605 ± 82 vs 867 ± 110 mgL·min, P =.001) and the area under the blood concentration-time curve (0 - ∞) (697 ± 111 vs 991 ± 121 mgL·min, P =.001) were less, when compared with the LCT/MCT group.",The Effect of Lipid Emulsion on Pharmacokinetics of Bupivacaine in Rats: Long-Chain Triglyceride Versus Long- and Medium-Chain Triglyceride. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27224931/),min,0.0070,40499,DB00297,Bupivacaine
,27224931,area under the blood concentration-time curve 0 - t,"In the LCT group, the clearance (15 ± 2 vs 10 ± 1 mL·min·kg, P = .003) was higher; the volume of distribution (0.57 ± 0.10 vs 0.36 ± 0.11 L·kg, P = .007) and K21 (0.0100 ± 0.0018 vs 0.0070 ± 0.0020 min, P = .021, P' = .032) were larger; and the area under the blood concentration-time curve 0 - t; (605 ± 82 vs 867 ± 110 mgL·min, P =.001) and the area under the blood concentration-time curve (0 - ∞) (697 ± 111 vs 991 ± 121 mgL·min, P =.001) were less, when compared with the LCT/MCT group.",The Effect of Lipid Emulsion on Pharmacokinetics of Bupivacaine in Rats: Long-Chain Triglyceride Versus Long- and Medium-Chain Triglyceride. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27224931/),mgl·min,605,40500,DB00297,Bupivacaine
,27224931,area under the blood concentration-time curve 0 - t,"In the LCT group, the clearance (15 ± 2 vs 10 ± 1 mL·min·kg, P = .003) was higher; the volume of distribution (0.57 ± 0.10 vs 0.36 ± 0.11 L·kg, P = .007) and K21 (0.0100 ± 0.0018 vs 0.0070 ± 0.0020 min, P = .021, P' = .032) were larger; and the area under the blood concentration-time curve 0 - t; (605 ± 82 vs 867 ± 110 mgL·min, P =.001) and the area under the blood concentration-time curve (0 - ∞) (697 ± 111 vs 991 ± 121 mgL·min, P =.001) were less, when compared with the LCT/MCT group.",The Effect of Lipid Emulsion on Pharmacokinetics of Bupivacaine in Rats: Long-Chain Triglyceride Versus Long- and Medium-Chain Triglyceride. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27224931/),mgl·min,867,40501,DB00297,Bupivacaine
,27224931,area under the blood concentration-time curve (0 - ∞),"In the LCT group, the clearance (15 ± 2 vs 10 ± 1 mL·min·kg, P = .003) was higher; the volume of distribution (0.57 ± 0.10 vs 0.36 ± 0.11 L·kg, P = .007) and K21 (0.0100 ± 0.0018 vs 0.0070 ± 0.0020 min, P = .021, P' = .032) were larger; and the area under the blood concentration-time curve 0 - t; (605 ± 82 vs 867 ± 110 mgL·min, P =.001) and the area under the blood concentration-time curve (0 - ∞) (697 ± 111 vs 991 ± 121 mgL·min, P =.001) were less, when compared with the LCT/MCT group.",The Effect of Lipid Emulsion on Pharmacokinetics of Bupivacaine in Rats: Long-Chain Triglyceride Versus Long- and Medium-Chain Triglyceride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27224931/),mgl·min,697,40502,DB00297,Bupivacaine
,27224931,area under the blood concentration-time curve (0 - ∞),"In the LCT group, the clearance (15 ± 2 vs 10 ± 1 mL·min·kg, P = .003) was higher; the volume of distribution (0.57 ± 0.10 vs 0.36 ± 0.11 L·kg, P = .007) and K21 (0.0100 ± 0.0018 vs 0.0070 ± 0.0020 min, P = .021, P' = .032) were larger; and the area under the blood concentration-time curve 0 - t; (605 ± 82 vs 867 ± 110 mgL·min, P =.001) and the area under the blood concentration-time curve (0 - ∞) (697 ± 111 vs 991 ± 121 mgL·min, P =.001) were less, when compared with the LCT/MCT group.",The Effect of Lipid Emulsion on Pharmacokinetics of Bupivacaine in Rats: Long-Chain Triglyceride Versus Long- and Medium-Chain Triglyceride. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27224931/),mgl·min,991,40503,DB00297,Bupivacaine
,27227503,Maximum bupivacaine plasma concentration,"Maximum bupivacaine plasma concentration was 1,030 ± 497.5 ng/mL at a mean ± SD value of 30 ± 24 minutes after administration.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[ng] / [ml],"1,030",40903,DB00297,Bupivacaine
,27227503,elimination half-life,Mean elimination half-life was 4.79 ± 2.7 hours.,Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),h,4.79,40904,DB00297,Bupivacaine
,27227503,clearance,"Mean clearance indexed by bioavailability and volume of distribution indexed by bioavailability were 0.35 ± 0.18 L•h/kg and 2.10 ± 0.84 L/kg, respectively.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[h·l] / [kg],0.35,40905,DB00297,Bupivacaine
,27227503,volume of distribution,"Mean clearance indexed by bioavailability and volume of distribution indexed by bioavailability were 0.35 ± 0.18 L•h/kg and 2.10 ± 0.84 L/kg, respectively.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[h·l] / [kg],0.35,40906,DB00297,Bupivacaine
,27227503,volume of distribution,"Mean clearance indexed by bioavailability and volume of distribution indexed by bioavailability were 0.35 ± 0.18 L•h/kg and 2.10 ± 0.84 L/kg, respectively.",Pharmacokinetics of bupivacaine after intraperitoneal administration to cats undergoing ovariohysterectomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27227503/),[l] / [kg],2.10,40907,DB00297,Bupivacaine
,16327164,flow rate,"The mobile phase solvent consisted of acetonitrile, methanol and 0.05 M phosphate buffer adjusted to pH 4.0 (10 : 30 : 60, v/v) was pumped at a flow rate of 0.8 ml/min.",Liquid chromatographic determination of plasma ropivacaine for assessing pharmacokinetics of the viscous preparation. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16327164/),[ml] / [min],0.8,41287,DB00297,Bupivacaine
,16327164,C(max),Our preliminary pharmacokinetic data showed that ropivacaine viscous could be used safely based on the plasma ropivacaine concentrations (C(max): 89-125 ng/ml) for pain relief in oral mucosa.,Liquid chromatographic determination of plasma ropivacaine for assessing pharmacokinetics of the viscous preparation. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16327164/),[ng] / [ml],89-125,41288,DB00297,Bupivacaine
,30032887,volume of distribution,Levobupivacaine volume of distribution after Caesarean section was higher than in healthy volunteers [172 L (70 kg)-1 (95% confidence interval: 137-207) vs 94.3 L (70 kg)-1 (95% CI: 62-128); P<0.01].,Pharmacokinetics of levobupivacaine with epinephrine in transversus abdominis plane block for postoperative analgesia after Caesarean section. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032887/),l,172,42369,DB00297,Bupivacaine
,30032887,volume of distribution,Levobupivacaine volume of distribution after Caesarean section was higher than in healthy volunteers [172 L (70 kg)-1 (95% confidence interval: 137-207) vs 94.3 L (70 kg)-1 (95% CI: 62-128); P<0.01].,Pharmacokinetics of levobupivacaine with epinephrine in transversus abdominis plane block for postoperative analgesia after Caesarean section. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30032887/),1/[kg],94.3,42370,DB00297,Bupivacaine
,16192762,bioavailability,The median bioavailability of the rapid component was approximately 20% higher when epinephrine was not used.,Arterial and venous pharmacokinetics of ropivacaine with and without epinephrine after thoracic paravertebral block. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16192762/),%,20,42423,DB00297,Bupivacaine
,16192762,mean absorption times,"The mean absorption times were 7.8 min for the rapid absorption phase and 697 min for the slow absorption phase, with wide dispersion of the absorption function for the acute phase.",Arterial and venous pharmacokinetics of ropivacaine with and without epinephrine after thoracic paravertebral block. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16192762/),min,7.8,42424,DB00297,Bupivacaine
,16192762,mean absorption times,"The mean absorption times were 7.8 min for the rapid absorption phase and 697 min for the slow absorption phase, with wide dispersion of the absorption function for the acute phase.",Arterial and venous pharmacokinetics of ropivacaine with and without epinephrine after thoracic paravertebral block. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16192762/),min,697,42425,DB00297,Bupivacaine
,16192762,half-time,The half-time of arterial-venous equilibration was 1.5 min.,Arterial and venous pharmacokinetics of ropivacaine with and without epinephrine after thoracic paravertebral block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16192762/),min,1.5,42426,DB00297,Bupivacaine
,19862987,AUC(o-t),The AUC(o-t) was (192 +/- 34)mg x L(-1) x min(-1) versus (271 +/- 81) mg x L(-1) x min(-1) and the AUC(0-infinity) was (231 +/- 62) mg x L(-1) x min(-1) versus (368 +/- 140) mg x L(-1) x min(-1) in the experiment group and the control group respectively.,[Effects of lipid emulsion on hemodynamics and pharmacokinetics of mongrel dogs with bupivacaine-induced cardiac depression]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19862987/),[mg] / [l·min],192,45651,DB00297,Bupivacaine
,19862987,AUC(o-t),The AUC(o-t) was (192 +/- 34)mg x L(-1) x min(-1) versus (271 +/- 81) mg x L(-1) x min(-1) and the AUC(0-infinity) was (231 +/- 62) mg x L(-1) x min(-1) versus (368 +/- 140) mg x L(-1) x min(-1) in the experiment group and the control group respectively.,[Effects of lipid emulsion on hemodynamics and pharmacokinetics of mongrel dogs with bupivacaine-induced cardiac depression]. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19862987/),[mg] / [l·min],271,45652,DB00297,Bupivacaine
,19862987,AUC(0-infinity),The AUC(o-t) was (192 +/- 34)mg x L(-1) x min(-1) versus (271 +/- 81) mg x L(-1) x min(-1) and the AUC(0-infinity) was (231 +/- 62) mg x L(-1) x min(-1) versus (368 +/- 140) mg x L(-1) x min(-1) in the experiment group and the control group respectively.,[Effects of lipid emulsion on hemodynamics and pharmacokinetics of mongrel dogs with bupivacaine-induced cardiac depression]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19862987/),[mg] / [l·min],231,45653,DB00297,Bupivacaine
,19862987,AUC(0-infinity),The AUC(o-t) was (192 +/- 34)mg x L(-1) x min(-1) versus (271 +/- 81) mg x L(-1) x min(-1) and the AUC(0-infinity) was (231 +/- 62) mg x L(-1) x min(-1) versus (368 +/- 140) mg x L(-1) x min(-1) in the experiment group and the control group respectively.,[Effects of lipid emulsion on hemodynamics and pharmacokinetics of mongrel dogs with bupivacaine-induced cardiac depression]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19862987/),[mg] / [l·min],368,45654,DB00297,Bupivacaine
,19862987,Vz,Vz (4.5 +/- 1.1 L/kg versus 3.3 +/- 0.9 L/kg) of bupivacaine in the experiment group was significantly higher than that in the control group (P < 0.05).,[Effects of lipid emulsion on hemodynamics and pharmacokinetics of mongrel dogs with bupivacaine-induced cardiac depression]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19862987/),[l] / [kg],4.5,45655,DB00297,Bupivacaine
,19862987,Vz,Vz (4.5 +/- 1.1 L/kg versus 3.3 +/- 0.9 L/kg) of bupivacaine in the experiment group was significantly higher than that in the control group (P < 0.05).,[Effects of lipid emulsion on hemodynamics and pharmacokinetics of mongrel dogs with bupivacaine-induced cardiac depression]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19862987/),[l] / [kg],3.3,45656,DB00297,Bupivacaine
,29755192,plasma concentrations (Cmax),"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),[ng] / [ml],1155,48784,DB00297,Bupivacaine
,29755192,plasma concentrations (Cmax),"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),[ng] / [ml],1678,48785,DB00297,Bupivacaine
,29755192,Tmax,"Maximum bupivacaine plasma concentrations (Cmax) for BE and BD were 1155 ± 168 ng/mL and 1678 ± 364 ng/mL (P = 0.29) at 67 ± 13 min (Tmax) and 123 ± 59 min (P = 0.17), respectively.",Efficacy and pharmacokinetics of bupivacaine with epinephrine or dexmedetomidine after intraperitoneal administration in cats undergoing ovariohysterectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29755192/),min,67,48786,DB00297,Bupivacaine
,7486273,plasma peak concentration,"The median plasma peak concentration was 1.74 mg.L-1 after 10 min for lidocaine, and 0.52 mg.L-1 after 7.5 min for bupivacaine respectively.",[Pharmacokinetics of lidocaine and bupivacaine after peribulbar block with additional hyaluronidase]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486273/),[mg] / [l],1.74,49113,DB00297,Bupivacaine
,7486273,plasma peak concentration,"The median plasma peak concentration was 1.74 mg.L-1 after 10 min for lidocaine, and 0.52 mg.L-1 after 7.5 min for bupivacaine respectively.",[Pharmacokinetics of lidocaine and bupivacaine after peribulbar block with additional hyaluronidase]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7486273/),[mg] / [l],0.52,49114,DB00297,Bupivacaine
,12402722,peak plasma concentration,"The peak plasma concentration achieved was significantly higher in the bupivacaine group compared with the ropivacaine group (2.2 vs 1.2 micrograms ml-1, P = 0.025).",Pharmacokinetics of 0.75% ropivacaine and 0.5% bupivacaine after ilioinguinal-iliohypogastric nerve block in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402722/),[μg] / [ml],2.2,49115,DB00297,Bupivacaine
,12402722,peak plasma concentration,"The peak plasma concentration achieved was significantly higher in the bupivacaine group compared with the ropivacaine group (2.2 vs 1.2 micrograms ml-1, P = 0.025).",Pharmacokinetics of 0.75% ropivacaine and 0.5% bupivacaine after ilioinguinal-iliohypogastric nerve block in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402722/),[μg] / [ml],1.2,49116,DB00297,Bupivacaine
,12402722,time to peak plasma concentration,"The time to peak plasma concentration was significantly shorter in the bupivacaine group (24 vs 35 min, P = 0.024).",Pharmacokinetics of 0.75% ropivacaine and 0.5% bupivacaine after ilioinguinal-iliohypogastric nerve block in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402722/),min,24,49117,DB00297,Bupivacaine
,12402722,time to peak plasma concentration,"The time to peak plasma concentration was significantly shorter in the bupivacaine group (24 vs 35 min, P = 0.024).",Pharmacokinetics of 0.75% ropivacaine and 0.5% bupivacaine after ilioinguinal-iliohypogastric nerve block in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402722/),min,35,49118,DB00297,Bupivacaine
,12402722,initial distribution half time,"The initial distribution half time of bupivacaine was significantly shorter (3.6 vs 6.5 min, P = 0.020) compared with that of ropivacaine.",Pharmacokinetics of 0.75% ropivacaine and 0.5% bupivacaine after ilioinguinal-iliohypogastric nerve block in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402722/),min,3.6,49119,DB00297,Bupivacaine
,12402722,initial distribution half time,"The initial distribution half time of bupivacaine was significantly shorter (3.6 vs 6.5 min, P = 0.020) compared with that of ropivacaine.",Pharmacokinetics of 0.75% ropivacaine and 0.5% bupivacaine after ilioinguinal-iliohypogastric nerve block in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12402722/),min,6.5,49120,DB00297,Bupivacaine
,9422890,Cpmax,"After the main dose, Cpmax (total) of ropivacaine (0.50 mg litre-1) was similar to that of bupivacaine (0.48 mg litre-1).",Pharmacokinetic and clinical study of ropivacaine and bupivacaine in women receiving extradural analgesia in labour. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422890/),[mg] / [l],0.50,53184,DB00297,Bupivacaine
,9422890,Cpmax,"After the main dose, Cpmax (total) of ropivacaine (0.50 mg litre-1) was similar to that of bupivacaine (0.48 mg litre-1).",Pharmacokinetic and clinical study of ropivacaine and bupivacaine in women receiving extradural analgesia in labour. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422890/),[mg] / [l],0.48,53185,DB00297,Bupivacaine
,9422890,Cpmax,"At 20 min, Cpmax (free) of ropivacaine (0.04 mg litre-1) was higher than that of bupivacaine (0.02 mg litre-1) (P = 0.0025).",Pharmacokinetic and clinical study of ropivacaine and bupivacaine in women receiving extradural analgesia in labour. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422890/),[mg] / [l],0.04,53186,DB00297,Bupivacaine
,9422890,Cpmax,"At 20 min, Cpmax (free) of ropivacaine (0.04 mg litre-1) was higher than that of bupivacaine (0.02 mg litre-1) (P = 0.0025).",Pharmacokinetic and clinical study of ropivacaine and bupivacaine in women receiving extradural analgesia in labour. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9422890/),[mg] / [l],0.02,53187,DB00297,Bupivacaine
,11064622,Maximal median concentrations of plasma,Maximal median concentrations of plasma (0.117-0.247 ng ml-1 for fentanyl and 0.027-0.074 ng ml-1 for sufentanil) were reached approximately 30 and 20 min respectively after the loading doses.,Fentanyl versus sufentanil: plasma concentrations during continuous epidural postoperative infusion in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11064622/),[ng] / [ml],0.117-0.247,54451,DB00297,Bupivacaine
,11064622,Maximal median concentrations of plasma,Maximal median concentrations of plasma (0.117-0.247 ng ml-1 for fentanyl and 0.027-0.074 ng ml-1 for sufentanil) were reached approximately 30 and 20 min respectively after the loading doses.,Fentanyl versus sufentanil: plasma concentrations during continuous epidural postoperative infusion in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11064622/),[ng] / [ml],0.027-0.074,54452,DB00297,Bupivacaine
,23460566,t1/2β,"After treatment with the lipid emulsion, t1/2β of bupivacaine in the lipid group was significantly shorter (110 ± 25 minutes vs 199 ± 38 minutes, P = 0.001), the clearance was higher (14 ± 4 mL·mg(-1)·kg(-1) vs 9 ± 4 mL·mg(-1)·kg(-1), P = 0.038), and the t1/2α was longer than that of the control group (4 ± 1 minutes vs 2 ± 1 minutes, P = 0.014); the K12 in the lipid group was less than that of the control group (0.13 ± 0.04 vs 0.32 ± 0.13, P = 0.011).",The effect of lipid emulsion on pharmacokinetics and tissue distribution of bupivacaine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23460566/),min,110,54791,DB00297,Bupivacaine
,23460566,t1/2β,"After treatment with the lipid emulsion, t1/2β of bupivacaine in the lipid group was significantly shorter (110 ± 25 minutes vs 199 ± 38 minutes, P = 0.001), the clearance was higher (14 ± 4 mL·mg(-1)·kg(-1) vs 9 ± 4 mL·mg(-1)·kg(-1), P = 0.038), and the t1/2α was longer than that of the control group (4 ± 1 minutes vs 2 ± 1 minutes, P = 0.014); the K12 in the lipid group was less than that of the control group (0.13 ± 0.04 vs 0.32 ± 0.13, P = 0.011).",The effect of lipid emulsion on pharmacokinetics and tissue distribution of bupivacaine in rats. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23460566/),min,199,54792,DB00297,Bupivacaine
,23460566,clearance,"After treatment with the lipid emulsion, t1/2β of bupivacaine in the lipid group was significantly shorter (110 ± 25 minutes vs 199 ± 38 minutes, P = 0.001), the clearance was higher (14 ± 4 mL·mg(-1)·kg(-1) vs 9 ± 4 mL·mg(-1)·kg(-1), P = 0.038), and the t1/2α was longer than that of the control group (4 ± 1 minutes vs 2 ± 1 minutes, P = 0.014); the K12 in the lipid group was less than that of the control group (0.13 ± 0.04 vs 0.32 ± 0.13, P = 0.011).",The effect of lipid emulsion on pharmacokinetics and tissue distribution of bupivacaine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23460566/),[ml] / [kg·mg],14,54793,DB00297,Bupivacaine
,23460566,clearance,"After treatment with the lipid emulsion, t1/2β of bupivacaine in the lipid group was significantly shorter (110 ± 25 minutes vs 199 ± 38 minutes, P = 0.001), the clearance was higher (14 ± 4 mL·mg(-1)·kg(-1) vs 9 ± 4 mL·mg(-1)·kg(-1), P = 0.038), and the t1/2α was longer than that of the control group (4 ± 1 minutes vs 2 ± 1 minutes, P = 0.014); the K12 in the lipid group was less than that of the control group (0.13 ± 0.04 vs 0.32 ± 0.13, P = 0.011).",The effect of lipid emulsion on pharmacokinetics and tissue distribution of bupivacaine in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23460566/),[ml] / [kg·mg],9,54794,DB00297,Bupivacaine
,23460566,t1/2α,"After treatment with the lipid emulsion, t1/2β of bupivacaine in the lipid group was significantly shorter (110 ± 25 minutes vs 199 ± 38 minutes, P = 0.001), the clearance was higher (14 ± 4 mL·mg(-1)·kg(-1) vs 9 ± 4 mL·mg(-1)·kg(-1), P = 0.038), and the t1/2α was longer than that of the control group (4 ± 1 minutes vs 2 ± 1 minutes, P = 0.014); the K12 in the lipid group was less than that of the control group (0.13 ± 0.04 vs 0.32 ± 0.13, P = 0.011).",The effect of lipid emulsion on pharmacokinetics and tissue distribution of bupivacaine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23460566/),min,4,54795,DB00297,Bupivacaine
,23460566,t1/2α,"After treatment with the lipid emulsion, t1/2β of bupivacaine in the lipid group was significantly shorter (110 ± 25 minutes vs 199 ± 38 minutes, P = 0.001), the clearance was higher (14 ± 4 mL·mg(-1)·kg(-1) vs 9 ± 4 mL·mg(-1)·kg(-1), P = 0.038), and the t1/2α was longer than that of the control group (4 ± 1 minutes vs 2 ± 1 minutes, P = 0.014); the K12 in the lipid group was less than that of the control group (0.13 ± 0.04 vs 0.32 ± 0.13, P = 0.011).",The effect of lipid emulsion on pharmacokinetics and tissue distribution of bupivacaine in rats. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23460566/),min,2,54796,DB00297,Bupivacaine
,23460566,K12,"After treatment with the lipid emulsion, t1/2β of bupivacaine in the lipid group was significantly shorter (110 ± 25 minutes vs 199 ± 38 minutes, P = 0.001), the clearance was higher (14 ± 4 mL·mg(-1)·kg(-1) vs 9 ± 4 mL·mg(-1)·kg(-1), P = 0.038), and the t1/2α was longer than that of the control group (4 ± 1 minutes vs 2 ± 1 minutes, P = 0.014); the K12 in the lipid group was less than that of the control group (0.13 ± 0.04 vs 0.32 ± 0.13, P = 0.011).",The effect of lipid emulsion on pharmacokinetics and tissue distribution of bupivacaine in rats. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23460566/),,0.13,54797,DB00297,Bupivacaine
,23460566,K12,"After treatment with the lipid emulsion, t1/2β of bupivacaine in the lipid group was significantly shorter (110 ± 25 minutes vs 199 ± 38 minutes, P = 0.001), the clearance was higher (14 ± 4 mL·mg(-1)·kg(-1) vs 9 ± 4 mL·mg(-1)·kg(-1), P = 0.038), and the t1/2α was longer than that of the control group (4 ± 1 minutes vs 2 ± 1 minutes, P = 0.014); the K12 in the lipid group was less than that of the control group (0.13 ± 0.04 vs 0.32 ± 0.13, P = 0.011).",The effect of lipid emulsion on pharmacokinetics and tissue distribution of bupivacaine in rats. ,"K12, K21-Q48",[Article Link](https://pubmed.ncbi.nlm.nih.gov/23460566/),,0.32,54798,DB00297,Bupivacaine
,17959589,e,Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (sd 0.1) vs 0.4 (0.1) ml min(-1)] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min(-1)].,"Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959589/),[ml] / [min],0.6,55810,DB00297,Bupivacaine
,17959589,e,Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (sd 0.1) vs 0.4 (0.1) ml min(-1)] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min(-1)].,"Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959589/),[ml] / [min],0.4,55811,DB00297,Bupivacaine
,17959589,e,Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (sd 0.1) vs 0.4 (0.1) ml min(-1)] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min(-1)].,"Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959589/),[ml] / [min],1.2,55812,DB00297,Bupivacaine
,17959589,e,Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (sd 0.1) vs 0.4 (0.1) ml min(-1)] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min(-1)].,"Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. ",Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959589/),[ml] / [min],0.8,55813,DB00297,Bupivacaine
,17959589,clearance,Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (sd 0.1) vs 0.4 (0.1) ml min(-1)] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min(-1)].,"Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959589/),[ml] / [min],0.6,55814,DB00297,Bupivacaine
,17959589,clearance,Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (sd 0.1) vs 0.4 (0.1) ml min(-1)] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min(-1)].,"Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959589/),[ml] / [min],0.4,55815,DB00297,Bupivacaine
,17959589,clearance,Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (sd 0.1) vs 0.4 (0.1) ml min(-1)] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min(-1)].,"Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959589/),[ml] / [min],1.2,55816,DB00297,Bupivacaine
,17959589,clearance,Co-administration of epinephrine decreased epidural clearance for ropivacaine [0.6 (sd 0.1) vs 0.4 (0.1) ml min(-1)] but not significantly for bupivacaine [1.2 (0.4) vs 0.8 (0.3) ml min(-1)].,"Effect of epinephrine on epidural, intrathecal, and plasma pharmacokinetics of ropivacaine and bupivacaine in sheep. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17959589/),[ml] / [min],0.8,55817,DB00297,Bupivacaine
,26982080,half-life,"As is shown in pharmacokinetic parameters, the half-life of LBP injection (2.7 h) was shorter than that of LBP in situ gels (23.9 h), suggesting that LBP injection was taken up by other tissues more rapidly than gels.",Preparation and investigation of a novel levobupivacaine in situ implant gel for prolonged local anesthetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26982080/),h,2.7,55946,DB00297,Bupivacaine
,26982080,half-life,"As is shown in pharmacokinetic parameters, the half-life of LBP injection (2.7 h) was shorter than that of LBP in situ gels (23.9 h), suggesting that LBP injection was taken up by other tissues more rapidly than gels.",Preparation and investigation of a novel levobupivacaine in situ implant gel for prolonged local anesthetics. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26982080/),h,23.9,55947,DB00297,Bupivacaine
,6480788,extraction efficiency,"The calibration graph is linear over the range 0.02-5.00 mg/l and the extraction efficiency is 91.8 +/- 3.8% (+/- S.D., n = 7).",High-performance liquid chromatographic determination of bupivacaine in human serum. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/6480788/),%,91.8,56646,DB00297,Bupivacaine
,7999650,infusion rates,"Mean infusion rates were 9.3 +/- 2.1 mL/hour and 9.6 +/- 1.7 mL/hour for groups A and B, respectively.",Plasma concentration profile of epidural alfentanil. Bolus followed by continuous infusion technique in the parturient: effect of epidural alfentanil and fentanyl on fetal heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999650/),[ml] / [h],9.3,57278,DB00297,Bupivacaine
,7999650,infusion rates,"Mean infusion rates were 9.3 +/- 2.1 mL/hour and 9.6 +/- 1.7 mL/hour for groups A and B, respectively.",Plasma concentration profile of epidural alfentanil. Bolus followed by continuous infusion technique in the parturient: effect of epidural alfentanil and fentanyl on fetal heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999650/),[ml] / [h],9.6,57279,DB00297,Bupivacaine
,7999650,study duration,"Mean study duration was 3.7 hours in group A, and 3.0 hours in group B.",Plasma concentration profile of epidural alfentanil. Bolus followed by continuous infusion technique in the parturient: effect of epidural alfentanil and fentanyl on fetal heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999650/),h,3.7,57280,DB00297,Bupivacaine
,7999650,study duration,"Mean study duration was 3.7 hours in group A, and 3.0 hours in group B.",Plasma concentration profile of epidural alfentanil. Bolus followed by continuous infusion technique in the parturient: effect of epidural alfentanil and fentanyl on fetal heart rate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7999650/),h,3.0,57281,DB00297,Bupivacaine
,7793647,Cmax,Pharmacokinetic analysis showed that the Cmax was similar for both drugs (1.3 +/- 0.09 for ropivacaine and 1.1 +/- 0.09 micrograms/ml for bupivacaine).,Clinical effects and maternal and fetal plasma concentrations of epidural ropivacaine versus bupivacaine for cesarean section. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793647/),[μg] / [ml],1.3,60262,DB00297,Bupivacaine
,7793647,Cmax,Pharmacokinetic analysis showed that the Cmax was similar for both drugs (1.3 +/- 0.09 for ropivacaine and 1.1 +/- 0.09 micrograms/ml for bupivacaine).,Clinical effects and maternal and fetal plasma concentrations of epidural ropivacaine versus bupivacaine for cesarean section. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793647/),[μg] / [ml],1.1,60263,DB00297,Bupivacaine
,7793647,T1/2 of the terminal decline in plasma concentration,"The T1/2 of the terminal decline in plasma concentration was shorter for ropivacaine versus bupivacaine (5.2 +/- 0.60 versus 10.9 +/- 1.08 h, respectively; P < 0.01).",Clinical effects and maternal and fetal plasma concentrations of epidural ropivacaine versus bupivacaine for cesarean section. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793647/),h,5.2,60264,DB00297,Bupivacaine
,7793647,T1/2 of the terminal decline in plasma concentration,"The T1/2 of the terminal decline in plasma concentration was shorter for ropivacaine versus bupivacaine (5.2 +/- 0.60 versus 10.9 +/- 1.08 h, respectively; P < 0.01).",Clinical effects and maternal and fetal plasma concentrations of epidural ropivacaine versus bupivacaine for cesarean section. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7793647/),h,10.9,60265,DB00297,Bupivacaine
,22285545,AUC,"Mean AUC of NRS-A scores through Day 4 were 20.7, 19.5, 18.8, and 19.1 for the 133-mg, 266-mg, 399-mg, and 532-mg DepoFoam bupivacaine groups vs 20.4 for bupivacaine HCl.","A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22285545/),,20.7,62422,DB00297,Bupivacaine
,22285545,AUC,"Mean AUC of NRS-A scores through Day 4 were 20.7, 19.5, 18.8, and 19.1 for the 133-mg, 266-mg, 399-mg, and 532-mg DepoFoam bupivacaine groups vs 20.4 for bupivacaine HCl.","A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22285545/),,19.5,62423,DB00297,Bupivacaine
,22285545,AUC,"Mean AUC of NRS-A scores through Day 4 were 20.7, 19.5, 18.8, and 19.1 for the 133-mg, 266-mg, 399-mg, and 532-mg DepoFoam bupivacaine groups vs 20.4 for bupivacaine HCl.","A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22285545/),,18.8,62424,DB00297,Bupivacaine
,22285545,AUC,"Mean AUC of NRS-A scores through Day 4 were 20.7, 19.5, 18.8, and 19.1 for the 133-mg, 266-mg, 399-mg, and 532-mg DepoFoam bupivacaine groups vs 20.4 for bupivacaine HCl.","A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22285545/),,19.1,62425,DB00297,Bupivacaine
,22285545,AUC,"Mean AUC of NRS-A scores through Day 4 were 20.7, 19.5, 18.8, and 19.1 for the 133-mg, 266-mg, 399-mg, and 532-mg DepoFoam bupivacaine groups vs 20.4 for bupivacaine HCl.","A randomized, double-blind, dose-ranging study comparing wound infiltration of DepoFoam bupivacaine, an extended-release liposomal bupivacaine, to bupivacaine HCl for postsurgical analgesia in total knee arthroplasty. ",AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22285545/),,20.4,62426,DB00297,Bupivacaine
,22211825,Maximum unbound concentrations,Maximum unbound concentrations for bupivacaine and ropivacaine were 0.12 mg · l(-1) (bupivacaine) and 0.13 mg · l(-1) (ropivacaine).,Pharmacokinetic profiles of epidural bupivacaine and ropivacaine following single-shot and continuous epidural use in young infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22211825/),[mg] / [l],0.12,64007,DB00297,Bupivacaine
,22211825,Maximum unbound concentrations,Maximum unbound concentrations for bupivacaine and ropivacaine were 0.12 mg · l(-1) (bupivacaine) and 0.13 mg · l(-1) (ropivacaine).,Pharmacokinetic profiles of epidural bupivacaine and ropivacaine following single-shot and continuous epidural use in young infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22211825/),[mg] / [l],0.13,64008,DB00297,Bupivacaine
,22211825,clearance/bioavailability,Typical clearance/bioavailability estimates of total (unbound) bupivacaine were 0.215 (4.65) l · h(-1) · kg(-1) and of total (unbound) ropivacaine were 0.288 (3.31) l · h(-1) · kg(-1).,Pharmacokinetic profiles of epidural bupivacaine and ropivacaine following single-shot and continuous epidural use in young infants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22211825/),[l] / [h·kg],0.215,64009,DB00297,Bupivacaine
,22211825,clearance/bioavailability,Typical clearance/bioavailability estimates of total (unbound) bupivacaine were 0.215 (4.65) l · h(-1) · kg(-1) and of total (unbound) ropivacaine were 0.288 (3.31) l · h(-1) · kg(-1).,Pharmacokinetic profiles of epidural bupivacaine and ropivacaine following single-shot and continuous epidural use in young infants. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22211825/),[l] / [h·kg],0.288,64010,DB00297,Bupivacaine
,3396545,maximum mean concentration (CPmax),"In children of Group 1, maximum mean concentration (CPmax) was 0.64 +/- 0.05 microgram ml-1, time to maximum concentration (Tmax) 19.2 +/- 3.9 min, vascular absorption (T1/2 abs) 4.3 +/- 1.5 min, terminal half-life (T1/2 beta) 227 +/- 37.7 min, volume of distribution (Vd) 3.4 +/- 0.51 kg-1, and total body clearance (Clt) 11.0 +/- 2.0 ml min-1 kg-1.",Bupivacaine pharmacokinetics during epidural anaesthesia in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396545/),[μg] / [ml],0.64,64483,DB00297,Bupivacaine
,3396545,time to maximum concentration (Tmax),"In children of Group 1, maximum mean concentration (CPmax) was 0.64 +/- 0.05 microgram ml-1, time to maximum concentration (Tmax) 19.2 +/- 3.9 min, vascular absorption (T1/2 abs) 4.3 +/- 1.5 min, terminal half-life (T1/2 beta) 227 +/- 37.7 min, volume of distribution (Vd) 3.4 +/- 0.51 kg-1, and total body clearance (Clt) 11.0 +/- 2.0 ml min-1 kg-1.",Bupivacaine pharmacokinetics during epidural anaesthesia in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396545/),min,19.2,64484,DB00297,Bupivacaine
,3396545,vascular absorption (T1/2 abs),"In children of Group 1, maximum mean concentration (CPmax) was 0.64 +/- 0.05 microgram ml-1, time to maximum concentration (Tmax) 19.2 +/- 3.9 min, vascular absorption (T1/2 abs) 4.3 +/- 1.5 min, terminal half-life (T1/2 beta) 227 +/- 37.7 min, volume of distribution (Vd) 3.4 +/- 0.51 kg-1, and total body clearance (Clt) 11.0 +/- 2.0 ml min-1 kg-1.",Bupivacaine pharmacokinetics during epidural anaesthesia in children. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396545/),min,4.3,64485,DB00297,Bupivacaine
,3396545,terminal half-life (T1/2 beta),"In children of Group 1, maximum mean concentration (CPmax) was 0.64 +/- 0.05 microgram ml-1, time to maximum concentration (Tmax) 19.2 +/- 3.9 min, vascular absorption (T1/2 abs) 4.3 +/- 1.5 min, terminal half-life (T1/2 beta) 227 +/- 37.7 min, volume of distribution (Vd) 3.4 +/- 0.51 kg-1, and total body clearance (Clt) 11.0 +/- 2.0 ml min-1 kg-1.",Bupivacaine pharmacokinetics during epidural anaesthesia in children. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396545/),min,227,64486,DB00297,Bupivacaine
,3396545,volume of distribution (Vd),"In children of Group 1, maximum mean concentration (CPmax) was 0.64 +/- 0.05 microgram ml-1, time to maximum concentration (Tmax) 19.2 +/- 3.9 min, vascular absorption (T1/2 abs) 4.3 +/- 1.5 min, terminal half-life (T1/2 beta) 227 +/- 37.7 min, volume of distribution (Vd) 3.4 +/- 0.51 kg-1, and total body clearance (Clt) 11.0 +/- 2.0 ml min-1 kg-1.",Bupivacaine pharmacokinetics during epidural anaesthesia in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396545/),1/[kg],3.4,64487,DB00297,Bupivacaine
,3396545,total body clearance (Clt),"In children of Group 1, maximum mean concentration (CPmax) was 0.64 +/- 0.05 microgram ml-1, time to maximum concentration (Tmax) 19.2 +/- 3.9 min, vascular absorption (T1/2 abs) 4.3 +/- 1.5 min, terminal half-life (T1/2 beta) 227 +/- 37.7 min, volume of distribution (Vd) 3.4 +/- 0.51 kg-1, and total body clearance (Clt) 11.0 +/- 2.0 ml min-1 kg-1.",Bupivacaine pharmacokinetics during epidural anaesthesia in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3396545/),[ml] / [kg·min],11.0,64488,DB00297,Bupivacaine
,24741194,population clearance,"The selected model predicts a population clearance of 930 ml/min (residual standard error [RSE] = 15.48%, IC 95% = 930 ± 282.24) with inter individual variability of 75.29%.",Population pharmacokinetics of bupivacaine in combined lumbar and sciatic nerve block. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741194/),[ml] / [min],930,69035,DB00297,Bupivacaine
,24741194,central volume of distribution,"The central volume of distribution was 134 l (RSE = 12.76%, IC = 134 ± 33.51 L) with inter individual variability of 63.40%.",Population pharmacokinetics of bupivacaine in combined lumbar and sciatic nerve block. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741194/),l,134,69036,DB00297,Bupivacaine
,24741194,IC,"The central volume of distribution was 134 l (RSE = 12.76%, IC = 134 ± 33.51 L) with inter individual variability of 63.40%.",Population pharmacokinetics of bupivacaine in combined lumbar and sciatic nerve block. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741194/),l,134,69037,DB00297,Bupivacaine
,24741194,Ka1,The absorption of bupivacaine in two sites Ka1 and Ka2 were 0.00462/min for the lumbar site and 0.292/min for the sciatic site.,Population pharmacokinetics of bupivacaine in combined lumbar and sciatic nerve block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741194/),1/[min],0.00462,69038,DB00297,Bupivacaine
,24741194,Ka2,The absorption of bupivacaine in two sites Ka1 and Ka2 were 0.00462/min for the lumbar site and 0.292/min for the sciatic site.,Population pharmacokinetics of bupivacaine in combined lumbar and sciatic nerve block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24741194/),1/[min],0.292,69039,DB00297,Bupivacaine
,2722118,Maximal plasma concentration,Maximal plasma concentration was 0.73 +/- 0.33 micrograms.,Pharmacokinetics of lidocaine and bupivacaine in retrobulbar and facial block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2722118/),μg,0.73,69112,DB00297,Bupivacaine
,2722118,CSF/plasma ratio,CSF/plasma ratio was in the range 0.05-0.26 for lidocaine and 0.56-1.33 for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine in retrobulbar and facial block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2722118/),,0.05-0.26,69113,DB00297,Bupivacaine
,2722118,CSF/plasma ratio,CSF/plasma ratio was in the range 0.05-0.26 for lidocaine and 0.56-1.33 for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine in retrobulbar and facial block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2722118/),,0.56-1.33,69114,DB00297,Bupivacaine
,25188774,half-life,"Clonidine levels could be demonstrated during the 24-h postoperative period, with an average half-life of 22 h.",Clonidine as an adjuvant to prolong local analgesia in conventional scleral buckle surgery. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25188774/),h,22,69632,DB00297,Bupivacaine
,7605766,total plasma bupivacaine level,The highest total plasma bupivacaine level was 20.3 micrograms/mL.,Bupivacaine toxicity secondary to continuous cervical epidural infusion. Case report. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605766/),,20,69888,DB00297,Bupivacaine
,7605766,Total body clearance,Total body clearance of bupivacaine was 20 mL/min and elimination half-life was 27 hours.,Bupivacaine toxicity secondary to continuous cervical epidural infusion. Case report. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605766/),[ml] / [min],20,69889,DB00297,Bupivacaine
,7605766,elimination half-life,Total body clearance of bupivacaine was 20 mL/min and elimination half-life was 27 hours.,Bupivacaine toxicity secondary to continuous cervical epidural infusion. Case report. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605766/),h,27,69890,DB00297,Bupivacaine
,7818121,maximum measured concentrations,"The blood enantiomer concentration difference was reflected in the maximum measured concentrations which, after the first dose, were, respectively, 0.38 (SD 0.19) and 0.52 (SD 0.28) mg.L-1.100 mg-1 RS-bupivacaine administered (P = 0.0003).",Bupivacaine enantiomer pharmacokinetics after intercostal neural blockade in liver transplantation patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818121/),[mg] / [l·mg],0.38,70305,DB00297,Bupivacaine
,7818121,maximum measured concentrations,"The blood enantiomer concentration difference was reflected in the maximum measured concentrations which, after the first dose, were, respectively, 0.38 (SD 0.19) and 0.52 (SD 0.28) mg.L-1.100 mg-1 RS-bupivacaine administered (P = 0.0003).",Bupivacaine enantiomer pharmacokinetics after intercostal neural blockade in liver transplantation patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818121/),[mg] / [l·mg],0.52,70306,DB00297,Bupivacaine
,33386432,time to reach maximum plasma concentration,"In either of experiments, the time to reach maximum plasma concentration of levobupivacaine was shorter in the IP group than in the SC group (IP: 2 [2-5] min; SC: 5 [2-10] min; P = 0.04), and the maximum concentration of levobupivacaine did not differ between the IP and SC groups (IP: 0.45 [0.05-0.67] µg/mL; SC: 0.47 [0.21-0.62] µg/mL; P = 0.90).",Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),min,2,73226,DB00297,Bupivacaine
,33386432,time to reach maximum plasma concentration,"In either of experiments, the time to reach maximum plasma concentration of levobupivacaine was shorter in the IP group than in the SC group (IP: 2 [2-5] min; SC: 5 [2-10] min; P = 0.04), and the maximum concentration of levobupivacaine did not differ between the IP and SC groups (IP: 0.45 [0.05-0.67] µg/mL; SC: 0.47 [0.21-0.62] µg/mL; P = 0.90).",Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),min,5,73227,DB00297,Bupivacaine
,33386432,maximum concentration,"In either of experiments, the time to reach maximum plasma concentration of levobupivacaine was shorter in the IP group than in the SC group (IP: 2 [2-5] min; SC: 5 [2-10] min; P = 0.04), and the maximum concentration of levobupivacaine did not differ between the IP and SC groups (IP: 0.45 [0.05-0.67] µg/mL; SC: 0.47 [0.21-0.62] µg/mL; P = 0.90).",Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),[μg] / [ml],0.45,73228,DB00297,Bupivacaine
,33386432,maximum concentration,"In either of experiments, the time to reach maximum plasma concentration of levobupivacaine was shorter in the IP group than in the SC group (IP: 2 [2-5] min; SC: 5 [2-10] min; P = 0.04), and the maximum concentration of levobupivacaine did not differ between the IP and SC groups (IP: 0.45 [0.05-0.67] µg/mL; SC: 0.47 [0.21-0.62] µg/mL; P = 0.90).",Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),[μg] / [ml],0.47,73229,DB00297,Bupivacaine
,33386432,area under the curve from time 0 to 120 min,The area under the curve from time 0 to 120 min after levobupivacaine administration was significantly higher in the SC group than in the IP group in both experiments (IP: 0.29 [0.10-0.54] mg h/L; SC: 0.78 [0.39-0.98] mg h/L; P = 0.04).,Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),[h·mg] / [l],0.29,73230,DB00297,Bupivacaine
,33386432,area under the curve from time 0 to 120 min,The area under the curve from time 0 to 120 min after levobupivacaine administration was significantly higher in the SC group than in the IP group in both experiments (IP: 0.29 [0.10-0.54] mg h/L; SC: 0.78 [0.39-0.98] mg h/L; P = 0.04).,Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),[h·mg] / [l],0.78,73231,DB00297,Bupivacaine
exceed,33386432,Tmax,"On the other hand, when levobupivacaine is given subcutaneously, Tmax can exceed 1 h, so we need to be aware of local anesthetic toxicity during this period.",Pharmacokinetics of intraperitoneal and subcutaneous levobupivacaine in anesthetized rats. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33386432/),h,1,73232,DB00297,Bupivacaine
,7981012,total plasma clearance,3. The total plasma clearance of R(+)-bupivacaine (mean +/- s.d.: 0.395 +/- 0.076 l min-1) was greater (P < 0.0001) than that of S(-)-bupivacaine (0.317 +/- 0.067 l min-1).,Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981012/),[l] / [min],0.395,78734,DB00297,Bupivacaine
,7981012,total plasma clearance,3. The total plasma clearance of R(+)-bupivacaine (mean +/- s.d.: 0.395 +/- 0.076 l min-1) was greater (P < 0.0001) than that of S(-)-bupivacaine (0.317 +/- 0.067 l min-1).,Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981012/),[l] / [min],0.317,78735,DB00297,Bupivacaine
,7981012,volumes of distribution,"The volumes of distribution of R(+)-bupivacaine at steady state (84 +/- 29 l) and during the terminal log-linear phase (117 +/- 47 l) were larger (P < 0.0002) than those of S(-)-bupivacaine (54 +/- 20 l and 71 +/- 34 l, respectively).",Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981012/),l,84,78736,DB00297,Bupivacaine
,7981012,volumes of distribution,"The volumes of distribution of R(+)-bupivacaine at steady state (84 +/- 29 l) and during the terminal log-linear phase (117 +/- 47 l) were larger (P < 0.0002) than those of S(-)-bupivacaine (54 +/- 20 l and 71 +/- 34 l, respectively).",Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981012/),l,117,78737,DB00297,Bupivacaine
,7981012,volumes of distribution,"The volumes of distribution of R(+)-bupivacaine at steady state (84 +/- 29 l) and during the terminal log-linear phase (117 +/- 47 l) were larger (P < 0.0002) than those of S(-)-bupivacaine (54 +/- 20 l and 71 +/- 34 l, respectively).",Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981012/),l,54,78738,DB00297,Bupivacaine
,7981012,volumes of distribution,"The volumes of distribution of R(+)-bupivacaine at steady state (84 +/- 29 l) and during the terminal log-linear phase (117 +/- 47 l) were larger (P < 0.0002) than those of S(-)-bupivacaine (54 +/- 20 l and 71 +/- 34 l, respectively).",Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981012/),l,71,78739,DB00297,Bupivacaine
,7981012,terminal half-life,"The terminal half-life (210 +/- 95 min) and mean residence time (215 +/- 74 min) of R(+)-bupivacaine were longer than those of S(-)-bupivacaine (157 +/- 77 min, P < 0.01, and 172 +/- 55 min, P < 0.02, respectively).",Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981012/),min,210,78740,DB00297,Bupivacaine
,7981012,mean residence time,"The terminal half-life (210 +/- 95 min) and mean residence time (215 +/- 74 min) of R(+)-bupivacaine were longer than those of S(-)-bupivacaine (157 +/- 77 min, P < 0.01, and 172 +/- 55 min, P < 0.02, respectively).",Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981012/),min,215,78741,DB00297,Bupivacaine
,7981012,mean residence time,"The terminal half-life (210 +/- 95 min) and mean residence time (215 +/- 74 min) of R(+)-bupivacaine were longer than those of S(-)-bupivacaine (157 +/- 77 min, P < 0.01, and 172 +/- 55 min, P < 0.02, respectively).",Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981012/),min,157,78742,DB00297,Bupivacaine
,7981012,mean residence time,"The terminal half-life (210 +/- 95 min) and mean residence time (215 +/- 74 min) of R(+)-bupivacaine were longer than those of S(-)-bupivacaine (157 +/- 77 min, P < 0.01, and 172 +/- 55 min, P < 0.02, respectively).",Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981012/),min,172,78743,DB00297,Bupivacaine
,7981012,plasma clearance of unbound,5. The plasma clearance of unbound R(+)-bupivacaine (7.26 +/- 3.60 1 min-1) was smaller (P < 0.01) than that of S(-)-bupivacaine (8.71 +/- 4.27 l min-1).,Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981012/),[1] / [min],7.26,78744,DB00297,Bupivacaine
,7981012,plasma clearance of unbound,5. The plasma clearance of unbound R(+)-bupivacaine (7.26 +/- 3.60 1 min-1) was smaller (P < 0.01) than that of S(-)-bupivacaine (8.71 +/- 4.27 l min-1).,Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981012/),[l] / [min],8.71,78745,DB00297,Bupivacaine
,7981012,Vuss,Volumes of distribution based on unbound R(+)-bupivacaine concentrations (Vuss: 1576 +/- 934 l; Vu: 2233 +/- 1442 l) did not differ from those of S(-)-bupivacaine (Vuss: 1498 +/- 892 l; Vu: 1978 +/- 1302 l).,Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981012/),l,1576,78746,DB00297,Bupivacaine
,7981012,Vu,Volumes of distribution based on unbound R(+)-bupivacaine concentrations (Vuss: 1576 +/- 934 l; Vu: 2233 +/- 1442 l) did not differ from those of S(-)-bupivacaine (Vuss: 1498 +/- 892 l; Vu: 1978 +/- 1302 l).,Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981012/),l,2233,78747,DB00297,Bupivacaine
,7981012,Vuss,Volumes of distribution based on unbound R(+)-bupivacaine concentrations (Vuss: 1576 +/- 934 l; Vu: 2233 +/- 1442 l) did not differ from those of S(-)-bupivacaine (Vuss: 1498 +/- 892 l; Vu: 1978 +/- 1302 l).,Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981012/),l,1498,78748,DB00297,Bupivacaine
,7981012,Vu,Volumes of distribution based on unbound R(+)-bupivacaine concentrations (Vuss: 1576 +/- 934 l; Vu: 2233 +/- 1442 l) did not differ from those of S(-)-bupivacaine (Vuss: 1498 +/- 892 l; Vu: 1978 +/- 1302 l).,Pharmacokinetics of the enantiomers of bupivacaine following intravenous administration of the racemate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7981012/),l,1978,78749,DB00297,Bupivacaine
,11996823,clearance,After i.v. infusion the mean clearance value was 1.53+/-0.53 l/min and the mean elimination half-life was 120.5+/-73.1 min.,Spray-dryed bupivacaine-loaded microspheres: in vitro evaluation and biopharmaceutics of bupivacaine following brachial plexus administration in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996823/),[l] / [min],1.53,79281,DB00297,Bupivacaine
,11996823,elimination half-life,After i.v. infusion the mean clearance value was 1.53+/-0.53 l/min and the mean elimination half-life was 120.5+/-73.1 min.,Spray-dryed bupivacaine-loaded microspheres: in vitro evaluation and biopharmaceutics of bupivacaine following brachial plexus administration in sheep. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996823/),min,120.5,79282,DB00297,Bupivacaine
lower,11996823,C(max),"Following brachial plexus nerve injection, bupivacaine C(max) were lower than 100 ng/ml following either solution or microspheres administration.",Spray-dryed bupivacaine-loaded microspheres: in vitro evaluation and biopharmaceutics of bupivacaine following brachial plexus administration in sheep. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11996823/),[ng] / [ml],100,79283,DB00297,Bupivacaine
,31633607,Cmax,"From the pharmacokinetic parameters obtained, median Cmax, tmax,, and area under the concentration versus time curve were 0.315 mg/L, 17 minutes, and 41 mg/L·min, respectively.",Population Pharmacokinetics of Levobupivacaine During Transversus Abdominis Plane Block in Children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31633607/),[mg] / [l],0.315,79878,DB00297,Bupivacaine
,31633607,tmax,"From the pharmacokinetic parameters obtained, median Cmax, tmax,, and area under the concentration versus time curve were 0.315 mg/L, 17 minutes, and 41 mg/L·min, respectively.",Population Pharmacokinetics of Levobupivacaine During Transversus Abdominis Plane Block in Children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31633607/),min,17,79879,DB00297,Bupivacaine
,31633607,area under the concentration versus time curve,"From the pharmacokinetic parameters obtained, median Cmax, tmax,, and area under the concentration versus time curve were 0.315 mg/L, 17 minutes, and 41 mg/L·min, respectively.",Population Pharmacokinetics of Levobupivacaine During Transversus Abdominis Plane Block in Children. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31633607/),[mg] / [l·min],41,79880,DB00297,Bupivacaine
,7978472,maximum plasma concentrations (Cmax),"There was no significant difference between the maximum plasma concentrations (Cmax) obtained for either drug (ropivacaine 1.1 +/- 0.4 microgram/ml, bupivacaine 0.9 +/- 0.2 microgram/ml, P = 0.39), and there were no toxic signs observed in the obtained plasma concentration ranges.",Pharmacokinetics of ropivacaine and bupivacaine for bilateral intercostal blockade in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978472/),[μg] / [ml],1.1,83126,DB00297,Bupivacaine
,7978472,maximum plasma concentrations (Cmax),"There was no significant difference between the maximum plasma concentrations (Cmax) obtained for either drug (ropivacaine 1.1 +/- 0.4 microgram/ml, bupivacaine 0.9 +/- 0.2 microgram/ml, P = 0.39), and there were no toxic signs observed in the obtained plasma concentration ranges.",Pharmacokinetics of ropivacaine and bupivacaine for bilateral intercostal blockade in healthy male volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978472/),[μg] / [ml],0.9,83127,DB00297,Bupivacaine
,7978472,tmax,"Plasma concentrations tended to peak (tmax) earlier with ropivacaine (21 +/- 9 versus 30 +/- 8 min, P = 0.09).",Pharmacokinetics of ropivacaine and bupivacaine for bilateral intercostal blockade in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978472/),min,21,83128,DB00297,Bupivacaine
,7978472,tmax,"Plasma concentrations tended to peak (tmax) earlier with ropivacaine (21 +/- 9 versus 30 +/- 8 min, P = 0.09).",Pharmacokinetics of ropivacaine and bupivacaine for bilateral intercostal blockade in healthy male volunteers. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978472/),min,30,83129,DB00297,Bupivacaine
,7978472,terminal half-life (t1/2 beta),"The terminal half-life (t1/2 beta) of ropivacaine (2.3 +/- 0.8 h) was significantly less than that for bupivacaine (4.6 +/- 2.6 h, P = 0.04).",Pharmacokinetics of ropivacaine and bupivacaine for bilateral intercostal blockade in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978472/),h,2.3,83130,DB00297,Bupivacaine
,7978472,terminal half-life (t1/2 beta),"The terminal half-life (t1/2 beta) of ropivacaine (2.3 +/- 0.8 h) was significantly less than that for bupivacaine (4.6 +/- 2.6 h, P = 0.04).",Pharmacokinetics of ropivacaine and bupivacaine for bilateral intercostal blockade in healthy male volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978472/),h,4.6,83131,DB00297,Bupivacaine
,8533982,half-life,"Plasma BPV concentration curves after IV administration were adjusted to biexponential kinetics: a rapid distribution phase was followed by a slower elimination phase, with half-life of 34.5 +/- 7.8 minutes.",Bupivacaine disposition and pharmacologic effects after intravenous and epidural administrations in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533982/),min,34.5,83595,DB00297,Bupivacaine
,8533982,plasma clearance,"Mean plasma clearance was 20.2 +/- 7.4 ml/min/kg of body weight, and mean volume of distribution at steady state was 0.7 +/- 0.2 L/kg.",Bupivacaine disposition and pharmacologic effects after intravenous and epidural administrations in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533982/),[ml] / [kg·min],20.2,83596,DB00297,Bupivacaine
,8533982,volume of distribution at steady state,"Mean plasma clearance was 20.2 +/- 7.4 ml/min/kg of body weight, and mean volume of distribution at steady state was 0.7 +/- 0.2 L/kg.",Bupivacaine disposition and pharmacologic effects after intravenous and epidural administrations in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533982/),[l] / [kg],0.7,83597,DB00297,Bupivacaine
,8533982,Peak plasma concentration,"Peak plasma concentration, 1.4 +/- 0.4 microgram/ml, was detected approximately 5 minutes after BPV administration.",Bupivacaine disposition and pharmacologic effects after intravenous and epidural administrations in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533982/),[μg] / [ml],1.4,83598,DB00297,Bupivacaine
,8533982,half-life,"The half-life corresponding to epidural administration (179 +/- 33.6 minutes) was 5 to 6 times longer than that observed after IV administration, possibly because of the slow release of BPV from the epidural space.",Bupivacaine disposition and pharmacologic effects after intravenous and epidural administrations in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533982/),min,179,83599,DB00297,Bupivacaine
,8533982,Induction times,Induction times were short (2.3 +/- 2.2 minutes); anesthesia quickly began and lasted for more than 2 hours (158 +/- 48.8 minutes).,Bupivacaine disposition and pharmacologic effects after intravenous and epidural administrations in dogs. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533982/),min,2.3,83600,DB00297,Bupivacaine
,8533982,plasma concentration,"During that period, BPV plasma concentration ranged between 1.4 and 0.2 microgram/ml.",Bupivacaine disposition and pharmacologic effects after intravenous and epidural administrations in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8533982/),,1.4 and 0.2,83601,DB00297,Bupivacaine
,1869600,t1/2a,The plasma levels versus time corresponded to a biexponential process with a very rapid distribution phase (t1/2a = 5.7 +/- 2.4 min) and an elimination phase (t1/2 beta = 66 +/- 37 min).,Pharmacokinetics of intravenous midazolam during epidural anaesthesia. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1869600/),min,5.7,83746,DB00297,Bupivacaine
,1869600,t1/2 beta,The plasma levels versus time corresponded to a biexponential process with a very rapid distribution phase (t1/2a = 5.7 +/- 2.4 min) and an elimination phase (t1/2 beta = 66 +/- 37 min).,Pharmacokinetics of intravenous midazolam during epidural anaesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1869600/),min,66,83747,DB00297,Bupivacaine
,1869600,Vc,Mean values for distribution volumes in the central compartment and extrapolated values were Vc = 0.12 +/- 0.04 l/kg and V beta = 1.28 +/- 0.92 l/kg.,Pharmacokinetics of intravenous midazolam during epidural anaesthesia. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1869600/),[l] / [kg],0.12,83748,DB00297,Bupivacaine
,1869600,V beta,Mean values for distribution volumes in the central compartment and extrapolated values were Vc = 0.12 +/- 0.04 l/kg and V beta = 1.28 +/- 0.92 l/kg.,Pharmacokinetics of intravenous midazolam during epidural anaesthesia. ,Vb-Q62,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1869600/),[l] / [kg],1.28,83749,DB00297,Bupivacaine
,1869600,induction time,"The induction time, estimated from the start of hypnosis (eye closure), was from 60 to 120 s with i.v. injection.",Pharmacokinetics of intravenous midazolam during epidural anaesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1869600/),s,60 to 120,83750,DB00297,Bupivacaine
,9448069,flow-rate,"The mobile phase consisted of methanol-acetonitrile-50 mM monobasic ammonium phosphate (5:7:63, v/v/v) and was maintained at a flow-rate of 0.4 ml/min.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),[ml] / [min],0.4,90866,DB00297,Bupivacaine
,9448069,absolute extraction efficiencies,"The absolute extraction efficiencies for BE, COC, NC, CE and bupivacaine were 56.6%, 78.6%, 61.1%, 76.4% and 67.0%, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),%,56.6,90867,DB00297,Bupivacaine
,9448069,absolute extraction efficiencies,"The absolute extraction efficiencies for BE, COC, NC, CE and bupivacaine were 56.6%, 78.6%, 61.1%, 76.4% and 67.0%, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),%,78.6,90868,DB00297,Bupivacaine
,9448069,absolute extraction efficiencies,"The absolute extraction efficiencies for BE, COC, NC, CE and bupivacaine were 56.6%, 78.6%, 61.1%, 76.4% and 67.0%, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),%,61.1,90869,DB00297,Bupivacaine
,9448069,absolute extraction efficiencies,"The absolute extraction efficiencies for BE, COC, NC, CE and bupivacaine were 56.6%, 78.6%, 61.1%, 76.4% and 67.0%, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),%,76.4,90870,DB00297,Bupivacaine
,9448069,absolute extraction efficiencies,"The absolute extraction efficiencies for BE, COC, NC, CE and bupivacaine were 56.6%, 78.6%, 61.1%, 76.4% and 67.0%, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),%,67.0,90871,DB00297,Bupivacaine
,9448069,limits of detection,"The limits of detection for BE, COC, NC and CE were 20, 24, 15 and 12.9 ng/ml, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),[ng] / [ml],20,90872,DB00297,Bupivacaine
,9448069,limits of detection,"The limits of detection for BE, COC, NC and CE were 20, 24, 15 and 12.9 ng/ml, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),[ng] / [ml],24,90873,DB00297,Bupivacaine
,9448069,limits of detection,"The limits of detection for BE, COC, NC and CE were 20, 24, 15 and 12.9 ng/ml, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),[ng] / [ml],15,90874,DB00297,Bupivacaine
,9448069,limits of detection,"The limits of detection for BE, COC, NC and CE were 20, 24, 15 and 12.9 ng/ml, respectively.",Sensitive and specific high-performance liquid chromatographic assay with ultraviolet detection for the determination of cocaine and its metabolites in rat plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9448069/),[ng] / [ml],12.9,90875,DB00297,Bupivacaine
,1911010,clearance,The hepatic clearance of R(+)- was greater than that of S(-)-bupivacaine (P less than 0.05) with mean (SD) clearance at the two respective time periods being 1.37 (0.78) and 1.47 (0.57) litre min-1 and 1.01 (0.72) and 1.29 (0.47) litre min-1.,Cardiovascular effects and regional clearances of i.v. bupivacaine in sheep: enantiomeric analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911010/),[l] / [min],1.37,91642,DB00297,Bupivacaine
,1911010,clearance,The hepatic clearance of R(+)- was greater than that of S(-)-bupivacaine (P less than 0.05) with mean (SD) clearance at the two respective time periods being 1.37 (0.78) and 1.47 (0.57) litre min-1 and 1.01 (0.72) and 1.29 (0.47) litre min-1.,Cardiovascular effects and regional clearances of i.v. bupivacaine in sheep: enantiomeric analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911010/),[l] / [min],1.47,91643,DB00297,Bupivacaine
,1911010,clearance,The hepatic clearance of R(+)- was greater than that of S(-)-bupivacaine (P less than 0.05) with mean (SD) clearance at the two respective time periods being 1.37 (0.78) and 1.47 (0.57) litre min-1 and 1.01 (0.72) and 1.29 (0.47) litre min-1.,Cardiovascular effects and regional clearances of i.v. bupivacaine in sheep: enantiomeric analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911010/),[l] / [min],1.01,91644,DB00297,Bupivacaine
,1911010,clearance,The hepatic clearance of R(+)- was greater than that of S(-)-bupivacaine (P less than 0.05) with mean (SD) clearance at the two respective time periods being 1.37 (0.78) and 1.47 (0.57) litre min-1 and 1.01 (0.72) and 1.29 (0.47) litre min-1.,Cardiovascular effects and regional clearances of i.v. bupivacaine in sheep: enantiomeric analysis. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911010/),[l] / [min],1.29,91645,DB00297,Bupivacaine
,7614654,maximal concentration in serum (Cmax,"The maximal concentration in serum (Cmax, 2.553 +/- 0.862 micrograms.ml-1 versus 0.962 +/- 0.141 microgram.ml01 for Groups 2 and 1, respectively, P = 0.01) and the area under the concentration curve (AUC, 3.530 +/- 0.330 micrograms.ml-1.hr-1 versus 1.755 +/- 0.252 micrograms.ml-1.hr-1 for Groups 2 and 1, respectively, P < 0.01) of bupivacaine were higher in clonidine pretreated mice while the Clearance (Cl) was decreased in clonidine pretreated animals (0.603 +/- 0.054 micrograms.ml-1 versus 1.264 +/- 0.447 micrograms.ml-1 for Groups 2 and 1, respectively, P < 0.01).",Kinetics of bupivacaine after clonidine pretreatment in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614654/),[μg] / [ml],2.553,93265,DB00297,Bupivacaine
,7614654,maximal concentration in serum (Cmax,"The maximal concentration in serum (Cmax, 2.553 +/- 0.862 micrograms.ml-1 versus 0.962 +/- 0.141 microgram.ml01 for Groups 2 and 1, respectively, P = 0.01) and the area under the concentration curve (AUC, 3.530 +/- 0.330 micrograms.ml-1.hr-1 versus 1.755 +/- 0.252 micrograms.ml-1.hr-1 for Groups 2 and 1, respectively, P < 0.01) of bupivacaine were higher in clonidine pretreated mice while the Clearance (Cl) was decreased in clonidine pretreated animals (0.603 +/- 0.054 micrograms.ml-1 versus 1.264 +/- 0.447 micrograms.ml-1 for Groups 2 and 1, respectively, P < 0.01).",Kinetics of bupivacaine after clonidine pretreatment in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614654/),ml01·μg,0.962,93266,DB00297,Bupivacaine
,7614654,area under the concentration curve (AUC,"The maximal concentration in serum (Cmax, 2.553 +/- 0.862 micrograms.ml-1 versus 0.962 +/- 0.141 microgram.ml01 for Groups 2 and 1, respectively, P = 0.01) and the area under the concentration curve (AUC, 3.530 +/- 0.330 micrograms.ml-1.hr-1 versus 1.755 +/- 0.252 micrograms.ml-1.hr-1 for Groups 2 and 1, respectively, P < 0.01) of bupivacaine were higher in clonidine pretreated mice while the Clearance (Cl) was decreased in clonidine pretreated animals (0.603 +/- 0.054 micrograms.ml-1 versus 1.264 +/- 0.447 micrograms.ml-1 for Groups 2 and 1, respectively, P < 0.01).",Kinetics of bupivacaine after clonidine pretreatment in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614654/),[μg] / [h·ml],3.530,93267,DB00297,Bupivacaine
,7614654,area under the concentration curve (AUC,"The maximal concentration in serum (Cmax, 2.553 +/- 0.862 micrograms.ml-1 versus 0.962 +/- 0.141 microgram.ml01 for Groups 2 and 1, respectively, P = 0.01) and the area under the concentration curve (AUC, 3.530 +/- 0.330 micrograms.ml-1.hr-1 versus 1.755 +/- 0.252 micrograms.ml-1.hr-1 for Groups 2 and 1, respectively, P < 0.01) of bupivacaine were higher in clonidine pretreated mice while the Clearance (Cl) was decreased in clonidine pretreated animals (0.603 +/- 0.054 micrograms.ml-1 versus 1.264 +/- 0.447 micrograms.ml-1 for Groups 2 and 1, respectively, P < 0.01).",Kinetics of bupivacaine after clonidine pretreatment in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614654/),[μg] / [h·ml],1.755,93268,DB00297,Bupivacaine
,7614654,Clearance (Cl),"The maximal concentration in serum (Cmax, 2.553 +/- 0.862 micrograms.ml-1 versus 0.962 +/- 0.141 microgram.ml01 for Groups 2 and 1, respectively, P = 0.01) and the area under the concentration curve (AUC, 3.530 +/- 0.330 micrograms.ml-1.hr-1 versus 1.755 +/- 0.252 micrograms.ml-1.hr-1 for Groups 2 and 1, respectively, P < 0.01) of bupivacaine were higher in clonidine pretreated mice while the Clearance (Cl) was decreased in clonidine pretreated animals (0.603 +/- 0.054 micrograms.ml-1 versus 1.264 +/- 0.447 micrograms.ml-1 for Groups 2 and 1, respectively, P < 0.01).",Kinetics of bupivacaine after clonidine pretreatment in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614654/),[μg] / [ml],0.603,93269,DB00297,Bupivacaine
,7614654,Clearance (Cl),"The maximal concentration in serum (Cmax, 2.553 +/- 0.862 micrograms.ml-1 versus 0.962 +/- 0.141 microgram.ml01 for Groups 2 and 1, respectively, P = 0.01) and the area under the concentration curve (AUC, 3.530 +/- 0.330 micrograms.ml-1.hr-1 versus 1.755 +/- 0.252 micrograms.ml-1.hr-1 for Groups 2 and 1, respectively, P < 0.01) of bupivacaine were higher in clonidine pretreated mice while the Clearance (Cl) was decreased in clonidine pretreated animals (0.603 +/- 0.054 micrograms.ml-1 versus 1.264 +/- 0.447 micrograms.ml-1 for Groups 2 and 1, respectively, P < 0.01).",Kinetics of bupivacaine after clonidine pretreatment in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614654/),[μg] / [ml],1.264,93270,DB00297,Bupivacaine
,7614654,ratio,"The ratio of AUC PPX/AUC bupivacaine (which may partially indicate the rate of metabolism) was lower in presence of clonidine (0.220 +/- 0.019 against 0.425 +/- 0.033 for Groups 2 and 1, respectively, P < 0.01).",Kinetics of bupivacaine after clonidine pretreatment in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614654/),,0.220,93271,DB00297,Bupivacaine
,7614654,ratio,"The ratio of AUC PPX/AUC bupivacaine (which may partially indicate the rate of metabolism) was lower in presence of clonidine (0.220 +/- 0.019 against 0.425 +/- 0.033 for Groups 2 and 1, respectively, P < 0.01).",Kinetics of bupivacaine after clonidine pretreatment in mice. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7614654/),,0.425,93272,DB00297,Bupivacaine
,2929998,maximum bupivacaine plasma concentration,"The maximum bupivacaine plasma concentration was 0.89 +/- 0.37 microgram/ml, obtained 24.4 +/- 12.6 min after the end of the injection.",Femoral nerve blockade in children using bupivacaine. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2929998/),[μg] / [ml],0.89,94821,DB00297,Bupivacaine
,22352703,half-life,Intravenous lipid emulsion infusion reduced the context-sensitive half-life of total plasma bupivacaine from 45 (95% CI 32-76)min to 25 (95% CI 20-33)min; p=0.01.,Effect of intravenous lipid emulsion on bupivacaine plasma concentration in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22352703/),min,45,97801,DB00297,Bupivacaine
,22352703,half-life,Intravenous lipid emulsion infusion reduced the context-sensitive half-life of total plasma bupivacaine from 45 (95% CI 32-76)min to 25 (95% CI 20-33)min; p=0.01.,Effect of intravenous lipid emulsion on bupivacaine plasma concentration in humans. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/22352703/),min,25,97802,DB00297,Bupivacaine
,10360857,maximum concentrations,"The maximum concentrations were 1.017 and 1.053 microg/ml, and the areas were 4.082 and 3.765 h(microg/ml) for the levobupivacaine and bupivacaine groups, respectively.",Clinical effects and maternal and fetal plasma concentrations of 0.5% epidural levobupivacaine versus bupivacaine for cesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360857/),[μg] / [ml],1.017,99171,DB00297,Bupivacaine
,10360857,maximum concentrations,"The maximum concentrations were 1.017 and 1.053 microg/ml, and the areas were 4.082 and 3.765 h(microg/ml) for the levobupivacaine and bupivacaine groups, respectively.",Clinical effects and maternal and fetal plasma concentrations of 0.5% epidural levobupivacaine versus bupivacaine for cesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360857/),[μg] / [ml],1.053,99172,DB00297,Bupivacaine
,10360857,areas,"The maximum concentrations were 1.017 and 1.053 microg/ml, and the areas were 4.082 and 3.765 h(microg/ml) for the levobupivacaine and bupivacaine groups, respectively.",Clinical effects and maternal and fetal plasma concentrations of 0.5% epidural levobupivacaine versus bupivacaine for cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360857/),[h(μg] / [ml],4.082,99173,DB00297,Bupivacaine
,10360857,areas,"The maximum concentrations were 1.017 and 1.053 microg/ml, and the areas were 4.082 and 3.765 h(microg/ml) for the levobupivacaine and bupivacaine groups, respectively.",Clinical effects and maternal and fetal plasma concentrations of 0.5% epidural levobupivacaine versus bupivacaine for cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360857/),[h(μg] / [ml],3.765,99174,DB00297,Bupivacaine
,10360857,Um,Umbilical vein-to-maternal vein ratios were 0.303 for the levobupivacaine group and 0.254 for the bupivacaine group.,Clinical effects and maternal and fetal plasma concentrations of 0.5% epidural levobupivacaine versus bupivacaine for cesarean delivery. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360857/),,0.303,99175,DB00297,Bupivacaine
,10360857,Um,Umbilical vein-to-maternal vein ratios were 0.303 for the levobupivacaine group and 0.254 for the bupivacaine group.,Clinical effects and maternal and fetal plasma concentrations of 0.5% epidural levobupivacaine versus bupivacaine for cesarean delivery. ,Q-Q54,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10360857/),,0.254,99176,DB00297,Bupivacaine
,3189894,maximum arterial concentrations (Cmax),"After 15-minute IV infusions of 3.0 mg/kg ropivacaine (n = 6) and 3.4 mg/kg bupivacaine (n = 4), the maximum arterial concentrations (Cmax) of ropivacaine averaged 2.41 +/- 0.52 micrograms/ml compared with 3.35 +/- 0.16 micrograms/ml of bupivacaine.","Comparative pharmacokinetics of bupivacaine and ropivacaine, a new amide local anesthetic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189894/),[μg] / [ml],2.41,99510,DB00297,Bupivacaine
,3189894,maximum arterial concentrations (Cmax),"After 15-minute IV infusions of 3.0 mg/kg ropivacaine (n = 6) and 3.4 mg/kg bupivacaine (n = 4), the maximum arterial concentrations (Cmax) of ropivacaine averaged 2.41 +/- 0.52 micrograms/ml compared with 3.35 +/- 0.16 micrograms/ml of bupivacaine.","Comparative pharmacokinetics of bupivacaine and ropivacaine, a new amide local anesthetic. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189894/),[μg] / [ml],3.35,99511,DB00297,Bupivacaine
,3189894,elimination half life (t 1/2 beta),The elimination half life (t 1/2 beta) of ropivacaine (25.9 +/- 1.7 min) was significantly shorter than for bupivacaine (39.1 +/- 13.3 min) after IV infusion.,"Comparative pharmacokinetics of bupivacaine and ropivacaine, a new amide local anesthetic. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189894/),min,25.9,99512,DB00297,Bupivacaine
,3189894,elimination half life (t 1/2 beta),The elimination half life (t 1/2 beta) of ropivacaine (25.9 +/- 1.7 min) was significantly shorter than for bupivacaine (39.1 +/- 13.3 min) after IV infusion.,"Comparative pharmacokinetics of bupivacaine and ropivacaine, a new amide local anesthetic. ","t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189894/),min,39.1,99513,DB00297,Bupivacaine
,3189894,clearance values (Cl),"This was reflected by mean clearance values (Cl) for ropivacaine of 41.1 +/- 8.2 ml.min-1.kg-1 compared with 32.3 +/- 4.8 ml.min-1.kg-1 for bupivacaine, although the difference was not statistically significant.","Comparative pharmacokinetics of bupivacaine and ropivacaine, a new amide local anesthetic. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189894/),[ml] / [kg·min],41.1,99514,DB00297,Bupivacaine
,3189894,clearance values (Cl),"This was reflected by mean clearance values (Cl) for ropivacaine of 41.1 +/- 8.2 ml.min-1.kg-1 compared with 32.3 +/- 4.8 ml.min-1.kg-1 for bupivacaine, although the difference was not statistically significant.","Comparative pharmacokinetics of bupivacaine and ropivacaine, a new amide local anesthetic. ",CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3189894/),[ml] / [kg·min],32.3,99515,DB00297,Bupivacaine
,29923955,Total,"Total and free maximum plasma levobupivacaine concentrations were lower in the lipid group than in control subjects (865 ± 98 vs 1145 ± 177 μg/L and 56.8 ± 7.5 vs 78.2 ± 13.7 μg/L, respectively; P < 0.01).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),[μg] / [l],865,100387,DB00297,Bupivacaine
,29923955,Total,"Total and free maximum plasma levobupivacaine concentrations were lower in the lipid group than in control subjects (865 ± 98 vs 1145 ± 177 μg/L and 56.8 ± 7.5 vs 78.2 ± 13.7 μg/L, respectively; P < 0.01).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),[μg] / [l],1145,100388,DB00297,Bupivacaine
,29923955,free maximum plasma levobupivacaine,"Total and free maximum plasma levobupivacaine concentrations were lower in the lipid group than in control subjects (865 ± 98 vs 1145 ± 177 μg/L and 56.8 ± 7.5 vs 78.2 ± 13.7 μg/L, respectively; P < 0.01).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),[μg] / [l],56.8,100389,DB00297,Bupivacaine
,29923955,concentrations,"Total and free maximum plasma levobupivacaine concentrations were lower in the lipid group than in control subjects (865 ± 98 vs 1145 ± 177 μg/L and 56.8 ± 7.5 vs 78.2 ± 13.7 μg/L, respectively; P < 0.01).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),[μg] / [l],1145,100390,DB00297,Bupivacaine
,29923955,concentrations,"Total and free maximum plasma levobupivacaine concentrations were lower in the lipid group than in control subjects (865 ± 98 vs 1145 ± 177 μg/L and 56.8 ± 7.5 vs 78.2 ± 13.7 μg/L, respectively; P < 0.01).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),[μg] / [l],56.8,100391,DB00297,Bupivacaine
,29923955,concentrations,"Total and free maximum plasma levobupivacaine concentrations were lower in the lipid group than in control subjects (865 ± 98 vs 1145 ± 177 μg/L and 56.8 ± 7.5 vs 78.2 ± 13.7 μg/L, respectively; P < 0.01).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),[μg] / [l],78.2,100392,DB00297,Bupivacaine
,29923955,Apparent volume of distribution,"Apparent volume of distribution and clearance were higher in the lipid group than in control subjects (211 ± 35 vs 170 ± 21 L and 35.1 ± 8.0 vs 25.8 ± 2.6 L/h, respectively; P < 0.05).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),l,211,100393,DB00297,Bupivacaine
,29923955,Apparent volume of distribution,"Apparent volume of distribution and clearance were higher in the lipid group than in control subjects (211 ± 35 vs 170 ± 21 L and 35.1 ± 8.0 vs 25.8 ± 2.6 L/h, respectively; P < 0.05).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),l,170,100394,DB00297,Bupivacaine
,29923955,clearance,"Apparent volume of distribution and clearance were higher in the lipid group than in control subjects (211 ± 35 vs 170 ± 21 L and 35.1 ± 8.0 vs 25.8 ± 2.6 L/h, respectively; P < 0.05).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),l,170,100395,DB00297,Bupivacaine
,29923955,clearance,"Apparent volume of distribution and clearance were higher in the lipid group than in control subjects (211 ± 35 vs 170 ± 21 L and 35.1 ± 8.0 vs 25.8 ± 2.6 L/h, respectively; P < 0.05).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),[l] / [h],35.1,100396,DB00297,Bupivacaine
,29923955,clearance,"Apparent volume of distribution and clearance were higher in the lipid group than in control subjects (211 ± 35 vs 170 ± 21 L and 35.1 ± 8.0 vs 25.8 ± 2.6 L/h, respectively; P < 0.05).",Lipid Emulsion Pretreatment Decreased the Maximum Total and Free Plasma Concentration of Levobupivacaine for Femoral and Sciatic Nerve Block in Below-Knee Fracture Surgery. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29923955/),[l] / [h],25.8,100397,DB00297,Bupivacaine
,15321929,fraction absorbed (F(1)),"The fraction absorbed (F(1)) was 0.07 (95% CI: 0.02-013) smaller and the absorption half-life (t(1/2,a1)), characterizing the initial fast absorption phase, 3.6 min (95% CI: 0.8-6.4) shorter in the oldest group compared with the youngest group.",Effect of age on the clinical profile and systemic absorption and disposition of levobupivacaine after epidural administration. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15321929/),,0.07,102575,DB00297,Bupivacaine
,15321929,"absorption half-life (t(1/2,a1))","The fraction absorbed (F(1)) was 0.07 (95% CI: 0.02-013) smaller and the absorption half-life (t(1/2,a1)), characterizing the initial fast absorption phase, 3.6 min (95% CI: 0.8-6.4) shorter in the oldest group compared with the youngest group.",Effect of age on the clinical profile and systemic absorption and disposition of levobupivacaine after epidural administration. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15321929/),min,3.6,102576,DB00297,Bupivacaine
,10407475,half-life,"After i.v. administration, plasma concentration versus time curves were adjusted, using biexponential equations that indicated a rapid distribution phase followed by a slower elimination phase, with a mean +/- SD half-life of 33.5 +/- 17.0 minutes.",Pharmacokinetics and pharmacologic effects of the S(-) isomer of bupivacaine after intravenous and epidural administration in dogs. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10407475/),min,33.5,106454,DB00297,Bupivacaine
,10407475,plasma clearance,"Mean plasma clearance was 21.0 +/- 10.7 ml/min/kg, and mean volume of distribution at steady state was 0.8 +/- 0.2 L/kg.",Pharmacokinetics and pharmacologic effects of the S(-) isomer of bupivacaine after intravenous and epidural administration in dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10407475/),[ml] / [kg·min],21.0,106455,DB00297,Bupivacaine
,10407475,volume of distribution at steady state,"Mean plasma clearance was 21.0 +/- 10.7 ml/min/kg, and mean volume of distribution at steady state was 0.8 +/- 0.2 L/kg.",Pharmacokinetics and pharmacologic effects of the S(-) isomer of bupivacaine after intravenous and epidural administration in dogs. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10407475/),[l] / [kg],0.8,106456,DB00297,Bupivacaine
,10407475,peak plasma concentration,"After i.v. administration, mean peak plasma concentration was 2.6 +/- 0.7 micrograms/ml; after epidural administration, it was 0.9 +/- 0.5 microgram/ml at approximately 3 minutes.",Pharmacokinetics and pharmacologic effects of the S(-) isomer of bupivacaine after intravenous and epidural administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10407475/),[μg] / [ml],2.6,106457,DB00297,Bupivacaine
,10407475,peak plasma concentration,"After i.v. administration, mean peak plasma concentration was 2.6 +/- 0.7 micrograms/ml; after epidural administration, it was 0.9 +/- 0.5 microgram/ml at approximately 3 minutes.",Pharmacokinetics and pharmacologic effects of the S(-) isomer of bupivacaine after intravenous and epidural administration in dogs. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10407475/),[μg] / [ml],0.9,106458,DB00297,Bupivacaine
,18806025,Cmax,Median (range) levobupivacaine Cmax and Tmax measured were 1.48 (0.62-2.40) microg/mL and 37 (10-60) min.,Pharmacokinetics of levobupivacaine (2.5 mg/kg) after caudal administration in children younger than 3 years. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806025/),[μg] / [ml],1.48,106980,DB00297,Bupivacaine
,18806025,Tmax,Median (range) levobupivacaine Cmax and Tmax measured were 1.48 (0.62-2.40) microg/mL and 37 (10-60) min.,Pharmacokinetics of levobupivacaine (2.5 mg/kg) after caudal administration in children younger than 3 years. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18806025/),min,37,106981,DB00297,Bupivacaine
,605767,extraction ratio,"While the splanchnic extraction ratio decreased during infusion of bupivacaine to 0.41 +/- 0.13, the same variable did not change (0.76 +/- 0.07) when etidocaine was infused.",Splanchnic elimination and systemic toxicity of bupivacaine and etidocaine in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/605767/),,0.41,110161,DB00297,Bupivacaine
,605767,extraction ratio,"While the splanchnic extraction ratio decreased during infusion of bupivacaine to 0.41 +/- 0.13, the same variable did not change (0.76 +/- 0.07) when etidocaine was infused.",Splanchnic elimination and systemic toxicity of bupivacaine and etidocaine in man. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/605767/),,0.76,110162,DB00297,Bupivacaine
,605767,s,"After 150 min infusion, the splanchnic clearance of bupivacaine and etidocaine was 0.76 +/- 0.27 and 1.32 +/- 0.21 1.min-1, respectively.",Splanchnic elimination and systemic toxicity of bupivacaine and etidocaine in man. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/605767/),[1] / [min],0.76,110163,DB00297,Bupivacaine
,605767,s,"After 150 min infusion, the splanchnic clearance of bupivacaine and etidocaine was 0.76 +/- 0.27 and 1.32 +/- 0.21 1.min-1, respectively.",Splanchnic elimination and systemic toxicity of bupivacaine and etidocaine in man. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/605767/),[1] / [min],1.32,110164,DB00297,Bupivacaine
,605767,clearance,"After 150 min infusion, the splanchnic clearance of bupivacaine and etidocaine was 0.76 +/- 0.27 and 1.32 +/- 0.21 1.min-1, respectively.",Splanchnic elimination and systemic toxicity of bupivacaine and etidocaine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/605767/),[1] / [min],0.76,110165,DB00297,Bupivacaine
,605767,clearance,"After 150 min infusion, the splanchnic clearance of bupivacaine and etidocaine was 0.76 +/- 0.27 and 1.32 +/- 0.21 1.min-1, respectively.",Splanchnic elimination and systemic toxicity of bupivacaine and etidocaine in man. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/605767/),[1] / [min],1.32,110166,DB00297,Bupivacaine
,19151302,onset,The onset of bupivacaine-lidocaine was 16 +/- 9 min versus 28 +/- 12 min for bupivacaine alone.,"A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151302/),min,16,110784,DB00297,Bupivacaine
,19151302,onset,The onset of bupivacaine-lidocaine was 16 +/- 9 min versus 28 +/- 12 min for bupivacaine alone.,"A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151302/),min,28,110785,DB00297,Bupivacaine
,19151302,onset,The onset of ropivacaine-lidocaine was 16 +/- 12 min versus 23 +/- 12 for ropivacaine alone.,"A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151302/),min,16,110786,DB00297,Bupivacaine
,19151302,onset,The onset of ropivacaine-lidocaine was 16 +/- 12 min versus 23 +/- 12 for ropivacaine alone.,"A comparison of the pharmacodynamics and pharmacokinetics of bupivacaine, ropivacaine (with epinephrine) and their equal volume mixtures with lidocaine used for femoral and sciatic nerve blocks: a double-blind randomized study. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19151302/),,23,110787,DB00297,Bupivacaine
,3729087,greatest concentrations,The greatest concentrations observed between 15 and 30 min after the injection were of 2.40 +/- 0.86 micrograms .,[Plasma determination of lidocaine and bupivacaine after caudal anesthesia in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3729087/),μg,2.40,114322,DB00297,Bupivacaine
,3584862,half life of distribution through the circulation,The half life of distribution through the circulation has been worked out at 4 minutes and the half for elimination of the drug at 460 minutes.,[Fentanyl in peridural obstetrical analgesia. Evaluation after 4 years' use]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3584862/),min,4,114873,DB00297,Bupivacaine
,3584862,half for elimination,The half life of distribution through the circulation has been worked out at 4 minutes and the half for elimination of the drug at 460 minutes.,[Fentanyl in peridural obstetrical analgesia. Evaluation after 4 years' use]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3584862/),min,460,114874,DB00297,Bupivacaine
,7547659,maximum plasma concentrations,"Celiac plexus block resulted in maximum plasma concentrations of 0.7-2.5 mg/L bupivacaine (mean, 1.5 +/- 0.6 mg/L).",Plasma concentrations of bupivacaine in celiac plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7547659/),[mg] / [l],0.7-2.5,116012,DB00297,Bupivacaine
,7547659,maximum plasma concentrations,"Celiac plexus block resulted in maximum plasma concentrations of 0.7-2.5 mg/L bupivacaine (mean, 1.5 +/- 0.6 mg/L).",Plasma concentrations of bupivacaine in celiac plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7547659/),[mg] / [l],1.5,116013,DB00297,Bupivacaine
,10391601,AUC,"Gastric emptying rates were reduced in both group 1 (AUC = 14.98 (3.8) and 11.05 (4.6) pre- and postoperatively, respectively) and group 2 (AUC = 13.93 (3.59) and 6.4 (3.42) pre- and postoperatively, respectively); the magnitude of the reduction was greater in group 2 [AUC (P = 0.04), Cmax (P = 0.05), tCmax (P = 0.13)].",Delayed postoperative gastric emptying following intrathecal morphine and intrathecal bupivacaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391601/),,14.98,116251,DB00297,Bupivacaine
,10391601,AUC,"Gastric emptying rates were reduced in both group 1 (AUC = 14.98 (3.8) and 11.05 (4.6) pre- and postoperatively, respectively) and group 2 (AUC = 13.93 (3.59) and 6.4 (3.42) pre- and postoperatively, respectively); the magnitude of the reduction was greater in group 2 [AUC (P = 0.04), Cmax (P = 0.05), tCmax (P = 0.13)].",Delayed postoperative gastric emptying following intrathecal morphine and intrathecal bupivacaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391601/),,11.05,116252,DB00297,Bupivacaine
,10391601,AUC,"Gastric emptying rates were reduced in both group 1 (AUC = 14.98 (3.8) and 11.05 (4.6) pre- and postoperatively, respectively) and group 2 (AUC = 13.93 (3.59) and 6.4 (3.42) pre- and postoperatively, respectively); the magnitude of the reduction was greater in group 2 [AUC (P = 0.04), Cmax (P = 0.05), tCmax (P = 0.13)].",Delayed postoperative gastric emptying following intrathecal morphine and intrathecal bupivacaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391601/),,13.93,116253,DB00297,Bupivacaine
,10391601,AUC,"Gastric emptying rates were reduced in both group 1 (AUC = 14.98 (3.8) and 11.05 (4.6) pre- and postoperatively, respectively) and group 2 (AUC = 13.93 (3.59) and 6.4 (3.42) pre- and postoperatively, respectively); the magnitude of the reduction was greater in group 2 [AUC (P = 0.04), Cmax (P = 0.05), tCmax (P = 0.13)].",Delayed postoperative gastric emptying following intrathecal morphine and intrathecal bupivacaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10391601/),,6.4,116254,DB00297,Bupivacaine
,3421499,terminal half-life (T1/2Z),"The terminal half-life (T1/2Z) of bupivacaine increased after the PI compared with the SI, 167 +/- 86 vs 53 +/- 13 min, respectively (mean +/- SD; P less than 0.05), and total body clearance (Cl) decreased, 3.4 +/- 1.2 vs 9.5 +/- 4.5 ml.min-1.kg-1, (P less than 0.05), although the volumes of distribution (VZ and VSS) did not change.",Pharmacokinetics of bupivacaine after short and prolonged infusions in conscious dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3421499/),min,167,116515,DB00297,Bupivacaine
,3421499,terminal half-life (T1/2Z),"The terminal half-life (T1/2Z) of bupivacaine increased after the PI compared with the SI, 167 +/- 86 vs 53 +/- 13 min, respectively (mean +/- SD; P less than 0.05), and total body clearance (Cl) decreased, 3.4 +/- 1.2 vs 9.5 +/- 4.5 ml.min-1.kg-1, (P less than 0.05), although the volumes of distribution (VZ and VSS) did not change.",Pharmacokinetics of bupivacaine after short and prolonged infusions in conscious dogs. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3421499/),min,53,116516,DB00297,Bupivacaine
,3421499,total body clearance (Cl),"The terminal half-life (T1/2Z) of bupivacaine increased after the PI compared with the SI, 167 +/- 86 vs 53 +/- 13 min, respectively (mean +/- SD; P less than 0.05), and total body clearance (Cl) decreased, 3.4 +/- 1.2 vs 9.5 +/- 4.5 ml.min-1.kg-1, (P less than 0.05), although the volumes of distribution (VZ and VSS) did not change.",Pharmacokinetics of bupivacaine after short and prolonged infusions in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3421499/),[ml] / [kg·min],3.4,116517,DB00297,Bupivacaine
,3421499,total body clearance (Cl),"The terminal half-life (T1/2Z) of bupivacaine increased after the PI compared with the SI, 167 +/- 86 vs 53 +/- 13 min, respectively (mean +/- SD; P less than 0.05), and total body clearance (Cl) decreased, 3.4 +/- 1.2 vs 9.5 +/- 4.5 ml.min-1.kg-1, (P less than 0.05), although the volumes of distribution (VZ and VSS) did not change.",Pharmacokinetics of bupivacaine after short and prolonged infusions in conscious dogs. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3421499/),[ml] / [kg·min],9.5,116518,DB00297,Bupivacaine
,23394846,duration of,The duration of anaesthesia was 86.9 ± 66.0 min with the LIDO-BUPI combination.,"Comparing lidocaine, bupivacaine and a lidocaine-bupivacaine mixture as a metacarpal block in sheep. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23394846/),min,86.9,117304,DB00297,Bupivacaine
,1931477,steady-state plasma bupivacaine concentration,"The mean measured steady-state plasma bupivacaine concentration was 2.1 mg l-1 (s.d. +/- 0.54, range 1.3-3.2 mg l-1).",The disposition of bupivacaine following a 72 h interpleural infusion in cholecystectomy patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1931477/),[mg] / [l],2.1,120324,DB00297,Bupivacaine
,1931477,systemic clearance,"No statistically significant differences were noted and, in particular, the systemic clearance of bupivacaine (mean 10.2 l h-1 s.d +/- 3.0; range 6.3-16.0 1 h-1) remained unchanged following the long-term interpleural infusion.",The disposition of bupivacaine following a 72 h interpleural infusion in cholecystectomy patients. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1931477/),[l] / [h],10.2,120325,DB00297,Bupivacaine
,2400142,Pain score,Pain score recorded with an visual analogue scale was 5.0 +/- 1.9 before femoral block.,[Continuous block of the femoral nerve after surgery of the knee: pharmacokinetics of bupivacaine]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400142/),,5.0,124815,DB00297,Bupivacaine
,2400142,level at steady state,Mean plasma bupivacaine level at steady state was 1.78 +/- 0.59 micrograms.,[Continuous block of the femoral nerve after surgery of the knee: pharmacokinetics of bupivacaine]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400142/),μg,1.78,124816,DB00297,Bupivacaine
,2400142,Clearance,Clearance of bupivacaine was 2.59 +/- 0.91 ml.min-1.kg-1.,[Continuous block of the femoral nerve after surgery of the knee: pharmacokinetics of bupivacaine]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2400142/),[ml] / [kg·min],2.59,124817,DB00297,Bupivacaine
,11093399,peak venous plasma concentration,"The aqueous solution was absorbed rapidly and the mean (sd) peak venous plasma concentration of bupivacaine, 1.4 (0.4) microg/ml, was detected after five minutes.",Prolongation of epidural anaesthesia in dogs with bupivacaine in a lipid emulsion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093399/),[μg] / [ml],1.4,126848,DB00297,Bupivacaine
,11093399,peak plasma concentration,"After administration of the lipid emulsion, the peak plasma concentration of bupivacaine, 0.6 (0.2) microg/ml, was detected after 30 minutes.",Prolongation of epidural anaesthesia in dogs with bupivacaine in a lipid emulsion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093399/),[μg] / [ml],0.6,126849,DB00297,Bupivacaine
,11093399,t1/2beta,"The mean (sd) t1/2beta of the aqueous preparation was 149.1 (32.6) minutes, and of the lipid emulsion 119.2 (34.0) minutes.",Prolongation of epidural anaesthesia in dogs with bupivacaine in a lipid emulsion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093399/),min,149.1,126850,DB00297,Bupivacaine
,11093399,t1/2beta,"The mean (sd) t1/2beta of the aqueous preparation was 149.1 (32.6) minutes, and of the lipid emulsion 119.2 (34.0) minutes.",Prolongation of epidural anaesthesia in dogs with bupivacaine in a lipid emulsion. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093399/),min,119.2,126851,DB00297,Bupivacaine
,11093399,time to the onset of motor block,"The mean time to the onset of motor block after the administration of the aqueous solution, 2.3 (2.2) minutes, was significantly shorter (P=0.028) than after the administration of the lipid emulsion, 9.4 (1.9) minutes, and the duration of the motor block induced by the lipid emulsion, 217.6 (26.2) minutes, was significantly longer (P=0.043) than for the aqueous solution, 158 (48.8) minutes.",Prolongation of epidural anaesthesia in dogs with bupivacaine in a lipid emulsion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093399/),min,2.3,126852,DB00297,Bupivacaine
,11093399,time to the onset of motor block,"The mean time to the onset of motor block after the administration of the aqueous solution, 2.3 (2.2) minutes, was significantly shorter (P=0.028) than after the administration of the lipid emulsion, 9.4 (1.9) minutes, and the duration of the motor block induced by the lipid emulsion, 217.6 (26.2) minutes, was significantly longer (P=0.043) than for the aqueous solution, 158 (48.8) minutes.",Prolongation of epidural anaesthesia in dogs with bupivacaine in a lipid emulsion. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093399/),min,9.4,126853,DB00297,Bupivacaine
,11093399,duration of the motor block,"The mean time to the onset of motor block after the administration of the aqueous solution, 2.3 (2.2) minutes, was significantly shorter (P=0.028) than after the administration of the lipid emulsion, 9.4 (1.9) minutes, and the duration of the motor block induced by the lipid emulsion, 217.6 (26.2) minutes, was significantly longer (P=0.043) than for the aqueous solution, 158 (48.8) minutes.",Prolongation of epidural anaesthesia in dogs with bupivacaine in a lipid emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093399/),min,217.6,126854,DB00297,Bupivacaine
,11093399,duration of the motor block,"The mean time to the onset of motor block after the administration of the aqueous solution, 2.3 (2.2) minutes, was significantly shorter (P=0.028) than after the administration of the lipid emulsion, 9.4 (1.9) minutes, and the duration of the motor block induced by the lipid emulsion, 217.6 (26.2) minutes, was significantly longer (P=0.043) than for the aqueous solution, 158 (48.8) minutes.",Prolongation of epidural anaesthesia in dogs with bupivacaine in a lipid emulsion. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11093399/),min,158,126855,DB00297,Bupivacaine
,2882005,Cmax,"Statistically significant temporal changes were found in the following pharmacokinetic parameters: highest Cmax value = 0.900 +/- 0.080 micrograms mL-1 at 22:00 h (amplitude, maximum-minimum/mean X 100, is 64%); highest Cmax/Tmax ratio = 3.596 +/- 0.339 at 22:00 h (amplitude = 85%); highest beta elimination half-life, T1/2 beta, = 3.950 +/- 0.246 h at 22:00 h (amplitude = 35%); area under concentration curve (AUC infinity 0) was not found to be significantly different among the hours of administration.",Temporal changes in bupivacaine kinetics. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882005/),[μg] / [ml],0.900,127373,DB00297,Bupivacaine
,2882005,Cmax/Tmax ratio,"Statistically significant temporal changes were found in the following pharmacokinetic parameters: highest Cmax value = 0.900 +/- 0.080 micrograms mL-1 at 22:00 h (amplitude, maximum-minimum/mean X 100, is 64%); highest Cmax/Tmax ratio = 3.596 +/- 0.339 at 22:00 h (amplitude = 85%); highest beta elimination half-life, T1/2 beta, = 3.950 +/- 0.246 h at 22:00 h (amplitude = 35%); area under concentration curve (AUC infinity 0) was not found to be significantly different among the hours of administration.",Temporal changes in bupivacaine kinetics. ,Cmax ratio-Q33,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882005/),,3.596,127374,DB00297,Bupivacaine
,2882005,"beta elimination half-life, T1/2 beta","Statistically significant temporal changes were found in the following pharmacokinetic parameters: highest Cmax value = 0.900 +/- 0.080 micrograms mL-1 at 22:00 h (amplitude, maximum-minimum/mean X 100, is 64%); highest Cmax/Tmax ratio = 3.596 +/- 0.339 at 22:00 h (amplitude = 85%); highest beta elimination half-life, T1/2 beta, = 3.950 +/- 0.246 h at 22:00 h (amplitude = 35%); area under concentration curve (AUC infinity 0) was not found to be significantly different among the hours of administration.",Temporal changes in bupivacaine kinetics. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2882005/),h,3.950,127375,DB00297,Bupivacaine
,11992687,t(1/2),"t(1/2), t(max), C(max) and AUC(0-infinity) for the aqueous solution were 63+/-8 min, 19+/-16 min, 194+/-46 ng x ml(-1) and 25,000+/-3000 ng min x ml(-1), respectively, while the corresponding data for the oil solution were 368+/-89 min, 334+/-186 min, 36+/-25 ng x ml(-1) and 25,000+/-6000 ng x min x ml(-1).",In vivo release of bupivacaine from subcutaneously administered oily solution. Comparison with in vitro release. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11992687/),min,63,129304,DB00297,Bupivacaine
,11992687,t(max),"t(1/2), t(max), C(max) and AUC(0-infinity) for the aqueous solution were 63+/-8 min, 19+/-16 min, 194+/-46 ng x ml(-1) and 25,000+/-3000 ng min x ml(-1), respectively, while the corresponding data for the oil solution were 368+/-89 min, 334+/-186 min, 36+/-25 ng x ml(-1) and 25,000+/-6000 ng x min x ml(-1).",In vivo release of bupivacaine from subcutaneously administered oily solution. Comparison with in vitro release. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11992687/),min,19,129305,DB00297,Bupivacaine
,11992687,C(max),"t(1/2), t(max), C(max) and AUC(0-infinity) for the aqueous solution were 63+/-8 min, 19+/-16 min, 194+/-46 ng x ml(-1) and 25,000+/-3000 ng min x ml(-1), respectively, while the corresponding data for the oil solution were 368+/-89 min, 334+/-186 min, 36+/-25 ng x ml(-1) and 25,000+/-6000 ng x min x ml(-1).",In vivo release of bupivacaine from subcutaneously administered oily solution. Comparison with in vitro release. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11992687/),min,19,129306,DB00297,Bupivacaine
,11992687,AUC(0-infinity),"t(1/2), t(max), C(max) and AUC(0-infinity) for the aqueous solution were 63+/-8 min, 19+/-16 min, 194+/-46 ng x ml(-1) and 25,000+/-3000 ng min x ml(-1), respectively, while the corresponding data for the oil solution were 368+/-89 min, 334+/-186 min, 36+/-25 ng x ml(-1) and 25,000+/-6000 ng x min x ml(-1).",In vivo release of bupivacaine from subcutaneously administered oily solution. Comparison with in vitro release. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11992687/),[min·ng] / [ml],"25,000",129307,DB00297,Bupivacaine
,7818055,maximum bupivacaine concentration,"There was no clinical evidence of bupivacaine toxicity although the maximum bupivacaine concentration ranged from 0.74-6.52 mg/l, mean 2.90 (SEM 0.44) mg/l and vascular uptake was rapid in two patients.",Pharmacokinetics of bupivacaine enantiomers during interpleural infusion. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7818055/),[mg] / [l],2.90,130154,DB00297,Bupivacaine
,31150095,time to opioid rescue,"BPB with LB 133 mg was associated with significantly improved AUC of pain scores (least squares mean [SE] = 136.4 [12.09] vs 254.1 [11.77], P < 0.0001), opioid consumption (least squares mean [SE] = 12.0 [2.27] vs 54.3 [10.05] mg, P < 0.0001), median time to opioid rescue (4.2 vs 0.6 h, P < 0.0001), and percentage of opioid-free patients (treatment difference = 0.166, 95% confidence interval = 0.032-0.200, P = 0.008) through 48 hours vs placebo.","Brachial Plexus Block with Liposomal Bupivacaine for Shoulder Surgery Improves Analgesia and Reduces Opioid Consumption: Results from a Multicenter, Randomized, Double-Blind, Controlled Trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150095/),h,4.2,130676,DB00297,Bupivacaine
,31150095,time to opioid rescue,"BPB with LB 133 mg was associated with significantly improved AUC of pain scores (least squares mean [SE] = 136.4 [12.09] vs 254.1 [11.77], P < 0.0001), opioid consumption (least squares mean [SE] = 12.0 [2.27] vs 54.3 [10.05] mg, P < 0.0001), median time to opioid rescue (4.2 vs 0.6 h, P < 0.0001), and percentage of opioid-free patients (treatment difference = 0.166, 95% confidence interval = 0.032-0.200, P = 0.008) through 48 hours vs placebo.","Brachial Plexus Block with Liposomal Bupivacaine for Shoulder Surgery Improves Analgesia and Reduces Opioid Consumption: Results from a Multicenter, Randomized, Double-Blind, Controlled Trial. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31150095/),h,0.6,130677,DB00297,Bupivacaine
,24953218,milk/plasma ratios,The milk/plasma ratios were 0.34±0.13 for levobupivacaine and 0.37±0.14 for bupivacaine.,Evaluation of levobupivacaine passage to breast milk following epidural anesthesia for cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24953218/),,0.34,134973,DB00297,Bupivacaine
,24953218,milk/plasma ratios,The milk/plasma ratios were 0.34±0.13 for levobupivacaine and 0.37±0.14 for bupivacaine.,Evaluation of levobupivacaine passage to breast milk following epidural anesthesia for cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/24953218/),,0.37,134974,DB00297,Bupivacaine
,31696528,plasma unbound fraction,The plasma unbound fraction of the drug (0.09 vs 0.06) and the umbilical cord vein/maternal plasma ratio (0.47 vs 0.39) were higher for the R-bupivacaine enantiomer than the S-bupivacaine enantiomer (P < .05).,Pharmacokinetics and Placental Transfer of Bupivacaine Enantiomers in HIV-Infected Parturient Women on Antiretroviral Therapy. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31696528/),,0.09,135973,DB00297,Bupivacaine
,31696528,plasma unbound fraction,The plasma unbound fraction of the drug (0.09 vs 0.06) and the umbilical cord vein/maternal plasma ratio (0.47 vs 0.39) were higher for the R-bupivacaine enantiomer than the S-bupivacaine enantiomer (P < .05).,Pharmacokinetics and Placental Transfer of Bupivacaine Enantiomers in HIV-Infected Parturient Women on Antiretroviral Therapy. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31696528/),,0.06,135974,DB00297,Bupivacaine
,31696528,plasma ratio,The plasma unbound fraction of the drug (0.09 vs 0.06) and the umbilical cord vein/maternal plasma ratio (0.47 vs 0.39) were higher for the R-bupivacaine enantiomer than the S-bupivacaine enantiomer (P < .05).,Pharmacokinetics and Placental Transfer of Bupivacaine Enantiomers in HIV-Infected Parturient Women on Antiretroviral Therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31696528/),,0.47,135975,DB00297,Bupivacaine
,31696528,plasma ratio,The plasma unbound fraction of the drug (0.09 vs 0.06) and the umbilical cord vein/maternal plasma ratio (0.47 vs 0.39) were higher for the R-bupivacaine enantiomer than the S-bupivacaine enantiomer (P < .05).,Pharmacokinetics and Placental Transfer of Bupivacaine Enantiomers in HIV-Infected Parturient Women on Antiretroviral Therapy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31696528/),,0.39,135976,DB00297,Bupivacaine
,2323154,peak plasma drug concentration (Cmax),"The mean (+/- SD) peak plasma drug concentration (Cmax) [352 +/- 120 micrograms/L], time to peak (tmax) [0.83 +/- 0.51 h], and first-order absorption rate constant (ka) [5.46 +/- 4.95 h-1] after the twelfth dose were significantly different from the Cmax (206 +/- 81 micrograms/L), tmax (1.8 +/- 1.2h), and ka (1.8 +/- 1.47 h-1) determined after the first dose.",Clinical pharmacokinetics after repeated intrapleural bupivacaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2323154/),[μg] / [l],352,138739,DB00297,Bupivacaine
,2323154,time to peak (tmax),"The mean (+/- SD) peak plasma drug concentration (Cmax) [352 +/- 120 micrograms/L], time to peak (tmax) [0.83 +/- 0.51 h], and first-order absorption rate constant (ka) [5.46 +/- 4.95 h-1] after the twelfth dose were significantly different from the Cmax (206 +/- 81 micrograms/L), tmax (1.8 +/- 1.2h), and ka (1.8 +/- 1.47 h-1) determined after the first dose.",Clinical pharmacokinetics after repeated intrapleural bupivacaine administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2323154/),h,0.83,138740,DB00297,Bupivacaine
,2323154,first-order absorption rate constant (ka),"The mean (+/- SD) peak plasma drug concentration (Cmax) [352 +/- 120 micrograms/L], time to peak (tmax) [0.83 +/- 0.51 h], and first-order absorption rate constant (ka) [5.46 +/- 4.95 h-1] after the twelfth dose were significantly different from the Cmax (206 +/- 81 micrograms/L), tmax (1.8 +/- 1.2h), and ka (1.8 +/- 1.47 h-1) determined after the first dose.",Clinical pharmacokinetics after repeated intrapleural bupivacaine administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2323154/),1/[h],5.46,138741,DB00297,Bupivacaine
,2323154,Cmax,"The mean (+/- SD) peak plasma drug concentration (Cmax) [352 +/- 120 micrograms/L], time to peak (tmax) [0.83 +/- 0.51 h], and first-order absorption rate constant (ka) [5.46 +/- 4.95 h-1] after the twelfth dose were significantly different from the Cmax (206 +/- 81 micrograms/L), tmax (1.8 +/- 1.2h), and ka (1.8 +/- 1.47 h-1) determined after the first dose.",Clinical pharmacokinetics after repeated intrapleural bupivacaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2323154/),[μg] / [l],206,138742,DB00297,Bupivacaine
,2323154,tmax,"The mean (+/- SD) peak plasma drug concentration (Cmax) [352 +/- 120 micrograms/L], time to peak (tmax) [0.83 +/- 0.51 h], and first-order absorption rate constant (ka) [5.46 +/- 4.95 h-1] after the twelfth dose were significantly different from the Cmax (206 +/- 81 micrograms/L), tmax (1.8 +/- 1.2h), and ka (1.8 +/- 1.47 h-1) determined after the first dose.",Clinical pharmacokinetics after repeated intrapleural bupivacaine administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2323154/),h,1.8,138743,DB00297,Bupivacaine
,2323154,ka,"The mean (+/- SD) peak plasma drug concentration (Cmax) [352 +/- 120 micrograms/L], time to peak (tmax) [0.83 +/- 0.51 h], and first-order absorption rate constant (ka) [5.46 +/- 4.95 h-1] after the twelfth dose were significantly different from the Cmax (206 +/- 81 micrograms/L), tmax (1.8 +/- 1.2h), and ka (1.8 +/- 1.47 h-1) determined after the first dose.",Clinical pharmacokinetics after repeated intrapleural bupivacaine administration. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2323154/),1/[h],1.8,138744,DB00297,Bupivacaine
,2323154,Half-life,"Half-life (3.5 +/- 2.2h) and mean concentration (204 +/- 105 micrograms/L) were not significantly different on the fourth day from those on the first (4.1 +/- 2.6h and 142 +/- 71 micrograms/L, respectively).",Clinical pharmacokinetics after repeated intrapleural bupivacaine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2323154/),h,3.5,138745,DB00297,Bupivacaine
,2323154,Half-life,"Half-life (3.5 +/- 2.2h) and mean concentration (204 +/- 105 micrograms/L) were not significantly different on the fourth day from those on the first (4.1 +/- 2.6h and 142 +/- 71 micrograms/L, respectively).",Clinical pharmacokinetics after repeated intrapleural bupivacaine administration. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2323154/),h,4.1,138746,DB00297,Bupivacaine
,2323154,concentration,"Half-life (3.5 +/- 2.2h) and mean concentration (204 +/- 105 micrograms/L) were not significantly different on the fourth day from those on the first (4.1 +/- 2.6h and 142 +/- 71 micrograms/L, respectively).",Clinical pharmacokinetics after repeated intrapleural bupivacaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2323154/),[μg] / [l],204,138747,DB00297,Bupivacaine
,2323154,concentration,"Half-life (3.5 +/- 2.2h) and mean concentration (204 +/- 105 micrograms/L) were not significantly different on the fourth day from those on the first (4.1 +/- 2.6h and 142 +/- 71 micrograms/L, respectively).",Clinical pharmacokinetics after repeated intrapleural bupivacaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2323154/),h,4.1,138748,DB00297,Bupivacaine
,2323154,concentration,"Half-life (3.5 +/- 2.2h) and mean concentration (204 +/- 105 micrograms/L) were not significantly different on the fourth day from those on the first (4.1 +/- 2.6h and 142 +/- 71 micrograms/L, respectively).",Clinical pharmacokinetics after repeated intrapleural bupivacaine administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2323154/),[μg] / [l],142,138749,DB00297,Bupivacaine
greater,11465589,unbound concentrations,Two infants aged 1.8 months had unbound concentrations greater than 0.2 microg/ml.,Pharmacokinetics of bupivacaine after continuous epidural infusion in infants with and without biliary atresia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11465589/),[μg] / [ml],0.2,141006,DB00297,Bupivacaine
,11465589,Blood/plasma ratio,"Blood/plasma ratio was 0.77+/-0.08 and 0.85+/-0.24 at 2 and 20 microg/ml, respectively.",Pharmacokinetics of bupivacaine after continuous epidural infusion in infants with and without biliary atresia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11465589/),,0.77,141007,DB00297,Bupivacaine
,11465589,Blood/plasma ratio,"Blood/plasma ratio was 0.77+/-0.08 and 0.85+/-0.24 at 2 and 20 microg/ml, respectively.",Pharmacokinetics of bupivacaine after continuous epidural infusion in infants with and without biliary atresia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11465589/),,0.85,141008,DB00297,Bupivacaine
,11465589,maximum dose,"Thus, we propose the use of a maximum dose of 0.25 mg x kg(-1) x h(-1) in infants younger than 4 months and a maximum of 0.3 mg x kg(-1) x h(-1) in infants older than 4 months.",Pharmacokinetics of bupivacaine after continuous epidural infusion in infants with and without biliary atresia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11465589/),[mg] / [h·kg],0.25,141009,DB00297,Bupivacaine
,11465589,maximum,"Thus, we propose the use of a maximum dose of 0.25 mg x kg(-1) x h(-1) in infants younger than 4 months and a maximum of 0.3 mg x kg(-1) x h(-1) in infants older than 4 months.",Pharmacokinetics of bupivacaine after continuous epidural infusion in infants with and without biliary atresia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11465589/),[mg] / [h·kg],0.3,141010,DB00297,Bupivacaine
,7653818,onset times,"The median onset times for anesthesia and complete motor block were in the range of 12-48 min and 5-20 min, respectively.",A clinical and pharmacokinetic comparison of ropivacaine and bupivacaine in axillary plexus block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7653818/),min,12-48,142338,DB00297,Bupivacaine
,7653818,onset times,"The median onset times for anesthesia and complete motor block were in the range of 12-48 min and 5-20 min, respectively.",A clinical and pharmacokinetic comparison of ropivacaine and bupivacaine in axillary plexus block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7653818/),min,5-20,142339,DB00297,Bupivacaine
,7653818,peak plasma concentrations (Cmax),"In the pharmacokinetic study the mean peak plasma concentrations (Cmax) were 1.28 +/- 0.21 mg/L in the ropivacaine group and 1.28 +/- 0.47 mg/L in the bupivacaine group and the median times to peak plasma concentration (tmax) were 0.86 h and 0.96 h, respectively.",A clinical and pharmacokinetic comparison of ropivacaine and bupivacaine in axillary plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7653818/),[mg] / [l],1.28,142340,DB00297,Bupivacaine
,7653818,peak plasma concentrations (Cmax),"In the pharmacokinetic study the mean peak plasma concentrations (Cmax) were 1.28 +/- 0.21 mg/L in the ropivacaine group and 1.28 +/- 0.47 mg/L in the bupivacaine group and the median times to peak plasma concentration (tmax) were 0.86 h and 0.96 h, respectively.",A clinical and pharmacokinetic comparison of ropivacaine and bupivacaine in axillary plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7653818/),[mg] / [l],1.28,142341,DB00297,Bupivacaine
,7653818,times to peak plasma concentration (tmax),"In the pharmacokinetic study the mean peak plasma concentrations (Cmax) were 1.28 +/- 0.21 mg/L in the ropivacaine group and 1.28 +/- 0.47 mg/L in the bupivacaine group and the median times to peak plasma concentration (tmax) were 0.86 h and 0.96 h, respectively.",A clinical and pharmacokinetic comparison of ropivacaine and bupivacaine in axillary plexus block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7653818/),h,0.86,142342,DB00297,Bupivacaine
,7653818,times to peak plasma concentration (tmax),"In the pharmacokinetic study the mean peak plasma concentrations (Cmax) were 1.28 +/- 0.21 mg/L in the ropivacaine group and 1.28 +/- 0.47 mg/L in the bupivacaine group and the median times to peak plasma concentration (tmax) were 0.86 h and 0.96 h, respectively.",A clinical and pharmacokinetic comparison of ropivacaine and bupivacaine in axillary plexus block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7653818/),h,0.96,142343,DB00297,Bupivacaine
,7653818,terminal half-lives (t1/2),"The median terminal half-lives (t1/2) were 7.1 h and 11.5 h in the ropivacaine group and the bupivacaine group, respectively (P = 0.07).",A clinical and pharmacokinetic comparison of ropivacaine and bupivacaine in axillary plexus block. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7653818/),h,7.1,142344,DB00297,Bupivacaine
,7653818,terminal half-lives (t1/2),"The median terminal half-lives (t1/2) were 7.1 h and 11.5 h in the ropivacaine group and the bupivacaine group, respectively (P = 0.07).",A clinical and pharmacokinetic comparison of ropivacaine and bupivacaine in axillary plexus block. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7653818/),h,11.5,142345,DB00297,Bupivacaine
,2006723,peak concentration,The addition of epinephrine yielded only minor advantages from a pharmacokinetic point of view (median peak concentration of bupivacaine 1.8 micrograms/ml vs 2.0 micrograms/ml for bupivacaine alone).,[Intrapleural catheter analgesia in patients with multiple rib fractures]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2006723/),[μg] / [ml],1.8,143907,DB00297,Bupivacaine
,2006723,peak concentration,The addition of epinephrine yielded only minor advantages from a pharmacokinetic point of view (median peak concentration of bupivacaine 1.8 micrograms/ml vs 2.0 micrograms/ml for bupivacaine alone).,[Intrapleural catheter analgesia in patients with multiple rib fractures]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2006723/),[μg] / [ml],2.0,143908,DB00297,Bupivacaine
above,2006723,maximum total plasma concentrations,"Even though maximum total plasma concentrations of bupivacaine above 2 micrograms/ml were found in some patients, there were no signs of CNS toxicity, most probably because of the increased protein binding of bupivacaine following trauma.",[Intrapleural catheter analgesia in patients with multiple rib fractures]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2006723/),[μg] / [ml],2,143909,DB00297,Bupivacaine
below,2006723,maximum free plasma concentrations,"Accordingly, the maximum free plasma concentrations in all patients were below the threshold level of 0.24 micron/ml.",[Intrapleural catheter analgesia in patients with multiple rib fractures]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2006723/),[μn] / [ml],0.24,143910,DB00297,Bupivacaine
,26945692,maximum plasma concentration (Cmax),The mean maximum plasma concentration (Cmax) and mean time to reach Cmax (Tmax) as determined by non-linear regression analysis were 1.05 μg.,A comparison of plasma levobupivacaine concentrations following transversus abdominis plane block and rectus sheath block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26945692/),μg,1.05,146295,DB00297,Bupivacaine
,2378770,peak plasma concentrations,"However, peak plasma concentrations were lower in the adrenaline group (mean (SD) [range]: 2.57 (0.61) [1.52-3.11] vs 3.22 (0.27) [2.84-3.53] micrograms ml-1, P less than 0.05) and the time to maximum concentration was delayed (median [range]: 25 [15-30] vs 15 [10-20] min, P less than 0.05).",Effect of adrenaline on venous plasma concentrations of bupivacaine after interpleural administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378770/),[μg] / [ml],2.57,146426,DB00297,Bupivacaine
,2378770,peak plasma concentrations,"However, peak plasma concentrations were lower in the adrenaline group (mean (SD) [range]: 2.57 (0.61) [1.52-3.11] vs 3.22 (0.27) [2.84-3.53] micrograms ml-1, P less than 0.05) and the time to maximum concentration was delayed (median [range]: 25 [15-30] vs 15 [10-20] min, P less than 0.05).",Effect of adrenaline on venous plasma concentrations of bupivacaine after interpleural administration. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378770/),[μg] / [ml],3.22,146427,DB00297,Bupivacaine
,2378770,time to maximum concentration,"However, peak plasma concentrations were lower in the adrenaline group (mean (SD) [range]: 2.57 (0.61) [1.52-3.11] vs 3.22 (0.27) [2.84-3.53] micrograms ml-1, P less than 0.05) and the time to maximum concentration was delayed (median [range]: 25 [15-30] vs 15 [10-20] min, P less than 0.05).",Effect of adrenaline on venous plasma concentrations of bupivacaine after interpleural administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378770/),min,25,146428,DB00297,Bupivacaine
,2378770,time to maximum concentration,"However, peak plasma concentrations were lower in the adrenaline group (mean (SD) [range]: 2.57 (0.61) [1.52-3.11] vs 3.22 (0.27) [2.84-3.53] micrograms ml-1, P less than 0.05) and the time to maximum concentration was delayed (median [range]: 25 [15-30] vs 15 [10-20] min, P less than 0.05).",Effect of adrenaline on venous plasma concentrations of bupivacaine after interpleural administration. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378770/),min,15,146429,DB00297,Bupivacaine
,3344993,Peak serum concentrations,Peak serum concentrations ranged between 0.55 and 1.93 micrograms/ml.,Pharmacokinetics of bupivacaine following caudal anesthesia in infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3344993/),[μg] / [ml],0.55 and 1.93,147743,DB00297,Bupivacaine
,3344993,time to reach the peak,The time to reach the peak ranged from 10 to 60 min.,Pharmacokinetics of bupivacaine following caudal anesthesia in infants. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3344993/),min,10 to 60,147744,DB00297,Bupivacaine
,3344993,Terminal half-life (T1/2 beta),"Terminal half-life (T1/2 beta) was 7.7 +/- 2.4h (mean +/- SD), the volume of distribution (Vss) was 3.9 +/- 2.01.kg, and the total body clearance (CL) was 7.1 +/- 3.2 ml.min.kg-1.",Pharmacokinetics of bupivacaine following caudal anesthesia in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3344993/),h,7.7,147745,DB00297,Bupivacaine
,3344993,volume of distribution (Vss),"Terminal half-life (T1/2 beta) was 7.7 +/- 2.4h (mean +/- SD), the volume of distribution (Vss) was 3.9 +/- 2.01.kg, and the total body clearance (CL) was 7.1 +/- 3.2 ml.min.kg-1.",Pharmacokinetics of bupivacaine following caudal anesthesia in infants. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3344993/),kg,3.9,147746,DB00297,Bupivacaine
,3344993,total body clearance (CL),"Terminal half-life (T1/2 beta) was 7.7 +/- 2.4h (mean +/- SD), the volume of distribution (Vss) was 3.9 +/- 2.01.kg, and the total body clearance (CL) was 7.1 +/- 3.2 ml.min.kg-1.",Pharmacokinetics of bupivacaine following caudal anesthesia in infants. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3344993/),[min·ml] / [kg],7.1,147747,DB00297,Bupivacaine
,3344993,free fraction,"The free fraction was markedly increased (0.16 +/- 0.07) when compared with published adult values, and showed a highly significant negative correlation with age.",Pharmacokinetics of bupivacaine following caudal anesthesia in infants. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3344993/),,0.16,147748,DB00297,Bupivacaine
,9263767,elimination half-life,"Pharmacokinetic parameters were estimated in 17 women after the first injection: 87 +/- 35 min for elimination half-life, 60 +/- 19 L for apparent volume of distribution and 0.5 +/- 0.3 L/min for plasmatic clearance.",Serum bupivacaine concentrations and transplacental transfer following repeated epidural administrations in term parturients during labour. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263767/),min,87,149766,DB00297,Bupivacaine
,9263767,apparent volume of distribution,"Pharmacokinetic parameters were estimated in 17 women after the first injection: 87 +/- 35 min for elimination half-life, 60 +/- 19 L for apparent volume of distribution and 0.5 +/- 0.3 L/min for plasmatic clearance.",Serum bupivacaine concentrations and transplacental transfer following repeated epidural administrations in term parturients during labour. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263767/),l,60,149767,DB00297,Bupivacaine
,9263767,plasmatic clearance,"Pharmacokinetic parameters were estimated in 17 women after the first injection: 87 +/- 35 min for elimination half-life, 60 +/- 19 L for apparent volume of distribution and 0.5 +/- 0.3 L/min for plasmatic clearance.",Serum bupivacaine concentrations and transplacental transfer following repeated epidural administrations in term parturients during labour. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263767/),[l] / [min],0.5,149768,DB00297,Bupivacaine
,9263767,maximal serum concentration,The infant maximal serum concentration was 0.26 microgram/mL.,Serum bupivacaine concentrations and transplacental transfer following repeated epidural administrations in term parturients during labour. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9263767/),[μg] / [ml],0.26,149769,DB00297,Bupivacaine
,28120158,maximum observed plasma concentration (C max),The mean ± standard deviation maximum observed plasma concentration (C max) of bupivacaine after a single dose was 129 ± 47 ng/mL.,Pharmacokinetic Profile and Tolerability of Liposomal Bupivacaine Following a Repeated Dose via Local Subcutaneous Infiltration in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28120158/),[ng] / [ml],129,152119,DB00297,Bupivacaine
,28120158,C max,"The highest individual C max (589 ng/mL) was observed in a subject who received the second dose 24 h after the first dose (cohort 4), but was well below the reported thresholds for neurotoxicity and cardiac toxicity (2000 and 4000 ng/mL, respectively).",Pharmacokinetic Profile and Tolerability of Liposomal Bupivacaine Following a Repeated Dose via Local Subcutaneous Infiltration in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28120158/),[ng] / [ml],589,152120,DB00297,Bupivacaine
,28120158,C max,"The highest individual C max (589 ng/mL) was observed in a subject who received the second dose 24 h after the first dose (cohort 4), but was well below the reported thresholds for neurotoxicity and cardiac toxicity (2000 and 4000 ng/mL, respectively).",Pharmacokinetic Profile and Tolerability of Liposomal Bupivacaine Following a Repeated Dose via Local Subcutaneous Infiltration in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28120158/),[ng] / [ml],2000,152121,DB00297,Bupivacaine
,28120158,C max,"The highest individual C max (589 ng/mL) was observed in a subject who received the second dose 24 h after the first dose (cohort 4), but was well below the reported thresholds for neurotoxicity and cardiac toxicity (2000 and 4000 ng/mL, respectively).",Pharmacokinetic Profile and Tolerability of Liposomal Bupivacaine Following a Repeated Dose via Local Subcutaneous Infiltration in Healthy Volunteers. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28120158/),[ng] / [ml],4000,152122,DB00297,Bupivacaine
,28599806,area under the curve (AUC),Mean bupivacaine area under the curve (AUC) was calculated from 0 to 24hours.,Pharmacokinetics of bupivacaine after bilateral ultrasound-guided transversus abdominis plane block following cesarean delivery under spinal anesthesia. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28599806/),h,0 to 24,152860,DB00297,Bupivacaine
,28599806,peak concentration,Mean peak concentration was 802.36ng/mL (range 231.8 to 3504.5ng/mL).,Pharmacokinetics of bupivacaine after bilateral ultrasound-guided transversus abdominis plane block following cesarean delivery under spinal anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28599806/),[ng] / [ml],802.36,152861,DB00297,Bupivacaine
,28599806,time to peak concentration,Mean time to peak concentration was 30min and mean area-under-the-curve (0-24h) was 4505.4h.ng/mL.,Pharmacokinetics of bupivacaine after bilateral ultrasound-guided transversus abdominis plane block following cesarean delivery under spinal anesthesia. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28599806/),min,30,152862,DB00297,Bupivacaine
,28599806,area-under-the-curve (0-24h),Mean time to peak concentration was 30min and mean area-under-the-curve (0-24h) was 4505.4h.ng/mL.,Pharmacokinetics of bupivacaine after bilateral ultrasound-guided transversus abdominis plane block following cesarean delivery under spinal anesthesia. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/28599806/),[h·ng] / [ml],4505.4,152863,DB00297,Bupivacaine
,28599806,elimination half-life,Mean elimination half-life was 8.75h.,Pharmacokinetics of bupivacaine after bilateral ultrasound-guided transversus abdominis plane block following cesarean delivery under spinal anesthesia. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/28599806/),h,8.75,152864,DB00297,Bupivacaine
,9542557,Cmax,"Cmax and Tmax values of clonidine were found to be within the 0.45-0.77 ng/mL and 48-193 min range, respectively.",Plasma levels of clonidine following epidural bolus injection in children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542557/),[ng] / [ml],0.45-0.77,153629,DB00297,Bupivacaine
,9542557,Tmax,"Cmax and Tmax values of clonidine were found to be within the 0.45-0.77 ng/mL and 48-193 min range, respectively.",Plasma levels of clonidine following epidural bolus injection in children. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542557/),min,48-193,153630,DB00297,Bupivacaine
,9542557,time to absorb 95%,The time to absorb 95% of the clonidine dose from the epidural space into plasma varied between 36 min and 7.6 h.,Plasma levels of clonidine following epidural bolus injection in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542557/),min,36,153631,DB00297,Bupivacaine
,9542557,time to absorb 95%,The time to absorb 95% of the clonidine dose from the epidural space into plasma varied between 36 min and 7.6 h.,Plasma levels of clonidine following epidural bolus injection in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9542557/),h,7.6,153632,DB00297,Bupivacaine
,8866342,maximal concentration in the serum (Cmax,"The maximal concentration in the serum (Cmax 0.618 +/- 0.051 vs 0.408 +/- 0.041 microgram mL-1 for group 1 vs 2, P = 0.01) and the area under the concentration curve (AUC 1.039 +/- 0.051 vs 0.758 +/- 0.072 microgram mL-1 h for group 1 vs 2, P = 0.013) of bupivacaine were significantly lower in nicorandil-treated mice, while CL (0.579 +/- 0.025 vs 0.815 +/- 0.079 for group 1 vs 2, P = 0.022) and Vd (0.506 +/- 0.054 vs 0.981 +/- 0.117 for group 1 vs 2, P = 0.1006) were increased in nicorandil-treated animals.",Kinetics of bupivacaine after nicorandil treatment in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866342/),[μg] / [ml],0.618,154457,DB00297,Bupivacaine
,8866342,maximal concentration in the serum (Cmax,"The maximal concentration in the serum (Cmax 0.618 +/- 0.051 vs 0.408 +/- 0.041 microgram mL-1 for group 1 vs 2, P = 0.01) and the area under the concentration curve (AUC 1.039 +/- 0.051 vs 0.758 +/- 0.072 microgram mL-1 h for group 1 vs 2, P = 0.013) of bupivacaine were significantly lower in nicorandil-treated mice, while CL (0.579 +/- 0.025 vs 0.815 +/- 0.079 for group 1 vs 2, P = 0.022) and Vd (0.506 +/- 0.054 vs 0.981 +/- 0.117 for group 1 vs 2, P = 0.1006) were increased in nicorandil-treated animals.",Kinetics of bupivacaine after nicorandil treatment in mice. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866342/),[μg] / [ml],0.408,154458,DB00297,Bupivacaine
,8866342,area under the concentration curve (AUC,"The maximal concentration in the serum (Cmax 0.618 +/- 0.051 vs 0.408 +/- 0.041 microgram mL-1 for group 1 vs 2, P = 0.01) and the area under the concentration curve (AUC 1.039 +/- 0.051 vs 0.758 +/- 0.072 microgram mL-1 h for group 1 vs 2, P = 0.013) of bupivacaine were significantly lower in nicorandil-treated mice, while CL (0.579 +/- 0.025 vs 0.815 +/- 0.079 for group 1 vs 2, P = 0.022) and Vd (0.506 +/- 0.054 vs 0.981 +/- 0.117 for group 1 vs 2, P = 0.1006) were increased in nicorandil-treated animals.",Kinetics of bupivacaine after nicorandil treatment in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866342/),[h·μg] / [ml],1.039,154459,DB00297,Bupivacaine
,8866342,area under the concentration curve (AUC,"The maximal concentration in the serum (Cmax 0.618 +/- 0.051 vs 0.408 +/- 0.041 microgram mL-1 for group 1 vs 2, P = 0.01) and the area under the concentration curve (AUC 1.039 +/- 0.051 vs 0.758 +/- 0.072 microgram mL-1 h for group 1 vs 2, P = 0.013) of bupivacaine were significantly lower in nicorandil-treated mice, while CL (0.579 +/- 0.025 vs 0.815 +/- 0.079 for group 1 vs 2, P = 0.022) and Vd (0.506 +/- 0.054 vs 0.981 +/- 0.117 for group 1 vs 2, P = 0.1006) were increased in nicorandil-treated animals.",Kinetics of bupivacaine after nicorandil treatment in mice. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866342/),[h·μg] / [ml],0.758,154460,DB00297,Bupivacaine
,8866342,CL,"The maximal concentration in the serum (Cmax 0.618 +/- 0.051 vs 0.408 +/- 0.041 microgram mL-1 for group 1 vs 2, P = 0.01) and the area under the concentration curve (AUC 1.039 +/- 0.051 vs 0.758 +/- 0.072 microgram mL-1 h for group 1 vs 2, P = 0.013) of bupivacaine were significantly lower in nicorandil-treated mice, while CL (0.579 +/- 0.025 vs 0.815 +/- 0.079 for group 1 vs 2, P = 0.022) and Vd (0.506 +/- 0.054 vs 0.981 +/- 0.117 for group 1 vs 2, P = 0.1006) were increased in nicorandil-treated animals.",Kinetics of bupivacaine after nicorandil treatment in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866342/),,0.579,154461,DB00297,Bupivacaine
,8866342,CL,"The maximal concentration in the serum (Cmax 0.618 +/- 0.051 vs 0.408 +/- 0.041 microgram mL-1 for group 1 vs 2, P = 0.01) and the area under the concentration curve (AUC 1.039 +/- 0.051 vs 0.758 +/- 0.072 microgram mL-1 h for group 1 vs 2, P = 0.013) of bupivacaine were significantly lower in nicorandil-treated mice, while CL (0.579 +/- 0.025 vs 0.815 +/- 0.079 for group 1 vs 2, P = 0.022) and Vd (0.506 +/- 0.054 vs 0.981 +/- 0.117 for group 1 vs 2, P = 0.1006) were increased in nicorandil-treated animals.",Kinetics of bupivacaine after nicorandil treatment in mice. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866342/),,0.815,154462,DB00297,Bupivacaine
,8866342,Vd,"The maximal concentration in the serum (Cmax 0.618 +/- 0.051 vs 0.408 +/- 0.041 microgram mL-1 for group 1 vs 2, P = 0.01) and the area under the concentration curve (AUC 1.039 +/- 0.051 vs 0.758 +/- 0.072 microgram mL-1 h for group 1 vs 2, P = 0.013) of bupivacaine were significantly lower in nicorandil-treated mice, while CL (0.579 +/- 0.025 vs 0.815 +/- 0.079 for group 1 vs 2, P = 0.022) and Vd (0.506 +/- 0.054 vs 0.981 +/- 0.117 for group 1 vs 2, P = 0.1006) were increased in nicorandil-treated animals.",Kinetics of bupivacaine after nicorandil treatment in mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866342/),,0.506,154463,DB00297,Bupivacaine
,8866342,Vd,"The maximal concentration in the serum (Cmax 0.618 +/- 0.051 vs 0.408 +/- 0.041 microgram mL-1 for group 1 vs 2, P = 0.01) and the area under the concentration curve (AUC 1.039 +/- 0.051 vs 0.758 +/- 0.072 microgram mL-1 h for group 1 vs 2, P = 0.013) of bupivacaine were significantly lower in nicorandil-treated mice, while CL (0.579 +/- 0.025 vs 0.815 +/- 0.079 for group 1 vs 2, P = 0.022) and Vd (0.506 +/- 0.054 vs 0.981 +/- 0.117 for group 1 vs 2, P = 0.1006) were increased in nicorandil-treated animals.",Kinetics of bupivacaine after nicorandil treatment in mice. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8866342/),,0.981,154464,DB00297,Bupivacaine
,717764,t1/2,"From the course of the aortic bupivacaine concentrations after i.v. injection the following pharmacokinetic data were derived: t1/2 = 24,7 min; k2 = 1,467 h; V = 1,492 1.",[Metabolism and distribution of bupivacaine-experiments in rats. II. Distribution and elimination (author's transl)]. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/717764/),min,"24,7",156914,DB00297,Bupivacaine
,717764,k2,"From the course of the aortic bupivacaine concentrations after i.v. injection the following pharmacokinetic data were derived: t1/2 = 24,7 min; k2 = 1,467 h; V = 1,492 1.",[Metabolism and distribution of bupivacaine-experiments in rats. II. Distribution and elimination (author's transl)]. ,"λ1, λ2-Q67",[Article Link](https://pubmed.ncbi.nlm.nih.gov/717764/),h,"1,467",156915,DB00297,Bupivacaine
,717764,V,"From the course of the aortic bupivacaine concentrations after i.v. injection the following pharmacokinetic data were derived: t1/2 = 24,7 min; k2 = 1,467 h; V = 1,492 1.",[Metabolism and distribution of bupivacaine-experiments in rats. II. Distribution and elimination (author's transl)]. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/717764/),1,"1,492",156916,DB00297,Bupivacaine
,717764,hepatic clearance,The hepatic clearance of bupivacaine in the rat is 12 ml/kg b.w..min-1.,[Metabolism and distribution of bupivacaine-experiments in rats. II. Distribution and elimination (author's transl)]. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/717764/),[ml] / [kg],12,156917,DB00297,Bupivacaine
,20600721,area under curve (AUC),"For brain pharmacokinetics, the CsA pretreatment raised significantly the area under curve (AUC) of BU (24.0+/-5.9 vs. 14.6+/-4.4min microg/mL, p=0.015).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[min·μg] / [ml],24.0,157122,DB00297,Bupivacaine
,20600721,area under curve (AUC),"For brain pharmacokinetics, the CsA pretreatment raised significantly the area under curve (AUC) of BU (24.0+/-5.9 vs. 14.6+/-4.4min microg/mL, p=0.015).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[min·μg] / [ml],14.6,157123,DB00297,Bupivacaine
,20600721,AUC,"For bile pharmacokinetics, LB and BU went through hepatobiliary excretion, and the AUC of BU was significantly higher than that of the LB group (6.6+/-1.0 vs. 4.6+/-0.6min microg/mL, p=0.005).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[min·μg] / [ml],6.6,157124,DB00297,Bupivacaine
,20600721,AUC,"For bile pharmacokinetics, LB and BU went through hepatobiliary excretion, and the AUC of BU was significantly higher than that of the LB group (6.6+/-1.0 vs. 4.6+/-0.6min microg/mL, p=0.005).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[min·μg] / [ml],4.6,157125,DB00297,Bupivacaine
,20600721,AUC,"In addition, the pretreatment of CsA significantly reduced the hepatobiliary excretion of BU in terms of AUC (4.4+/-0.8 vs. 6.6+/-1.0minmicrog/mL, p=0.003).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[minμg] / [ml],4.4,157126,DB00297,Bupivacaine
,20600721,AUC,"In addition, the pretreatment of CsA significantly reduced the hepatobiliary excretion of BU in terms of AUC (4.4+/-0.8 vs. 6.6+/-1.0minmicrog/mL, p=0.003).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[minμg] / [ml],6.6,157127,DB00297,Bupivacaine
,20600721,maximum concentration (C(max)),"Furthermore, the maximum concentration (C(max)) of BU diminished significantly as a result of the CsA pretreatment (0.10+/-0.03 vs. 0.20+/-0.05microg/mL, p=0.002).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[μg] / [ml],0.10,157128,DB00297,Bupivacaine
,20600721,maximum concentration (C(max)),"Furthermore, the maximum concentration (C(max)) of BU diminished significantly as a result of the CsA pretreatment (0.10+/-0.03 vs. 0.20+/-0.05microg/mL, p=0.002).",Effects of a P-glycoprotein modulator on the pharmacokinetics and distribution of free levobupivacaine and bupivacaine in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20600721/),[μg] / [ml],0.20,157129,DB00297,Bupivacaine
,17131890,area under the curve,"There were no differences in area under the curve (1,551 +/- 387, 1,176 +/- 154 ng x hr x ml(-1)) and elimination half life (100 +/- 54, 78 +/- 37 min) between the two groups.",[Plasma levobupivacaine concentrations following epidural administration of levobupivacaine conjugated with or without maltosyl-beta-cyclodextrin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17131890/),[h·ng] / [ml],"1,551",159662,DB00297,Bupivacaine
,17131890,area under the curve,"There were no differences in area under the curve (1,551 +/- 387, 1,176 +/- 154 ng x hr x ml(-1)) and elimination half life (100 +/- 54, 78 +/- 37 min) between the two groups.",[Plasma levobupivacaine concentrations following epidural administration of levobupivacaine conjugated with or without maltosyl-beta-cyclodextrin]. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17131890/),[h·ng] / [ml],"1,176",159663,DB00297,Bupivacaine
,17131890,elimination half life,"There were no differences in area under the curve (1,551 +/- 387, 1,176 +/- 154 ng x hr x ml(-1)) and elimination half life (100 +/- 54, 78 +/- 37 min) between the two groups.",[Plasma levobupivacaine concentrations following epidural administration of levobupivacaine conjugated with or without maltosyl-beta-cyclodextrin]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17131890/),min,100,159664,DB00297,Bupivacaine
,17131890,elimination half life,"There were no differences in area under the curve (1,551 +/- 387, 1,176 +/- 154 ng x hr x ml(-1)) and elimination half life (100 +/- 54, 78 +/- 37 min) between the two groups.",[Plasma levobupivacaine concentrations following epidural administration of levobupivacaine conjugated with or without maltosyl-beta-cyclodextrin]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/17131890/),min,78,159665,DB00297,Bupivacaine
,23080351,duration of motor blockade,Median duration of motor blockade with liposome bupivacaine 266 mg was 1 hour versus 2.8 hours for bupivacaine HCl.,The pharmacokinetics and pharmacodynamics of liposome bupivacaine administered via a single epidural injection to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23080351/),h,1,162737,DB00297,Bupivacaine
,23080351,duration of motor blockade,Median duration of motor blockade with liposome bupivacaine 266 mg was 1 hour versus 2.8 hours for bupivacaine HCl.,The pharmacokinetics and pharmacodynamics of liposome bupivacaine administered via a single epidural injection to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23080351/),h,2.8,162738,DB00297,Bupivacaine
,23080351,durations,"Median durations of pinprick/cold sensitivity loss were 36 and 69 hours, respectively, in the liposome bupivacaine 266-mg group versus 12 hours for both pinprick and cold in the bupivacaine HCl group.",The pharmacokinetics and pharmacodynamics of liposome bupivacaine administered via a single epidural injection to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23080351/),h,36,162739,DB00297,Bupivacaine
,23080351,durations,"Median durations of pinprick/cold sensitivity loss were 36 and 69 hours, respectively, in the liposome bupivacaine 266-mg group versus 12 hours for both pinprick and cold in the bupivacaine HCl group.",The pharmacokinetics and pharmacodynamics of liposome bupivacaine administered via a single epidural injection to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23080351/),h,69,162740,DB00297,Bupivacaine
,23080351,durations,"Median durations of pinprick/cold sensitivity loss were 36 and 69 hours, respectively, in the liposome bupivacaine 266-mg group versus 12 hours for both pinprick and cold in the bupivacaine HCl group.",The pharmacokinetics and pharmacodynamics of liposome bupivacaine administered via a single epidural injection to healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23080351/),,12,162741,DB00297,Bupivacaine
,10514068,Maximum plasma bupivacaine concentration,"Maximum plasma bupivacaine concentration was 147.6 +/- 5.0 ng/ml 95 h after the device implantation, and the drug was detected in plasma for 17 days.",Bupivacaine-loaded comatrix formed by albumin microspheres included in a poly(lactide-co-glycolide) film: in vivo biocompatibility and drug release studies. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10514068/),[ng] / [ml],147.6,163582,DB00297,Bupivacaine
,34315419,maximum plasma concentration,Geometric mean maximum plasma concentration was 170.9 ng/mL; the highest plasma bupivacaine concentration detected in any participant was 374.0 ng/mL.,Pharmacokinetics and safety of liposomal bupivacaine after local infiltration in healthy Chinese adults: a phase 1 study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/34315419/),[ng] / [ml],170.9,164836,DB00297,Bupivacaine
,8785150,maximal concentration,"Mean maximal concentration in the 10-15-kg group (1.5 (SD 0.9) mg litre-1, range 0.43-4.0 mg litre-1, at 18 (5) min) was significantly higher (P < 0.05) than that in the 15-30-kg group (0.9 (0.3) mg litre-1 range 0.35-1.34 mg litre-1, at 16 (5) min).",Smaller children have greater bupivacaine plasma concentrations after ilioinguinal block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785150/),[mg] / [l],1.5,165569,DB00297,Bupivacaine
,8785150,maximal concentration,"Mean maximal concentration in the 10-15-kg group (1.5 (SD 0.9) mg litre-1, range 0.43-4.0 mg litre-1, at 18 (5) min) was significantly higher (P < 0.05) than that in the 15-30-kg group (0.9 (0.3) mg litre-1 range 0.35-1.34 mg litre-1, at 16 (5) min).",Smaller children have greater bupivacaine plasma concentrations after ilioinguinal block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785150/),[mg] / [l],0.9,165570,DB00297,Bupivacaine
,8785150,maximum safe plasma concentration,"The maximum safe plasma concentration of bupivacaine in small children, although not clearly established, is likely to be approximately 4 mg litre-1.",Smaller children have greater bupivacaine plasma concentrations after ilioinguinal block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8785150/),[mg] / [l],4,165571,DB00297,Bupivacaine
,17166193,minimum effective concentration,"The minimum effective concentration of fentanyl in serum (0.63 ng/mL) was achieved at 11.3 +/- 4.9 hours after application, and serum concentrations remained above this level until 13 hours after removal.",Pharmacokinetic profile and efficacy of a fentanyl transdermal delivery system for acute postoperative pain after intra-abdominal gynecologic surgery for cancer. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17166193/),[ng] / [ml],0.63,166182,DB00297,Bupivacaine
,8694326,elimination half-life,"The elimination half-life in plasma (mean +/- SEM) was 9.9 +/- 1.7 h (Ls), 8.6 +/- 0.7 h (Ts), and 11.7 +/- 2.2 h (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),h,9.9,168144,DB00297,Bupivacaine
,8694326,Ts,"The elimination half-life in plasma (mean +/- SEM) was 9.9 +/- 1.7 h (Ls), 8.6 +/- 0.7 h (Ts), and 11.7 +/- 2.2 h (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),h,8.6,168145,DB00297,Bupivacaine
,8694326,Tsb,"The elimination half-life in plasma (mean +/- SEM) was 9.9 +/- 1.7 h (Ls), 8.6 +/- 0.7 h (Ts), and 11.7 +/- 2.2 h (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),h,11.7,168146,DB00297,Bupivacaine
,8694326,distribution volume,"The distribution volume was 15.2 +/- 3.5 l/kg (Ls), 14.8 +/- 2.4 L/kg (Ts), and 12.9 +/- 1.2 L/kg (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[l] / [kg],15.2,168147,DB00297,Bupivacaine
,8694326,distribution volume,"The distribution volume was 15.2 +/- 3.5 l/kg (Ls), 14.8 +/- 2.4 L/kg (Ts), and 12.9 +/- 1.2 L/kg (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[l] / [kg],14.8,168148,DB00297,Bupivacaine
,8694326,distribution volume,"The distribution volume was 15.2 +/- 3.5 l/kg (Ls), 14.8 +/- 2.4 L/kg (Ts), and 12.9 +/- 1.2 L/kg (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[l] / [kg],12.9,168149,DB00297,Bupivacaine
,8694326,Ts,"The distribution volume was 15.2 +/- 3.5 l/kg (Ls), 14.8 +/- 2.4 L/kg (Ts), and 12.9 +/- 1.2 L/kg (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[l] / [kg],14.8,168150,DB00297,Bupivacaine
,8694326,Tsb,"The distribution volume was 15.2 +/- 3.5 l/kg (Ls), 14.8 +/- 2.4 L/kg (Ts), and 12.9 +/- 1.2 L/kg (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[l] / [kg],12.9,168151,DB00297,Bupivacaine
,8694326,clearance,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],17.8,168152,DB00297,Bupivacaine
,8694326,clearance,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],16.9,168153,DB00297,Bupivacaine
,8694326,clearance,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],22.9,168154,DB00297,Bupivacaine
,8694326,clearance,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],20.0,168155,DB00297,Bupivacaine
,8694326,Ts,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],20.0,168156,DB00297,Bupivacaine
,8694326,Tsb,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],22.4,168157,DB00297,Bupivacaine
,8694326,Tsb,"Total sufentanil clearance was 17.8 +/- 1.4 and 16.9 +/- 2.0 mL.kg-1.min-1 (Ls), 22.9 +/- 3.5 and 20.0 +/- 2.6 mL.kg-1.min-1 (Ts), and 22.4 +/- 3.0 and 14.5 +/- 1.3 mL.kg-1.min-1 (Tsb).",The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),[ml] / [kg·min],14.5,168158,DB00297,Bupivacaine
,8694326,terminal elimination half-life,The terminal elimination half-life of sufentanil in CSF was 7.2 +/- 0.6 h.,The pharmacokinetics of continuous epidural sufentanil and bupivacaine infusion after thoracotomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8694326/),h,7.2,168159,DB00297,Bupivacaine
,14576555,maximum,"The plasma concentration of levobupivacaine increased during the infusion period, reaching a maximum of 0.76 +/- 0.11 mug/ml in the 0.125% group and 0.48 +/- 0.12 mug/ml in the 0.0625% group by 24 h.","Efficacy, safety, and pharmacokinetics of levobupivacaine with and without fentanyl after continuous epidural infusion in children: a multicenter trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576555/),[μg] / [ml],0.76,170597,DB00297,Bupivacaine
,14576555,maximum,"The plasma concentration of levobupivacaine increased during the infusion period, reaching a maximum of 0.76 +/- 0.11 mug/ml in the 0.125% group and 0.48 +/- 0.12 mug/ml in the 0.0625% group by 24 h.","Efficacy, safety, and pharmacokinetics of levobupivacaine with and without fentanyl after continuous epidural infusion in children: a multicenter trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576555/),[μg] / [ml],0.48,170598,DB00297,Bupivacaine
,14576555,maximum concentration,"The plasma concentration of fentanyl also increased steadily, reaching a maximum concentration of 0.37 +/- 0.11 ng/ml by 24 h.","Efficacy, safety, and pharmacokinetics of levobupivacaine with and without fentanyl after continuous epidural infusion in children: a multicenter trial. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14576555/),[ng] / [ml],0.37,170599,DB00297,Bupivacaine
,20357145,Maximal plasma concentration,"Maximal plasma concentration was not significantly different between groups (0.87 +/- 0.45 microg/mL and 0.83 +/- 0.34 microg/mL for plain and liposomal bupivacaine, respectively; P = not significant, 0.83).",High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357145/),[μg] / [ml],0.87,170758,DB00297,Bupivacaine
,20357145,Maximal plasma concentration,"Maximal plasma concentration was not significantly different between groups (0.87 +/- 0.45 microg/mL and 0.83 +/- 0.34 microg/mL for plain and liposomal bupivacaine, respectively; P = not significant, 0.83).",High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357145/),[μg] / [ml],0.83,170759,DB00297,Bupivacaine
,20357145,Time to achieve maximal plasma concentration,"Time to achieve maximal plasma concentration was 7-fold greater for the liposomal preparation (262 +/- 149 minutes vs 37.5 +/- 16 minutes, P < 0.01).",High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357145/),min,262,170760,DB00297,Bupivacaine
,20357145,Time to achieve maximal plasma concentration,"Time to achieve maximal plasma concentration was 7-fold greater for the liposomal preparation (262 +/- 149 minutes vs 37.5 +/- 16 minutes, P < 0.01).",High-dose bupivacaine remotely loaded into multivesicular liposomes demonstrates slow drug release without systemic toxic plasma concentrations after subcutaneous administration in humans. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/20357145/),min,37.5,170761,DB00297,Bupivacaine
not exceed,25336967,Total plasma bupivacaine concentrations,"Total plasma bupivacaine concentrations following intrathecal and rectal bupivacaine application did not exceed 317.2 ng·mL(-1) and 235.7 ng·mL(-1), respectively.",Bupivacaine administered intrathecally versus rectally in the management of intractable rectal cancer pain in palliative care. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25336967/),[ng] / [ml],317.2,171599,DB00297,Bupivacaine
,25336967,Total plasma bupivacaine concentrations,"Total plasma bupivacaine concentrations following intrathecal and rectal bupivacaine application did not exceed 317.2 ng·mL(-1) and 235.7 ng·mL(-1), respectively.",Bupivacaine administered intrathecally versus rectally in the management of intractable rectal cancer pain in palliative care. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25336967/),[ng] / [ml],235.7,171600,DB00297,Bupivacaine
,25336967,t½,"Bupivacaine elimination was slower after rectal than after intrathecal administration (t½= 5.50 versus 2.02 hours, respectively).",Bupivacaine administered intrathecally versus rectally in the management of intractable rectal cancer pain in palliative care. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25336967/),h,5.50,171601,DB00297,Bupivacaine
,25336967,t½,"Bupivacaine elimination was slower after rectal than after intrathecal administration (t½= 5.50 versus 2.02 hours, respectively).",Bupivacaine administered intrathecally versus rectally in the management of intractable rectal cancer pain in palliative care. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25336967/),h,2.02,171602,DB00297,Bupivacaine
,8017669,time of onset,The time of onset of surgical anaesthesia was significantly shorter with spinal anaesthesia (7.6 +/- 4.4 vs 31 +/- 11.1 min; p < 0.01).,[Pharmacokinetics of epidural or intrathecal bupivacaine in elective cesarean section]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8017669/),min,7.6,174721,DB00297,Bupivacaine
,8017669,time of onset,The time of onset of surgical anaesthesia was significantly shorter with spinal anaesthesia (7.6 +/- 4.4 vs 31 +/- 11.1 min; p < 0.01).,[Pharmacokinetics of epidural or intrathecal bupivacaine in elective cesarean section]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8017669/),min,31,174722,DB00297,Bupivacaine
,8017669,duration,The sensory block had a longer duration in epidural group (223.2 +/- 15 vs 291 +/- 13.8; p < 0.001).,[Pharmacokinetics of epidural or intrathecal bupivacaine in elective cesarean section]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8017669/),,291,174723,DB00297,Bupivacaine
,2378769,maximum arterial,"Mean maximum arterial and venous concentrations in eight of 11 patients were 1.90 (SD 0.36) and 1.65 (0.48) mg litre-1 and occurred at 22 (10) min and 25 (10) min, respectively.",Pharmacokinetics of interpleural bupivacaine in patients undergoing cholecystectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378769/),[mg] / [l],1.90,175133,DB00297,Bupivacaine
,2378769,venous concentrations,"Mean maximum arterial and venous concentrations in eight of 11 patients were 1.90 (SD 0.36) and 1.65 (0.48) mg litre-1 and occurred at 22 (10) min and 25 (10) min, respectively.",Pharmacokinetics of interpleural bupivacaine in patients undergoing cholecystectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378769/),[mg] / [l],1.65,175134,DB00297,Bupivacaine
,2378769,systemic venous plasma clearance,Mean systemic venous plasma clearance (0.15 (0.08) litre h-1 kg-1) was less and the mean elimination half-life (6.85 (2.29) h) and mean body residence time (9.99 (3.00) h) were longer than reported previously for interpleural bupivacaine--possibly because of continued slow absorption of the drug from its absorption site.,Pharmacokinetics of interpleural bupivacaine in patients undergoing cholecystectomy. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378769/),[l] / [h·kg],0.15,175135,DB00297,Bupivacaine
,2378769,elimination half-life,Mean systemic venous plasma clearance (0.15 (0.08) litre h-1 kg-1) was less and the mean elimination half-life (6.85 (2.29) h) and mean body residence time (9.99 (3.00) h) were longer than reported previously for interpleural bupivacaine--possibly because of continued slow absorption of the drug from its absorption site.,Pharmacokinetics of interpleural bupivacaine in patients undergoing cholecystectomy. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378769/),h,6.85,175136,DB00297,Bupivacaine
,2378769,body residence time,Mean systemic venous plasma clearance (0.15 (0.08) litre h-1 kg-1) was less and the mean elimination half-life (6.85 (2.29) h) and mean body residence time (9.99 (3.00) h) were longer than reported previously for interpleural bupivacaine--possibly because of continued slow absorption of the drug from its absorption site.,Pharmacokinetics of interpleural bupivacaine in patients undergoing cholecystectomy. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2378769/),h,9.99,175137,DB00297,Bupivacaine
,23167288,Tabs,"While initial absorption was unchanged (Tabs 0.15 h 95%CI 0.12, 0.18 h), there was a late absorption peak characterized by a Tabs(LATE) 2.34 h (95%CI 1.44, 4.97 h).",Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),h,0.15,177557,DB00297,Bupivacaine
,23167288,Tabs(LATE),"While initial absorption was unchanged (Tabs 0.15 h 95%CI 0.12, 0.18 h), there was a late absorption peak characterized by a Tabs(LATE) 2.34 h (95%CI 1.44, 4.97 h).",Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),h,2.34,177558,DB00297,Bupivacaine
,23167288,volume of distribution,The population parameter estimate for volume of distribution was 157 l 70 kg(-1).,Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),[l] / [70·kg],157,177559,DB00297,Bupivacaine
,23167288,Clearance,Clearance was 6.5 l · h(-1) 70 kg(-1) at 1-month PNA and increased with a maturation half-time of 1.6 months to reach 90% of the mature value (18.5 l · h(-1) 70 kg(-1)) by 5 months PNA.,Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),[l] / [70·h·kg],6.5,177560,DB00297,Bupivacaine
,23167288,maturation half-time,Clearance was 6.5 l · h(-1) 70 kg(-1) at 1-month PNA and increased with a maturation half-time of 1.6 months to reach 90% of the mature value (18.5 l · h(-1) 70 kg(-1)) by 5 months PNA.,Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),month,1.6,177561,DB00297,Bupivacaine
,23167288,maturation half-time,Clearance was 6.5 l · h(-1) 70 kg(-1) at 1-month PNA and increased with a maturation half-time of 1.6 months to reach 90% of the mature value (18.5 l · h(-1) 70 kg(-1)) by 5 months PNA.,Absorption characteristics of epidural levobupivacaine with adrenaline and clonidine in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23167288/),[l] / [70·h·kg],18.5,177562,DB00297,Bupivacaine
,11226108,peak concentrations,"Observed peak concentrations were larger in the Ropivacaine group (4.25 [2.07-6.59 mg/L] vs 3.02 [0.98-5.82 mg/L]), but time to reach peak concentrations was comparable (5 [1-15 min] vs 5 [0-45 min] in the Ropivacaine and Bupivacaine groups, respectively).",A comparison of ropivacaine and bupivacaine for cervical plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11226108/),[mg] / [l],4.25,178162,DB00297,Bupivacaine
,11226108,peak concentrations,"Observed peak concentrations were larger in the Ropivacaine group (4.25 [2.07-6.59 mg/L] vs 3.02 [0.98-5.82 mg/L]), but time to reach peak concentrations was comparable (5 [1-15 min] vs 5 [0-45 min] in the Ropivacaine and Bupivacaine groups, respectively).",A comparison of ropivacaine and bupivacaine for cervical plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11226108/),[mg] / [l],3.02,178163,DB00297,Bupivacaine
,11226108,time to reach peak concentrations,"Observed peak concentrations were larger in the Ropivacaine group (4.25 [2.07-6.59 mg/L] vs 3.02 [0.98-5.82 mg/L]), but time to reach peak concentrations was comparable (5 [1-15 min] vs 5 [0-45 min] in the Ropivacaine and Bupivacaine groups, respectively).",A comparison of ropivacaine and bupivacaine for cervical plexus block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11226108/),,5,178164,DB00297,Bupivacaine
,11226108,time to reach peak concentrations,"Observed peak concentrations were larger in the Ropivacaine group (4.25 [2.07-6.59 mg/L] vs 3.02 [0.98-5.82 mg/L]), but time to reach peak concentrations was comparable (5 [1-15 min] vs 5 [0-45 min] in the Ropivacaine and Bupivacaine groups, respectively).",A comparison of ropivacaine and bupivacaine for cervical plexus block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11226108/),,5,178165,DB00297,Bupivacaine
,12703836,duration of action,"Despite the delayed onset of motor block, the incorporation of dexamethasone in bupivacaine-loaded microspheres dramatically increases the duration of action (700 +/- 485-5160 +/- 2136 min), which could be clinically relevant when such a drug-delivery system will be available.",Effect of dexamethasone on motor brachial plexus block with bupivacaine and with bupivacaine-loaded microspheres in a sheep model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12703836/),min,700,180565,DB00297,Bupivacaine
,12703836,duration of action,"Despite the delayed onset of motor block, the incorporation of dexamethasone in bupivacaine-loaded microspheres dramatically increases the duration of action (700 +/- 485-5160 +/- 2136 min), which could be clinically relevant when such a drug-delivery system will be available.",Effect of dexamethasone on motor brachial plexus block with bupivacaine and with bupivacaine-loaded microspheres in a sheep model. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12703836/),min,5160,180566,DB00297,Bupivacaine
under,3623743,tmax,All the tmax observed were under 2 h and the dose independence of the kinetic of BU is not admissible in this study.,Pharmacokinetics of bupivacaine after axillary brachial plexus block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3623743/),h,2,180682,DB00297,Bupivacaine
,19459553,maximal plasma concentration (Cmax),"The maximal plasma concentration (Cmax) of ropivacaine and bupivacaine were 964 (282) ng ml(-1) and 638 (366) ng ml(-1), respectively.",Local anaesthetic use for the iliac crest-donor site: pharmacokinetic and pharmacodynamic evaluations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19459553/),[ng] / [ml],964,183689,DB00297,Bupivacaine
,19459553,maximal plasma concentration (Cmax),"The maximal plasma concentration (Cmax) of ropivacaine and bupivacaine were 964 (282) ng ml(-1) and 638 (366) ng ml(-1), respectively.",Local anaesthetic use for the iliac crest-donor site: pharmacokinetic and pharmacodynamic evaluations. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19459553/),[ng] / [ml],638,183690,DB00297,Bupivacaine
,9914653,rate of excretion,"The rate of excretion of bupivacaine enantiomers' approximated a steady state after approximately 30 hr with values of 1.27 +/- 0.26 and 0.76 +/- 0.13 mg hr-1 for (R)- and (S)-enantiomers, respectively.",Stereoselective urinary excretion of bupivacaine and its metabolites during epidural infusion. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9914653/),[mg] / [h],1.27,184281,DB00297,Bupivacaine
,9914653,rate of excretion,"The rate of excretion of bupivacaine enantiomers' approximated a steady state after approximately 30 hr with values of 1.27 +/- 0.26 and 0.76 +/- 0.13 mg hr-1 for (R)- and (S)-enantiomers, respectively.",Stereoselective urinary excretion of bupivacaine and its metabolites during epidural infusion. ,ke-Q50,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9914653/),[mg] / [h],0.76,184282,DB00297,Bupivacaine
,15248626,elimination half-life,"In surgical patients the elimination half-life (mean +/- SD: 196 +/- 65 min), total body clearanc (349 +/- 114 mL min(-1)) and volume of distribution at steady state (56 +/- 14 L), derived by compartmental analysis, were similar to those obtained by non-compartmental analysis.",The systemic absorption and disposition of levobupivacaine 0.5% after epidural administration in surgical patients: a stable-isotope study. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248626/),min,196,187257,DB00297,Bupivacaine
,15248626,total body clearanc,"In surgical patients the elimination half-life (mean +/- SD: 196 +/- 65 min), total body clearanc (349 +/- 114 mL min(-1)) and volume of distribution at steady state (56 +/- 14 L), derived by compartmental analysis, were similar to those obtained by non-compartmental analysis.",The systemic absorption and disposition of levobupivacaine 0.5% after epidural administration in surgical patients: a stable-isotope study. ,Css-Q34,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248626/),[ml] / [min],349,187258,DB00297,Bupivacaine
,15248626,volume of distribution at steady state,"In surgical patients the elimination half-life (mean +/- SD: 196 +/- 65 min), total body clearanc (349 +/- 114 mL min(-1)) and volume of distribution at steady state (56 +/- 14 L), derived by compartmental analysis, were similar to those obtained by non-compartmental analysis.",The systemic absorption and disposition of levobupivacaine 0.5% after epidural administration in surgical patients: a stable-isotope study. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248626/),l,56,187259,DB00297,Bupivacaine
,15248626,fracti,"The fractio absorbed and half-life of the fast absorption process were 0.22 +/- 0.06 and 5.2 +/- 2.7 min, respectively.",The systemic absorption and disposition of levobupivacaine 0.5% after epidural administration in surgical patients: a stable-isotope study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248626/),min,0.22,187260,DB00297,Bupivacaine
,15248626,half-life,"The fractio absorbed and half-life of the fast absorption process were 0.22 +/- 0.06 and 5.2 +/- 2.7 min, respectively.",The systemic absorption and disposition of levobupivacaine 0.5% after epidural administration in surgical patients: a stable-isotope study. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248626/),min,5.2,187261,DB00297,Bupivacaine
,15248626,Th,"Th values for the slow absorption process were 0.84 +/- 0.14 and 386 +/- 91 min, respectively.",The systemic absorption and disposition of levobupivacaine 0.5% after epidural administration in surgical patients: a stable-isotope study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248626/),min,0.84,187262,DB00297,Bupivacaine
,15248626,Th,"Th values for the slow absorption process were 0.84 +/- 0.14 and 386 +/- 91 min, respectively.",The systemic absorption and disposition of levobupivacaine 0.5% after epidural administration in surgical patients: a stable-isotope study. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15248626/),min,386,187263,DB00297,Bupivacaine
,3177919,distribution,The distribution and elimination half-lives of the deuterium-labelled analogues were 25 +/- 13 min (mean +/- SD) and 121 +/- 31 min for lidocaine and 19 +/- 10 min and 131 +/- 33 min for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),min,25,188511,DB00297,Bupivacaine
,3177919,distribution,The distribution and elimination half-lives of the deuterium-labelled analogues were 25 +/- 13 min (mean +/- SD) and 121 +/- 31 min for lidocaine and 19 +/- 10 min and 131 +/- 33 min for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),min,19,188512,DB00297,Bupivacaine
,3177919,distribution,The distribution and elimination half-lives of the deuterium-labelled analogues were 25 +/- 13 min (mean +/- SD) and 121 +/- 31 min for lidocaine and 19 +/- 10 min and 131 +/- 33 min for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),min,131,188513,DB00297,Bupivacaine
,3177919,elimination half-lives,The distribution and elimination half-lives of the deuterium-labelled analogues were 25 +/- 13 min (mean +/- SD) and 121 +/- 31 min for lidocaine and 19 +/- 10 min and 131 +/- 33 min for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),min,121,188514,DB00297,Bupivacaine
,3177919,elimination half-lives,The distribution and elimination half-lives of the deuterium-labelled analogues were 25 +/- 13 min (mean +/- SD) and 121 +/- 31 min for lidocaine and 19 +/- 10 min and 131 +/- 33 min for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),min,131,188515,DB00297,Bupivacaine
,3177919,volumes of the central compartment,"The volumes of the central compartment and steady-state volumes of distribution were: lidocaine 57 +/- 10 l and 105 +/- 25 l, bupivacaine 25 +/- 6 l and 63 +/- 22 l.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),l,57,188516,DB00297,Bupivacaine
,3177919,volumes of the central compartment,"The volumes of the central compartment and steady-state volumes of distribution were: lidocaine 57 +/- 10 l and 105 +/- 25 l, bupivacaine 25 +/- 6 l and 63 +/- 22 l.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),l,25,188517,DB00297,Bupivacaine
,3177919,steady-state volumes of distribution,"The volumes of the central compartment and steady-state volumes of distribution were: lidocaine 57 +/- 10 l and 105 +/- 25 l, bupivacaine 25 +/- 6 l and 63 +/- 22 l.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),l,105,188518,DB00297,Bupivacaine
,3177919,steady-state volumes of distribution,"The volumes of the central compartment and steady-state volumes of distribution were: lidocaine 57 +/- 10 l and 105 +/- 25 l, bupivacaine 25 +/- 6 l and 63 +/- 22 l.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),l,63,188519,DB00297,Bupivacaine
,3177919,Total plasma clearance,Total plasma clearance values averaged 0.97 +/- 0.21 l/min for lidocaine and 0.56 +/- 0.14 l/min for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),[l] / [min],0.97,188520,DB00297,Bupivacaine
,3177919,Total plasma clearance,Total plasma clearance values averaged 0.97 +/- 0.21 l/min for lidocaine and 0.56 +/- 0.14 l/min for bupivacaine.,Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),[l] / [min],0.56,188521,DB00297,Bupivacaine
,3177919,half-life,"The absorption of lidocaine could be described by a single first order absorption process, characterized by a half-life of 71 +/- 17 min in five out of six patients.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),min,71,188522,DB00297,Bupivacaine
,3177919,half-lives,"The half-lives, characterizing the fast and slow absorption processes of bupivacaine, were 50 +/- 27 min and 408 +/- 275 min, respectively.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),min,50,188523,DB00297,Bupivacaine
,3177919,half-lives,"The half-lives, characterizing the fast and slow absorption processes of bupivacaine, were 50 +/- 27 min and 408 +/- 275 min, respectively.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),min,408,188524,DB00297,Bupivacaine
,3177919,fractions of,"The fractions of the dose, absorbed in the fast and slow processes, were 0.35 +/- 0.17 and 0.61 +/- 0.16, respectively.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),,0.35,188525,DB00297,Bupivacaine
,3177919,fractions of,"The fractions of the dose, absorbed in the fast and slow processes, were 0.35 +/- 0.17 and 0.61 +/- 0.16, respectively.",Pharmacokinetics of lidocaine and bupivacaine following subarachnoid administration in surgical patients: simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3177919/),,0.61,188526,DB00297,Bupivacaine
,31806432,target plasma concentration (TPC),"Dogs were allocated to group fTCI [target plasma concentration (TPC) 1 ng mL-1] or group PNB (nerve stimulator-guided femoral-sciatic block using 0.2 and 0.1 mL kg-1 of levobupivacaine 0.5%, respectively).",Peripheral nerve block versus systemic analgesia in dogs undergoing tibial plateau levelling osteotomy: Analgesic efficacy and pharmacoeconomics comparison. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31806432/),[ng] / [ml],1,190829,DB00297,Bupivacaine
,30924096,Cmax,The median (interquartile range [IQR]) Cmax was 0.82 μg/mL (0.47-1.03).,Safety and Pharmacokinetics of Levobupivacaine Following Fascia Iliaca Compartment Block in Elderly Patients. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924096/),[μg] / [ml],0.82,191511,DB00297,Bupivacaine
,30924096,tmax,tmax was 45 min (41:20-60:00).,Safety and Pharmacokinetics of Levobupivacaine Following Fascia Iliaca Compartment Block in Elderly Patients. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/30924096/),min,45,191512,DB00297,Bupivacaine
,3479919,maximum bupivacaine plasma level,The maximum bupivacaine plasma level recorded in any volunteer was 0.96 -g/mL (after 80 mg).,Absorption of bupivacaine after topical application to the oropharynx. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3479919/),[g] / [ml],0.96,194781,DB00297,Bupivacaine
,21642610,Cmax,Epidural lidocaine administration (20-35 mL) 1 hour before epidural EREM administration increased the Cmax in group E (11.1 ± 4.9) compared with group SE (8.3 ± 7.1 ng/mL) (P = 0.038).,Prior epidural lidocaine alters the pharmacokinetics and drug effects of extended-release epidural morphine (DepoDur®) after cesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21642610/),[ng] / [ml],11.1,195168,DB00297,Bupivacaine
,21642610,Cmax,Epidural lidocaine administration (20-35 mL) 1 hour before epidural EREM administration increased the Cmax in group E (11.1 ± 4.9) compared with group SE (8.3 ± 7.1 ng/mL) (P = 0.038).,Prior epidural lidocaine alters the pharmacokinetics and drug effects of extended-release epidural morphine (DepoDur®) after cesarean delivery. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21642610/),[ng] / [ml],8.3,195169,DB00297,Bupivacaine
,2034826,Peak bupivacaine plasma levels,Peak bupivacaine plasma levels (mean 1.30 microgram/ml) were found 10 min after application of the analgesic dose in the control patients.,[Pharmacokinetic studies of blood protein binding of bupivacaine following acute preoperative hemodilution]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034826/),[μg] / [ml],1.30,195331,DB00297,Bupivacaine
,2034826,peak levels,"In contrast, in hemodiluted patients mean maximum plasma levels of bupivacaine were measured between the 20th and 30th min, with peak levels of only 0.75 microgram/ml plasma.",[Pharmacokinetic studies of blood protein binding of bupivacaine following acute preoperative hemodilution]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2034826/),[μg] / [ml],0.75,195332,DB00297,Bupivacaine
,7715747,clearance,The clearance values differed only by 0.2 ml/min from the control parameters in sham perfusions.,Pulmonary uptake of bupivacaine in isolated perfused rat lung. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715747/),[ml] / [min],0.2,195462,DB00297,Bupivacaine
,7715747,extraction ratio,The calculated extraction ratio was 0.2% and the elimination half-life was about 210 min.,Pulmonary uptake of bupivacaine in isolated perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715747/),%,0.2,195463,DB00297,Bupivacaine
,7715747,elimination half-life,The calculated extraction ratio was 0.2% and the elimination half-life was about 210 min.,Pulmonary uptake of bupivacaine in isolated perfused rat lung. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715747/),min,210,195464,DB00297,Bupivacaine
,7715747,volume of distribution,The volume of distribution of bupivacaine was 133 ml which remarkably surmounted the reference values obtained for sham perfusions.,Pulmonary uptake of bupivacaine in isolated perfused rat lung. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715747/),ml,133,195465,DB00297,Bupivacaine
,7715747,flow rate,"The mean elimination time of model compounds for distribution into the intravascular space, 14C-insulin, and the total water space, 3H-water, were 68 and 75 s at a flow rate of 6 ml/min.",Pulmonary uptake of bupivacaine in isolated perfused rat lung. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715747/),[ml] / [min],6,195466,DB00297,Bupivacaine
,7715747,volume of distribution,The volume of distribution was 5.9 ml for inulin and 6.5 ml for water.,Pulmonary uptake of bupivacaine in isolated perfused rat lung. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715747/),ml,5.9,195467,DB00297,Bupivacaine
,7715747,volume of distribution,The volume of distribution was 5.9 ml for inulin and 6.5 ml for water.,Pulmonary uptake of bupivacaine in isolated perfused rat lung. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715747/),ml,6.5,195468,DB00297,Bupivacaine
,7715747,mean transit time,The mean transit time for concomitantly injected bupivacaine was 221 s and the volume of distribution was 14.4 ml.,Pulmonary uptake of bupivacaine in isolated perfused rat lung. ,MRT-Q53,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715747/),s,221,195469,DB00297,Bupivacaine
,7715747,volume of distribution,The mean transit time for concomitantly injected bupivacaine was 221 s and the volume of distribution was 14.4 ml.,Pulmonary uptake of bupivacaine in isolated perfused rat lung. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715747/),ml,14.4,195470,DB00297,Bupivacaine
,7715747,elimination time,"The respective parameters of sham perfusions performed without an isolated organ were substantially lower, i.e. mean elimination time 50, 50 and 61 s and distribution volume 4.9, 5.0 and 6.1 ml for inulin, water and bupivacaine.",Pulmonary uptake of bupivacaine in isolated perfused rat lung. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715747/),s,50,195471,DB00297,Bupivacaine
,7715747,elimination time,"The respective parameters of sham perfusions performed without an isolated organ were substantially lower, i.e. mean elimination time 50, 50 and 61 s and distribution volume 4.9, 5.0 and 6.1 ml for inulin, water and bupivacaine.",Pulmonary uptake of bupivacaine in isolated perfused rat lung. ,k-Q47,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715747/),s,61,195472,DB00297,Bupivacaine
,7715747,distribution volume,"The respective parameters of sham perfusions performed without an isolated organ were substantially lower, i.e. mean elimination time 50, 50 and 61 s and distribution volume 4.9, 5.0 and 6.1 ml for inulin, water and bupivacaine.",Pulmonary uptake of bupivacaine in isolated perfused rat lung. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715747/),ml,4.9,195473,DB00297,Bupivacaine
,7715747,distribution volume,"The respective parameters of sham perfusions performed without an isolated organ were substantially lower, i.e. mean elimination time 50, 50 and 61 s and distribution volume 4.9, 5.0 and 6.1 ml for inulin, water and bupivacaine.",Pulmonary uptake of bupivacaine in isolated perfused rat lung. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715747/),ml,5.0,195474,DB00297,Bupivacaine
,7715747,distribution volume,"The respective parameters of sham perfusions performed without an isolated organ were substantially lower, i.e. mean elimination time 50, 50 and 61 s and distribution volume 4.9, 5.0 and 6.1 ml for inulin, water and bupivacaine.",Pulmonary uptake of bupivacaine in isolated perfused rat lung. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7715747/),ml,6.1,195475,DB00297,Bupivacaine
,21693469,half-life,Ropivacaine half-life decreased with age from 13 h in the newborn to 3 h beyond 1 yr.,"Population pharmacokinetic analysis of ropivacaine and its metabolite 2',6'-pipecoloxylidide from pooled data in neonates, infants, and children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21693469/),h,13,197337,DB00297,Bupivacaine
,21693469,half-life,Ropivacaine half-life decreased with age from 13 h in the newborn to 3 h beyond 1 yr.,"Population pharmacokinetic analysis of ropivacaine and its metabolite 2',6'-pipecoloxylidide from pooled data in neonates, infants, and children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21693469/),h,3,197338,DB00297,Bupivacaine
,21693469,half-life,PPX half-life differed from 19 h in the newborn to 8-11 h between 1 and 12 months to 17 h after 1 yr.,"Population pharmacokinetic analysis of ropivacaine and its metabolite 2',6'-pipecoloxylidide from pooled data in neonates, infants, and children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21693469/),h,19,197339,DB00297,Bupivacaine
,21693469,half-life,PPX half-life differed from 19 h in the newborn to 8-11 h between 1 and 12 months to 17 h after 1 yr.,"Population pharmacokinetic analysis of ropivacaine and its metabolite 2',6'-pipecoloxylidide from pooled data in neonates, infants, and children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21693469/),h,8-11,197340,DB00297,Bupivacaine
,21693469,half-life,PPX half-life differed from 19 h in the newborn to 8-11 h between 1 and 12 months to 17 h after 1 yr.,"Population pharmacokinetic analysis of ropivacaine and its metabolite 2',6'-pipecoloxylidide from pooled data in neonates, infants, and children. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/21693469/),h,17,197341,DB00297,Bupivacaine
,3320904,retention times,"Under the conditions of the assay used, retention times were 3.3 minutes and 6.3 minutes for mepivacaine and bupivacaine, respectively.",[Pharmacokinetic study of bupivacaine in mice: proposal of a specific sensitive technic using gas chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3320904/),min,3.3,201726,DB00297,Bupivacaine
,3320904,retention times,"Under the conditions of the assay used, retention times were 3.3 minutes and 6.3 minutes for mepivacaine and bupivacaine, respectively.",[Pharmacokinetic study of bupivacaine in mice: proposal of a specific sensitive technic using gas chromatography]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3320904/),min,6.3,201727,DB00297,Bupivacaine
,29042063,Plasma peak,Plasma peak was 933.97 ± 328.03 ng.mL-1 (mean ± SD) in 0.25% Group and 1022.79 ± 253.81 ng.,[Pharmacokinetic and clinical effects of two bupivacaine concentrations on axillary brachial plexus block]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29042063/),[ng] / [ml],933.97,204471,DB00297,Bupivacaine
,29042063,Plasma peak,Plasma peak was 933.97 ± 328.03 ng.mL-1 (mean ± SD) in 0.25% Group and 1022.79 ± 253.81 ng.,[Pharmacokinetic and clinical effects of two bupivacaine concentrations on axillary brachial plexus block]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29042063/),ng,1022.79,204472,DB00297,Bupivacaine
,29042063,Latency,"Latency was lower in 0.5% Group than in 0.25% Group (10.67 ± 3.71 × 17.33min ± 5.30, respectively, p = 0.004).",[Pharmacokinetic and clinical effects of two bupivacaine concentrations on axillary brachial plexus block]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29042063/),min,10.67,204473,DB00297,Bupivacaine
,29042063,Latency,"Latency was lower in 0.5% Group than in 0.25% Group (10.67 ± 3.71 × 17.33min ± 5.30, respectively, p = 0.004).",[Pharmacokinetic and clinical effects of two bupivacaine concentrations on axillary brachial plexus block]. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/29042063/),min,17.33,204474,DB00297,Bupivacaine
,3662055,peak plasma concentration,"Addition of epinephrine to the local anesthetic solution reduced the mean peak plasma concentration of lidocaine from 526 to 376 ng/ml, but did not significantly reduce the mean peak plasma concentration of bupivacaine (70 vs 56 ng/ml).",Spinal anesthesia with hyperbaric lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662055/),[ng] / [ml],526,204683,DB00297,Bupivacaine
,3662055,peak plasma concentration,"Addition of epinephrine to the local anesthetic solution reduced the mean peak plasma concentration of lidocaine from 526 to 376 ng/ml, but did not significantly reduce the mean peak plasma concentration of bupivacaine (70 vs 56 ng/ml).",Spinal anesthesia with hyperbaric lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662055/),[ng] / [ml],376,204684,DB00297,Bupivacaine
,3662055,peak plasma concentration,"Addition of epinephrine to the local anesthetic solution reduced the mean peak plasma concentration of lidocaine from 526 to 376 ng/ml, but did not significantly reduce the mean peak plasma concentration of bupivacaine (70 vs 56 ng/ml).",Spinal anesthesia with hyperbaric lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662055/),[ng] / [ml],70,204685,DB00297,Bupivacaine
,3662055,peak plasma concentration,"Addition of epinephrine to the local anesthetic solution reduced the mean peak plasma concentration of lidocaine from 526 to 376 ng/ml, but did not significantly reduce the mean peak plasma concentration of bupivacaine (70 vs 56 ng/ml).",Spinal anesthesia with hyperbaric lidocaine and bupivacaine: effects of epinephrine on the plasma concentration profiles. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3662055/),[ng] / [ml],56,204686,DB00297,Bupivacaine
,7978410,maximum total plasma concentration,"Administration of 30 mL of plain bupivacaine 0.175%, via two needles, resulted in a maximum total plasma concentration of 0.2-1.0 mg/L (mean 0.49 mg/L).",Plasma concentrations of bupivacaine after lumbar sympathetic block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978410/),[mg] / [l],0.2-1.0,204775,DB00297,Bupivacaine
,7978410,maximum total plasma concentration,"Administration of 30 mL of plain bupivacaine 0.175%, via two needles, resulted in a maximum total plasma concentration of 0.2-1.0 mg/L (mean 0.49 mg/L).",Plasma concentrations of bupivacaine after lumbar sympathetic block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7978410/),[mg] / [l],0.49,204776,DB00297,Bupivacaine
,15200183,elimination half-life,The elimination half-life of ropivacaine was significantly less than that of bupivacaine (5.2 +/- 0.7 h vs. 10.8 +/- 1.06 h).,[Clinical effects and pharmacokinetics of ropivacaine and bupivacaine for epidural analgesia during labor]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15200183/),h,5.2,205076,DB00297,Bupivacaine
,15200183,elimination half-life,The elimination half-life of ropivacaine was significantly less than that of bupivacaine (5.2 +/- 0.7 h vs. 10.8 +/- 1.06 h).,[Clinical effects and pharmacokinetics of ropivacaine and bupivacaine for epidural analgesia during labor]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/15200183/),h,10.8,205077,DB00297,Bupivacaine
,7923523,sensitivity,The sensitivity of the method was 15 ng.,Cigarette smoke increases bupivacaine metabolism in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7923523/),ng,15,205509,DB00297,Bupivacaine
,1751278,peak venous serum concentrations (Cmax),"The peak venous serum concentrations (Cmax) of bupivacaine, measured by HPLC, were in the range 0.82-4.30 mg litre-1; there were no signs of toxicity.",Inverse correlation between the peak venous serum concentration of bupivacaine and the weight of the patient during interscalene brachial plexus block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1751278/),[mg] / [l],0.82-4.30,205865,DB00297,Bupivacaine
,18679666,Cmax,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ng] / [ml],879.11,206161,DB00297,Bupivacaine
,18679666,Cmax,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ng] / [ml],"1,145.58",206162,DB00297,Bupivacaine
,18679666,AUC(0-infinity),"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[μg] / [min·ml],256.01,206163,DB00297,Bupivacaine
,18679666,AUC(0-infinity),"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[μg] / [min·ml],455.95,206164,DB00297,Bupivacaine
,18679666,Cl/f/kg,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ml] / [kg·min],10.61,206165,DB00297,Bupivacaine
,18679666,Cl/f/kg,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,CLpo-Q27,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ml] / [kg·min],5.64,206166,DB00297,Bupivacaine
,18679666,Vd/f/kg,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[l] / [kg],3.26,206167,DB00297,Bupivacaine
,18679666,Vd/f/kg,"The median pharmacokinetic parameters of lidocaine for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 879.11 and 1,145.58 ng/ml, AUC(0-infinity) 256.01 and 455.95 mug min(-1) ml(-1), Cl/f/kg 10.61 and 5.64 ml min(-1) kg(-1), and Vd/f/kg 3.26 and 2.19 L/kg.",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[l] / [kg],2.19,206168,DB00297,Bupivacaine
,18679666,Cmax,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ng] / [ml],82.71,206169,DB00297,Bupivacaine
,18679666,Cmax,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[ng] / [ml],141.38,206170,DB00297,Bupivacaine
,18679666,Tmax,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),min,44.71,206171,DB00297,Bupivacaine
,18679666,Tmax,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),min,193.14,206172,DB00297,Bupivacaine
,18679666,t(1/2)alpha,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),min,7.64,206173,DB00297,Bupivacaine
,18679666,t(1/2)alpha,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),min,59.77,206174,DB00297,Bupivacaine
,18679666,alpha,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),1/[min],0.097,206175,DB00297,Bupivacaine
,18679666,alpha,"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),1/[min],0.012,206176,DB00297,Bupivacaine
,18679666,AUC(0-infinity),"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[μg] / [min·ml],29.91,206177,DB00297,Bupivacaine
,18679666,AUC(0-infinity),"The median pharmacokinetic parameters of MEGX for groups 1 and 2 (P </= 0.05), respectively, were as follows: for Cmax 82.71 and 141.38 ng/ml, Tmax 44.71 and 193.14 min, t(1/2)alpha 7.64 and 59.77 min, alpha 0.097 and 0.012/min, and AUC(0-infinity) 29.91 and 108.23 mug min(-1) ml(-1).",Pharmacokinetics of lidocaine and its metabolite in peridural anesthesia administered to pregnant women with gestational diabetes mellitus. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/18679666/),[μg] / [min·ml],108.23,206178,DB00297,Bupivacaine
,23038415,maximum arterial levobupivacaine concentrations,"The mean maximum arterial levobupivacaine concentrations with epinephrine were 0.36 (95% bootstrap confidence interval [95% CI], 0.30-0.42) μg/mL and 0.63 (95% CI, 0.49-0.85) μg/mL without epinephrine (P = 0.014, difference in means of 0.27 [95% CI, 0.12-0.46]).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),[μg] / [ml],0.36,206873,DB00297,Bupivacaine
,23038415,maximum arterial levobupivacaine concentrations,"The mean maximum arterial levobupivacaine concentrations with epinephrine were 0.36 (95% bootstrap confidence interval [95% CI], 0.30-0.42) μg/mL and 0.63 (95% CI, 0.49-0.85) μg/mL without epinephrine (P = 0.014, difference in means of 0.27 [95% CI, 0.12-0.46]).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),[μg] / [ml],0.63,206874,DB00297,Bupivacaine
,23038415,maximal venous levobupivacaine concentration,"The mean maximal venous levobupivacaine concentration was 0.32 (95% CI, 0.28-0.39) μg/mL and 0.49 (95% CI, 0.37-0.68) μg/mL, with and without epinephrine, respectively (P = 0.006, difference in means of 0.17 [95% CI, 0.08-0.33]).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),[μg] / [ml],0.32,206875,DB00297,Bupivacaine
,23038415,maximal venous levobupivacaine concentration,"The mean maximal venous levobupivacaine concentration was 0.32 (95% CI, 0.28-0.39) μg/mL and 0.49 (95% CI, 0.37-0.68) μg/mL, with and without epinephrine, respectively (P = 0.006, difference in means of 0.17 [95% CI, 0.08-0.33]).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),[μg] / [ml],0.49,206876,DB00297,Bupivacaine
,23038415,duration of the blockade,"The mean duration of the blockade was 10.2 hours (95% CI, 8.5-12.5 hours) with epinephrine and 10.3 hours (95% CI, 8.7-12.4 hours) without epinephrine (P = 1.000).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),h,10.2,206877,DB00297,Bupivacaine
,23038415,duration of the blockade,"The mean duration of the blockade was 10.2 hours (95% CI, 8.5-12.5 hours) with epinephrine and 10.3 hours (95% CI, 8.7-12.4 hours) without epinephrine (P = 1.000).",Comparison of plasma concentrations of levobupivacaine with and without epinephrine for transversus abdominis plane block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23038415/),h,10.3,206878,DB00297,Bupivacaine
,1608154,elimination half-life,"However, the mean elimination half-life of bupivacaine was significantly longer in patients with TMP [5.0 +/- 1.7 (SD) hr] compared with those with PGE1 (3.1 +/- 1.4 hr).",[Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608154/),h,5.0,208111,DB00297,Bupivacaine
,1608154,elimination half-life,"However, the mean elimination half-life of bupivacaine was significantly longer in patients with TMP [5.0 +/- 1.7 (SD) hr] compared with those with PGE1 (3.1 +/- 1.4 hr).",[Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension]. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608154/),h,3.1,208112,DB00297,Bupivacaine
,1608154,total clearance,The total clearance of bupivacaine was greater in patients with PGE1 (345 +/- 150 ml.min-1) compared with those with TMP (248 +/- 66 ml.min-1).,[Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608154/),[ml] / [min],345,208113,DB00297,Bupivacaine
,1608154,total clearance,The total clearance of bupivacaine was greater in patients with PGE1 (345 +/- 150 ml.min-1) compared with those with TMP (248 +/- 66 ml.min-1).,[Pharmacokinetics of epidurally administered bupivacaine during prostaglandin E1- or trimetaphan-induced hypotension]. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1608154/),[ml] / [min],248,208114,DB00297,Bupivacaine
,2895594,peak bupivacaine levels,"No significant difference was found between the peak bupivacaine levels: the mean (SD) values were 0.74 (0.17) microgram/ml, 0.81 (0.38) microgram/ml and 0.70 (0.24) microgram/ml in the control, cimetidine and ranitidine groups, respectively.",H2 antagonists and bupivacaine clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895594/),[μg] / [ml],0.74,209186,DB00297,Bupivacaine
,2895594,peak bupivacaine levels,"No significant difference was found between the peak bupivacaine levels: the mean (SD) values were 0.74 (0.17) microgram/ml, 0.81 (0.38) microgram/ml and 0.70 (0.24) microgram/ml in the control, cimetidine and ranitidine groups, respectively.",H2 antagonists and bupivacaine clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895594/),[μg] / [ml],0.81,209187,DB00297,Bupivacaine
,2895594,peak bupivacaine levels,"No significant difference was found between the peak bupivacaine levels: the mean (SD) values were 0.74 (0.17) microgram/ml, 0.81 (0.38) microgram/ml and 0.70 (0.24) microgram/ml in the control, cimetidine and ranitidine groups, respectively.",H2 antagonists and bupivacaine clearance. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2895594/),[μg] / [ml],0.70,209188,DB00297,Bupivacaine
,16021436,t(1/2)alpha,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),min,13.5,211876,DB00297,Bupivacaine
,16021436,t(1/2)beta,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),min,192.5,211877,DB00297,Bupivacaine
,16021436,t(1/2)gamma,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),min,620,211878,DB00297,Bupivacaine
,16021436,AUC(0-infinity),"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),[min·ng] / [milliliter],137.404,211879,DB00297,Bupivacaine
,16021436,C(l)/f,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),[ml] / [min],464.984,211880,DB00297,Bupivacaine
,16021436,V(d)/f,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),l,299.974,211881,DB00297,Bupivacaine
,16021436,C(l)/f/kg,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),[ml] / [kg·min],6.875,211882,DB00297,Bupivacaine
,16021436,V(d)/f/kg,"The values of the pharmacokinetic parameters were: t(1/2)alpha=13.5 min, t(1/2)beta=192.5 min, t(1/2)gamma=620 min, AUC(0-infinity)=137.404 ng.min per milliliter, C(l)/f=464.984 ml/min, V(d)/f=299.974 l, C(l)/f/kg=6.875 ml/min per kilogram, and V(d)/f/kg=4.441 l/kg.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),[l] / [kg],4.441,211883,DB00297,Bupivacaine
,16021436,latency,"The latency between drug administration and birth was 28.5 min, with a maternal and fetal plasma concentration of 0.310 and 0.245 ng/ml, respectively, at a median fetal/maternal ratio of 0.892.",Pharmacokinetics and transplacental distribution of fentanyl in epidural anesthesia for normal pregnant women. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16021436/),min,28.5,211884,DB00297,Bupivacaine
,12356276,duration of action,"With bupivacaine liposomes, the duration of action was 5-fold (447+/-28.9 vs 87+/-6.7 min), the maximum possible effect was 2-fold (100+/-0 vs 47.6+/-13%), and the peak plasma concentration (Cmax) was less than one-fifth (0.12+/-0.04 vs 0.65+/-0.04 microg mL(-1)) that with bupivacaine solution.",Kinetic and dynamic studies of liposomal bupivacaine and bupivacaine solution after subcutaneous injection in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12356276/),min,447,214363,DB00297,Bupivacaine
,12356276,duration of action,"With bupivacaine liposomes, the duration of action was 5-fold (447+/-28.9 vs 87+/-6.7 min), the maximum possible effect was 2-fold (100+/-0 vs 47.6+/-13%), and the peak plasma concentration (Cmax) was less than one-fifth (0.12+/-0.04 vs 0.65+/-0.04 microg mL(-1)) that with bupivacaine solution.",Kinetic and dynamic studies of liposomal bupivacaine and bupivacaine solution after subcutaneous injection in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12356276/),min,87,214364,DB00297,Bupivacaine
,12356276,maximum possible effect,"With bupivacaine liposomes, the duration of action was 5-fold (447+/-28.9 vs 87+/-6.7 min), the maximum possible effect was 2-fold (100+/-0 vs 47.6+/-13%), and the peak plasma concentration (Cmax) was less than one-fifth (0.12+/-0.04 vs 0.65+/-0.04 microg mL(-1)) that with bupivacaine solution.",Kinetic and dynamic studies of liposomal bupivacaine and bupivacaine solution after subcutaneous injection in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12356276/),%,100,214365,DB00297,Bupivacaine
,12356276,maximum possible effect,"With bupivacaine liposomes, the duration of action was 5-fold (447+/-28.9 vs 87+/-6.7 min), the maximum possible effect was 2-fold (100+/-0 vs 47.6+/-13%), and the peak plasma concentration (Cmax) was less than one-fifth (0.12+/-0.04 vs 0.65+/-0.04 microg mL(-1)) that with bupivacaine solution.",Kinetic and dynamic studies of liposomal bupivacaine and bupivacaine solution after subcutaneous injection in rats. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12356276/),%,47.6,214366,DB00297,Bupivacaine
,12356276,peak plasma concentration (Cmax),"With bupivacaine liposomes, the duration of action was 5-fold (447+/-28.9 vs 87+/-6.7 min), the maximum possible effect was 2-fold (100+/-0 vs 47.6+/-13%), and the peak plasma concentration (Cmax) was less than one-fifth (0.12+/-0.04 vs 0.65+/-0.04 microg mL(-1)) that with bupivacaine solution.",Kinetic and dynamic studies of liposomal bupivacaine and bupivacaine solution after subcutaneous injection in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12356276/),[μg] / [ml],0.12,214367,DB00297,Bupivacaine
,12356276,peak plasma concentration (Cmax),"With bupivacaine liposomes, the duration of action was 5-fold (447+/-28.9 vs 87+/-6.7 min), the maximum possible effect was 2-fold (100+/-0 vs 47.6+/-13%), and the peak plasma concentration (Cmax) was less than one-fifth (0.12+/-0.04 vs 0.65+/-0.04 microg mL(-1)) that with bupivacaine solution.",Kinetic and dynamic studies of liposomal bupivacaine and bupivacaine solution after subcutaneous injection in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12356276/),[μg] / [ml],0.65,214368,DB00297,Bupivacaine
,9052295,elimination half-life,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),min,113.9,214660,DB00297,Bupivacaine
,9052295,elimination half-life,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),min,110.4,214661,DB00297,Bupivacaine
,9052295,plasma clearance,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[ml] / [kg·min],6.1,214662,DB00297,Bupivacaine
,9052295,plasma clearance,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[ml] / [kg·min],13.6,214663,DB00297,Bupivacaine
,9052295,volume of distribution,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[l] / [kg],0.98,214664,DB00297,Bupivacaine
,9052295,volume of distribution,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[l] / [kg],1.67,214665,DB00297,Bupivacaine
,9052295,time to peak concentration,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),min,31,214666,DB00297,Bupivacaine
,9052295,time to peak concentration,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),min,40.5,214667,DB00297,Bupivacaine
,9052295,peak Ma concentration,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[μg] / [ml],6.4,214668,DB00297,Bupivacaine
,9052295,peak Ma concentration,"Results for lidocaine and bupivacaine, respectively, were (mean +/- SEM): age 30.4 +/- 1.5 and 24.7 +/- 1.6 yr; weight 74.0 +/- 4.2 and 74.9 +/- 4.5 kg; duration of surgery 55.5 +/- 4.3 and 53.1 +/- 3.5 min; epidural dosage 6.1 +/- 0.6 and 1.5 +/- 0.2 mg/kg; elimination half-life 113.9 +/- 5.6 and 110.4 +/- 20.4 min; plasma clearance 6.1 +/- 0.4 and 13.6 +/- 1.3 mL.kg-1.min-1; volume of distribution 0.98 +/- 0.1 and 1.67 +/- 0.3 L/kg; time to peak concentration 31 +/- 2.3 and 40.5 +/- 1.7 min; peak Ma concentration 6.4 +/- 0.65 and 0.8 +/- 0.1 microgram/mL; and Uv/Ma gradient 0.43 +/- 0.05 and 0.26 +/- 0.1.",The pharmacokinetics of epidural lidocaine and bupivacaine during cesarean section. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9052295/),[μg] / [ml],0.8,214669,DB00297,Bupivacaine
,3342287,distribution,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,8.4,215411,DB00297,Bupivacaine
,3342287,distribution,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,9.2,215412,DB00297,Bupivacaine
,3342287,distribution,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,15.3,215413,DB00297,Bupivacaine
,3342287,distribution,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,15.2,215414,DB00297,Bupivacaine
,3342287,elimination half-lives,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,96,215415,DB00297,Bupivacaine
,3342287,elimination half-lives,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,15.3,215416,DB00297,Bupivacaine
,3342287,elimination half-lives,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,111,215417,DB00297,Bupivacaine
,3342287,elimination half-lives,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,15.2,215418,DB00297,Bupivacaine
,3342287,elimination half-lives,"The mean distribution and elimination half-lives were 8.4 +/- 5.9 min and 96 +/- 26 min for lidocaine, 9.2 +/- 7.0 min and 98 +/- 27 min for deuterium-labelled lidocaine, 15.3 +/- 9.9 min and 111 +/- 32 min for bupivacaine, and 15.2 +/- 10.9 min and 109 +/- 31 min for deuterium-labelled bupivacaine, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),min,109,215419,DB00297,Bupivacaine
,3342287,volumes of the central compartment,"The mean volumes of the central compartment and mean steady state volumes of distribution were: lidocaine 37 +/- 151 and 97 +/- 201, deuterium-labelled lidocaine 39 +/- 161 and 98 +/- 181, bupivacaine 27 +/- 111 and 66 +/- 231 and deuterium-labelled bupivacaine 28 +/- 121, and 65 +/- 221, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),,37,215420,DB00297,Bupivacaine
,3342287,volumes of the central compartment,"The mean volumes of the central compartment and mean steady state volumes of distribution were: lidocaine 37 +/- 151 and 97 +/- 201, deuterium-labelled lidocaine 39 +/- 161 and 98 +/- 181, bupivacaine 27 +/- 111 and 66 +/- 231 and deuterium-labelled bupivacaine 28 +/- 121, and 65 +/- 221, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),,27,215421,DB00297,Bupivacaine
,3342287,volumes of the central compartment,"The mean volumes of the central compartment and mean steady state volumes of distribution were: lidocaine 37 +/- 151 and 97 +/- 201, deuterium-labelled lidocaine 39 +/- 161 and 98 +/- 181, bupivacaine 27 +/- 111 and 66 +/- 231 and deuterium-labelled bupivacaine 28 +/- 121, and 65 +/- 221, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),,28,215422,DB00297,Bupivacaine
,3342287,steady state volumes of distribution,"The mean volumes of the central compartment and mean steady state volumes of distribution were: lidocaine 37 +/- 151 and 97 +/- 201, deuterium-labelled lidocaine 39 +/- 161 and 98 +/- 181, bupivacaine 27 +/- 111 and 66 +/- 231 and deuterium-labelled bupivacaine 28 +/- 121, and 65 +/- 221, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),,27,215423,DB00297,Bupivacaine
,3342287,steady state volumes of distribution,"The mean volumes of the central compartment and mean steady state volumes of distribution were: lidocaine 37 +/- 151 and 97 +/- 201, deuterium-labelled lidocaine 39 +/- 161 and 98 +/- 181, bupivacaine 27 +/- 111 and 66 +/- 231 and deuterium-labelled bupivacaine 28 +/- 121, and 65 +/- 221, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),,66,215424,DB00297,Bupivacaine
,3342287,steady state volumes of distribution,"The mean volumes of the central compartment and mean steady state volumes of distribution were: lidocaine 37 +/- 151 and 97 +/- 201, deuterium-labelled lidocaine 39 +/- 161 and 98 +/- 181, bupivacaine 27 +/- 111 and 66 +/- 231 and deuterium-labelled bupivacaine 28 +/- 121, and 65 +/- 221, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),,28,215425,DB00297,Bupivacaine
,3342287,steady state volumes of distribution,"The mean volumes of the central compartment and mean steady state volumes of distribution were: lidocaine 37 +/- 151 and 97 +/- 201, deuterium-labelled lidocaine 39 +/- 161 and 98 +/- 181, bupivacaine 27 +/- 111 and 66 +/- 231 and deuterium-labelled bupivacaine 28 +/- 121, and 65 +/- 221, respectively.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),,65,215426,DB00297,Bupivacaine
,3342287,plasma clearances,"The respective mean plasma clearances were 0.88 +/- 0.181 min-1, 0.87 +/- 0.181 min-1, 0.61 +/- 0.151 min-1, and 0.62 +/- 0.171 min-1.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),1/[min],0.88,215427,DB00297,Bupivacaine
,3342287,plasma clearances,"The respective mean plasma clearances were 0.88 +/- 0.181 min-1, 0.87 +/- 0.181 min-1, 0.61 +/- 0.151 min-1, and 0.62 +/- 0.171 min-1.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),1/[min],0.87,215428,DB00297,Bupivacaine
,3342287,plasma clearances,"The respective mean plasma clearances were 0.88 +/- 0.181 min-1, 0.87 +/- 0.181 min-1, 0.61 +/- 0.151 min-1, and 0.62 +/- 0.171 min-1.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),1/[min],0.61,215429,DB00297,Bupivacaine
,3342287,plasma clearances,"The respective mean plasma clearances were 0.88 +/- 0.181 min-1, 0.87 +/- 0.181 min-1, 0.61 +/- 0.151 min-1, and 0.62 +/- 0.171 min-1.",Pharmacokinetics of lidocaine and bupivacaine and stable isotope labelled analogues: a study in healthy volunteers. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3342287/),1/[min],0.62,215430,DB00297,Bupivacaine
,33683791,mature,A one-compartment model with a mature clearance 21.5 L h-1 70 kg-1 (CV 47.3%) and central volume 189 L 70 kg-1 (CV 37%) adequately described time-concentration profiles.,Prediction of levobupivacaine concentrations in neonates and infants following neuraxial rescue blocks. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683791/),[l] / [70·h·kg],21.5,217522,DB00297,Bupivacaine
,33683791,clearance,A one-compartment model with a mature clearance 21.5 L h-1 70 kg-1 (CV 47.3%) and central volume 189 L 70 kg-1 (CV 37%) adequately described time-concentration profiles.,Prediction of levobupivacaine concentrations in neonates and infants following neuraxial rescue blocks. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683791/),[l] / [70·h·kg],21.5,217523,DB00297,Bupivacaine
,33683791,central volume,A one-compartment model with a mature clearance 21.5 L h-1 70 kg-1 (CV 47.3%) and central volume 189 L 70 kg-1 (CV 37%) adequately described time-concentration profiles.,Prediction of levobupivacaine concentrations in neonates and infants following neuraxial rescue blocks. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683791/),[l] / [70·kg],189,217524,DB00297,Bupivacaine
,33683791,maturation half-time,Clearance maturation was described using a maturation half-time of 11.5 weeks postnatal age.,Prediction of levobupivacaine concentrations in neonates and infants following neuraxial rescue blocks. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683791/),weeks,11.5,217525,DB00297,Bupivacaine
,33683791,absorption half-time,The absorption half-time for spinal levobupivacaine was 2.6 min (CV 56.8%).,Prediction of levobupivacaine concentrations in neonates and infants following neuraxial rescue blocks. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683791/),min,2.6,217526,DB00297,Bupivacaine
,33683791,peak concentrations,"The upper (97.5% prediction) for peak concentrations after rescue caudal levobupivacaine were 1.5 mg kg-1 , 2 mg kg-1 , and 2.5 mg kg-1 was 2.05 mg L-1 , 2.5 mg L-1 , and 2.9 mg L-1 respectively.",Prediction of levobupivacaine concentrations in neonates and infants following neuraxial rescue blocks. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683791/),[mg] / [l],2.05,217527,DB00297,Bupivacaine
,33683791,peak concentrations,"The upper (97.5% prediction) for peak concentrations after rescue caudal levobupivacaine were 1.5 mg kg-1 , 2 mg kg-1 , and 2.5 mg kg-1 was 2.05 mg L-1 , 2.5 mg L-1 , and 2.9 mg L-1 respectively.",Prediction of levobupivacaine concentrations in neonates and infants following neuraxial rescue blocks. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683791/),[mg] / [l],2.5,217528,DB00297,Bupivacaine
,33683791,peak concentrations,"The upper (97.5% prediction) for peak concentrations after rescue caudal levobupivacaine were 1.5 mg kg-1 , 2 mg kg-1 , and 2.5 mg kg-1 was 2.05 mg L-1 , 2.5 mg L-1 , and 2.9 mg L-1 respectively.",Prediction of levobupivacaine concentrations in neonates and infants following neuraxial rescue blocks. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/33683791/),[mg] / [l],2.9,217529,DB00297,Bupivacaine
,8251612,Vss,"Mean (+/- SD) disposition parameters included: Vss = 1.11 +/- 0.198 l kg-1; CL = 0.711 +/- 0.158 l h-1 kg-1; t1/2,z = 2.07 +/- 0.438 h.",Pharmacokinetics of intravenous and epidural ropivacaine in the rhesus monkey. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251612/),[l] / [kg],1.11,218807,DB00297,Bupivacaine
,8251612,CL,"Mean (+/- SD) disposition parameters included: Vss = 1.11 +/- 0.198 l kg-1; CL = 0.711 +/- 0.158 l h-1 kg-1; t1/2,z = 2.07 +/- 0.438 h.",Pharmacokinetics of intravenous and epidural ropivacaine in the rhesus monkey. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251612/),[l] / [h·kg],0.711,218808,DB00297,Bupivacaine
,8251612,"t1/2,z","Mean (+/- SD) disposition parameters included: Vss = 1.11 +/- 0.198 l kg-1; CL = 0.711 +/- 0.158 l h-1 kg-1; t1/2,z = 2.07 +/- 0.438 h.",Pharmacokinetics of intravenous and epidural ropivacaine in the rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251612/),h,2.07,218809,DB00297,Bupivacaine
,8251612,F1,"Mean (+/- SD) absorption parameters included: F1 = 0.506 +/- 0.221; t1/2,kal = 0.060 +/- 0.078 h; F2 = 0.444 +/- 0.182; t1/2,ka2 = 6.45 +/- 11.09 h.",Pharmacokinetics of intravenous and epidural ropivacaine in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251612/),,0.506,218810,DB00297,Bupivacaine
,8251612,"t1/2,","Mean (+/- SD) absorption parameters included: F1 = 0.506 +/- 0.221; t1/2,kal = 0.060 +/- 0.078 h; F2 = 0.444 +/- 0.182; t1/2,ka2 = 6.45 +/- 11.09 h.",Pharmacokinetics of intravenous and epidural ropivacaine in the rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251612/),h,0.060,218811,DB00297,Bupivacaine
,8251612,kal,"Mean (+/- SD) absorption parameters included: F1 = 0.506 +/- 0.221; t1/2,kal = 0.060 +/- 0.078 h; F2 = 0.444 +/- 0.182; t1/2,ka2 = 6.45 +/- 11.09 h.",Pharmacokinetics of intravenous and epidural ropivacaine in the rhesus monkey. ,ka-Q49,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251612/),h,0.060,218812,DB00297,Bupivacaine
,8251612,"t1/2,","Mean (+/- SD) absorption parameters included: F1 = 0.506 +/- 0.221; t1/2,kal = 0.060 +/- 0.078 h; F2 = 0.444 +/- 0.182; t1/2,ka2 = 6.45 +/- 11.09 h.",Pharmacokinetics of intravenous and epidural ropivacaine in the rhesus monkey. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251612/),h,6.45,218813,DB00297,Bupivacaine
,8251612,ka2,"Mean (+/- SD) absorption parameters included: F1 = 0.506 +/- 0.221; t1/2,kal = 0.060 +/- 0.078 h; F2 = 0.444 +/- 0.182; t1/2,ka2 = 6.45 +/- 11.09 h.",Pharmacokinetics of intravenous and epidural ropivacaine in the rhesus monkey. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8251612/),h,6.45,218814,DB00297,Bupivacaine
,1389817,plasma half-lives,"Maternal plasma half-lives for pethidine and bupivacaine were 1.0 and 2.0 h, and placental half-lives 1.9 and 2.5 h, respectively.",Elimination of bupivacaine and pethidine from the rabbit feto-placental unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389817/),h,1.0,219011,DB00297,Bupivacaine
,1389817,plasma half-lives,"Maternal plasma half-lives for pethidine and bupivacaine were 1.0 and 2.0 h, and placental half-lives 1.9 and 2.5 h, respectively.",Elimination of bupivacaine and pethidine from the rabbit feto-placental unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389817/),h,2.0,219012,DB00297,Bupivacaine
,1389817,half-lives,"Maternal plasma half-lives for pethidine and bupivacaine were 1.0 and 2.0 h, and placental half-lives 1.9 and 2.5 h, respectively.",Elimination of bupivacaine and pethidine from the rabbit feto-placental unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389817/),h,1.9,219013,DB00297,Bupivacaine
,1389817,half-lives,"Maternal plasma half-lives for pethidine and bupivacaine were 1.0 and 2.0 h, and placental half-lives 1.9 and 2.5 h, respectively.",Elimination of bupivacaine and pethidine from the rabbit feto-placental unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389817/),h,2.5,219014,DB00297,Bupivacaine
,1389817,apparent fetal plasma half-life,The apparent fetal plasma half-life of pethidine was 9.9 h while there was apparently no net elimination of bupivacaine from fetal plasma.,Elimination of bupivacaine and pethidine from the rabbit feto-placental unit. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1389817/),h,9.9,219015,DB00297,Bupivacaine
,10967444,in,"The intrathecal bioavailability of bupivacaine and lidocaine was 12.3 and 17.9%, respectively, while it was 5.5 and 17.7% following the separate administration of each agent [Clément, R., Malinovsky, J.M., Le Corre, P., Dollo, G., Chevanne, F., Le Verge, R., 1999.",Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967444/),%,12.3,220072,DB00297,Bupivacaine
,10967444,in,"The intrathecal bioavailability of bupivacaine and lidocaine was 12.3 and 17.9%, respectively, while it was 5.5 and 17.7% following the separate administration of each agent [Clément, R., Malinovsky, J.M., Le Corre, P., Dollo, G., Chevanne, F., Le Verge, R., 1999.",Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967444/),%,17.9,220073,DB00297,Bupivacaine
,10967444,in,"The intrathecal bioavailability of bupivacaine and lidocaine was 12.3 and 17.9%, respectively, while it was 5.5 and 17.7% following the separate administration of each agent [Clément, R., Malinovsky, J.M., Le Corre, P., Dollo, G., Chevanne, F., Le Verge, R., 1999.",Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967444/),%,5.5,220074,DB00297,Bupivacaine
,10967444,in,"The intrathecal bioavailability of bupivacaine and lidocaine was 12.3 and 17.9%, respectively, while it was 5.5 and 17.7% following the separate administration of each agent [Clément, R., Malinovsky, J.M., Le Corre, P., Dollo, G., Chevanne, F., Le Verge, R., 1999.",Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967444/),%,17.7,220075,DB00297,Bupivacaine
,10967444,bioavailability,"The intrathecal bioavailability of bupivacaine and lidocaine was 12.3 and 17.9%, respectively, while it was 5.5 and 17.7% following the separate administration of each agent [Clément, R., Malinovsky, J.M., Le Corre, P., Dollo, G., Chevanne, F., Le Verge, R., 1999.",Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967444/),%,12.3,220076,DB00297,Bupivacaine
,10967444,bioavailability,"The intrathecal bioavailability of bupivacaine and lidocaine was 12.3 and 17.9%, respectively, while it was 5.5 and 17.7% following the separate administration of each agent [Clément, R., Malinovsky, J.M., Le Corre, P., Dollo, G., Chevanne, F., Le Verge, R., 1999.",Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967444/),%,17.9,220077,DB00297,Bupivacaine
,10967444,bioavailability,"The intrathecal bioavailability of bupivacaine and lidocaine was 12.3 and 17.9%, respectively, while it was 5.5 and 17.7% following the separate administration of each agent [Clément, R., Malinovsky, J.M., Le Corre, P., Dollo, G., Chevanne, F., Le Verge, R., 1999.",Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967444/),%,5.5,220078,DB00297,Bupivacaine
,10967444,bioavailability,"The intrathecal bioavailability of bupivacaine and lidocaine was 12.3 and 17.9%, respectively, while it was 5.5 and 17.7% following the separate administration of each agent [Clément, R., Malinovsky, J.M., Le Corre, P., Dollo, G., Chevanne, F., Le Verge, R., 1999.",Spinal biopharmaceutics of bupivacaine and lidocaine by microdialysis after their simultaneous administration in rabbits. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10967444/),%,17.7,220079,DB00297,Bupivacaine
,10960398,fatal dose,The estimated fatal dose (mean +/- SD) was 277 +/- 51 mg for levobupivacaine (compared with 156 +/- 31 mg found previously for bupivacaine).,Tolerability of large-dose intravenous levobupivacaine in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10960398/),mg,277,220389,DB00297,Bupivacaine
,10960398,fatal dose,The estimated fatal dose (mean +/- SD) was 277 +/- 51 mg for levobupivacaine (compared with 156 +/- 31 mg found previously for bupivacaine).,Tolerability of large-dose intravenous levobupivacaine in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10960398/),mg,156,220390,DB00297,Bupivacaine
,10960398,initial,"Pharmacokinetic analysis indicated initial and total distribution volumes = 4.5 (+/-1.6) and 97 (+/-22) L, total clearance = 1.7 (+/-0.4) L/min, and slow half life = 70 (+/-29) min; these values did not differ from those found previously with smaller doses.",Tolerability of large-dose intravenous levobupivacaine in sheep. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10960398/),l,4.5,220391,DB00297,Bupivacaine
,10960398,total distribution volumes,"Pharmacokinetic analysis indicated initial and total distribution volumes = 4.5 (+/-1.6) and 97 (+/-22) L, total clearance = 1.7 (+/-0.4) L/min, and slow half life = 70 (+/-29) min; these values did not differ from those found previously with smaller doses.",Tolerability of large-dose intravenous levobupivacaine in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10960398/),l,4.5,220392,DB00297,Bupivacaine
,10960398,total distribution volumes,"Pharmacokinetic analysis indicated initial and total distribution volumes = 4.5 (+/-1.6) and 97 (+/-22) L, total clearance = 1.7 (+/-0.4) L/min, and slow half life = 70 (+/-29) min; these values did not differ from those found previously with smaller doses.",Tolerability of large-dose intravenous levobupivacaine in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10960398/),l,97,220393,DB00297,Bupivacaine
,10960398,total clearance,"Pharmacokinetic analysis indicated initial and total distribution volumes = 4.5 (+/-1.6) and 97 (+/-22) L, total clearance = 1.7 (+/-0.4) L/min, and slow half life = 70 (+/-29) min; these values did not differ from those found previously with smaller doses.",Tolerability of large-dose intravenous levobupivacaine in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10960398/),[l] / [min],1.7,220394,DB00297,Bupivacaine
,10960398,half life,"Pharmacokinetic analysis indicated initial and total distribution volumes = 4.5 (+/-1.6) and 97 (+/-22) L, total clearance = 1.7 (+/-0.4) L/min, and slow half life = 70 (+/-29) min; these values did not differ from those found previously with smaller doses.",Tolerability of large-dose intravenous levobupivacaine in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10960398/),min,70,220395,DB00297,Bupivacaine
,19809388,recoveries,"A liquid-liquid back extraction procedure was used to increase specificity, and very good and consistent recoveries were obtained: 93%-95% for ropivacaine and 90%-96% for bupivacaine.",High-performance liquid chromatography using UV detection for the simultaneous quantification of ropivacaine and bupivacaine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19809388/),%,93,222633,DB00297,Bupivacaine
,19809388,recoveries,"A liquid-liquid back extraction procedure was used to increase specificity, and very good and consistent recoveries were obtained: 93%-95% for ropivacaine and 90%-96% for bupivacaine.",High-performance liquid chromatography using UV detection for the simultaneous quantification of ropivacaine and bupivacaine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19809388/),%,95,222634,DB00297,Bupivacaine
,19809388,recoveries,"A liquid-liquid back extraction procedure was used to increase specificity, and very good and consistent recoveries were obtained: 93%-95% for ropivacaine and 90%-96% for bupivacaine.",High-performance liquid chromatography using UV detection for the simultaneous quantification of ropivacaine and bupivacaine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19809388/),%,90,222635,DB00297,Bupivacaine
,19809388,recoveries,"A liquid-liquid back extraction procedure was used to increase specificity, and very good and consistent recoveries were obtained: 93%-95% for ropivacaine and 90%-96% for bupivacaine.",High-performance liquid chromatography using UV detection for the simultaneous quantification of ropivacaine and bupivacaine in human plasma. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19809388/),%,96,222636,DB00297,Bupivacaine
,2589653,blood clearance,Its blood clearance (0.72 +/- 0.16 L/min) is intermediate between that of mepivacaine and bupivacaine.,Disposition kinetics of ropivacaine in humans. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589653/),[l] / [min],0.72,223615,DB00297,Bupivacaine
,2589653,Plasma binding,Plasma binding averaged 94% +/- 1% and the volume of distribution at steady state based on blood drug concentration was 59 +/- 7 L.,Disposition kinetics of ropivacaine in humans. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589653/),%,94,223616,DB00297,Bupivacaine
,2589653,volume of distribution at steady state,Plasma binding averaged 94% +/- 1% and the volume of distribution at steady state based on blood drug concentration was 59 +/- 7 L.,Disposition kinetics of ropivacaine in humans. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589653/),l,59,223617,DB00297,Bupivacaine
,2589653,terminal elimination half-life,The terminal elimination half-life was 111 +/- 62 min.,Disposition kinetics of ropivacaine in humans. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/2589653/),min,111,223618,DB00297,Bupivacaine
,16100236,clearance (CLt),"Population parameter estimates (between-subject variability) for total levobupivacaine were clearance (CLt) 12.8 [coefficient of variation (CV) 50.6%] litre h(-1) 70 kg(-1), volume of distribution (Vt) 202 (CV 31.6%) litre 70 kg(-1), absorption half-life (Tabs) 0.323 (CV 18.6%) h 70 kg(-1).",Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),[l] / [70·h·kg],12.8,224439,DB00297,Bupivacaine
,16100236,volume of distribution (Vt),"Population parameter estimates (between-subject variability) for total levobupivacaine were clearance (CLt) 12.8 [coefficient of variation (CV) 50.6%] litre h(-1) 70 kg(-1), volume of distribution (Vt) 202 (CV 31.6%) litre 70 kg(-1), absorption half-life (Tabs) 0.323 (CV 18.6%) h 70 kg(-1).",Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),[l] / [70·kg],202,224440,DB00297,Bupivacaine
,16100236,absorption half-life (Tabs),"Population parameter estimates (between-subject variability) for total levobupivacaine were clearance (CLt) 12.8 [coefficient of variation (CV) 50.6%] litre h(-1) 70 kg(-1), volume of distribution (Vt) 202 (CV 31.6%) litre 70 kg(-1), absorption half-life (Tabs) 0.323 (CV 18.6%) h 70 kg(-1).",Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),[h] / [70·kg],0.323,224441,DB00297,Bupivacaine
,16100236,clearance (CLfree),"Estimates for the unbound drug were clearance (CLfree) 104 (CV 43.5%) litre h(-1) 70 kg(-1), volume of distribution (Vfree) 1700 (CV 44.9%) litre 70 kg(-1), absorption half-life (Tabsfree) 0.175 (CV 83.7%) h 70 kg(-1).",Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),[l] / [70·h·kg],104,224442,DB00297,Bupivacaine
,16100236,volume of distribution (Vfree),"Estimates for the unbound drug were clearance (CLfree) 104 (CV 43.5%) litre h(-1) 70 kg(-1), volume of distribution (Vfree) 1700 (CV 44.9%) litre 70 kg(-1), absorption half-life (Tabsfree) 0.175 (CV 83.7%) h 70 kg(-1).",Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),[l] / [70·kg],1700,224443,DB00297,Bupivacaine
,16100236,absorption half-life (Tabsfree),"Estimates for the unbound drug were clearance (CLfree) 104 (CV 43.5%) litre h(-1) 70 kg(-1), volume of distribution (Vfree) 1700 (CV 44.9%) litre 70 kg(-1), absorption half-life (Tabsfree) 0.175 (CV 83.7%) h 70 kg(-1).",Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),[h] / [70·kg],0.175,224444,DB00297,Bupivacaine
,16100236,Time to peak plasma concentration (Tmax),There was no effect attributable to PNA on CL or V. Time to peak plasma concentration (Tmax) was 0.82 (CV 18%) h.,Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),h,0.82,224445,DB00297,Bupivacaine
,16100236,Peak plasma concentration (Cmax),Peak plasma concentration (Cmax) was 0.69 (CV 25%) microg ml(-1) for total levobupivacaine and 0.09 (CV 37%) microg ml(-1) for unbound levobupivacaine.,Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),[μg] / [ml],0.69,224446,DB00297,Bupivacaine
,16100236,Peak plasma concentration (Cmax),Peak plasma concentration (Cmax) was 0.69 (CV 25%) microg ml(-1) for total levobupivacaine and 0.09 (CV 37%) microg ml(-1) for unbound levobupivacaine.,Pharmacokinetics of levobupivacaine after caudal epidural administration in infants less than 3 months of age. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16100236/),[μg] / [ml],0.09,224447,DB00297,Bupivacaine
,27061607,total venous levobupivacaine plasma concentrations,The median (IQR) total venous levobupivacaine plasma concentrations was 0.33 (0.25-0.42) μg·ml(-1) and unbound venous levobupivacaine was 19.5 (14.5-38) ng·ml(-1) . Median protein binding was 93.5 (91.4-96%).,Pharmacokinetics of levobupivacaine following infant spinal anesthesia. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27061607/),[μg] / [ml],0.33,225806,DB00297,Bupivacaine
,27061607,unbound venous levobupivacaine,The median (IQR) total venous levobupivacaine plasma concentrations was 0.33 (0.25-0.42) μg·ml(-1) and unbound venous levobupivacaine was 19.5 (14.5-38) ng·ml(-1) . Median protein binding was 93.5 (91.4-96%).,Pharmacokinetics of levobupivacaine following infant spinal anesthesia. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27061607/),[ng] / [ml],19.5,225807,DB00297,Bupivacaine
,27061607,protein binding,The median (IQR) total venous levobupivacaine plasma concentrations was 0.33 (0.25-0.42) μg·ml(-1) and unbound venous levobupivacaine was 19.5 (14.5-38) ng·ml(-1) . Median protein binding was 93.5 (91.4-96%).,Pharmacokinetics of levobupivacaine following infant spinal anesthesia. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/27061607/),,93.5,225808,DB00297,Bupivacaine
,12088972,time to sensory block,"The median time to sensory block was 12.5 min and 12.9 min, and mean duration of the block was 19 h and 22 h in normal versus ESRD patients, respectively.",Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088972/),min,12.5,225855,DB00297,Bupivacaine
,12088972,time to sensory block,"The median time to sensory block was 12.5 min and 12.9 min, and mean duration of the block was 19 h and 22 h in normal versus ESRD patients, respectively.",Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088972/),min,12.9,225856,DB00297,Bupivacaine
,12088972,duration of the,"The median time to sensory block was 12.5 min and 12.9 min, and mean duration of the block was 19 h and 22 h in normal versus ESRD patients, respectively.",Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088972/),h,19,225857,DB00297,Bupivacaine
,12088972,duration of the,"The median time to sensory block was 12.5 min and 12.9 min, and mean duration of the block was 19 h and 22 h in normal versus ESRD patients, respectively.",Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088972/),h,22,225858,DB00297,Bupivacaine
,12088972,peak concentration (C(max)),"mL(-1)) of 11 and 13, peak concentration (C(max)) (microg/mL) of 1.2 and 1.6, and a time to peak concentration (T(max)) (min) of 55 and 48, respectively.",Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088972/),[μg] / [ml],1.2,225859,DB00297,Bupivacaine
,12088972,peak concentration (C(max)),"mL(-1)) of 11 and 13, peak concentration (C(max)) (microg/mL) of 1.2 and 1.6, and a time to peak concentration (T(max)) (min) of 55 and 48, respectively.",Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088972/),[μg] / [ml],1.6,225860,DB00297,Bupivacaine
,12088972,time to peak concentration (T(max)),"mL(-1)) of 11 and 13, peak concentration (C(max)) (microg/mL) of 1.2 and 1.6, and a time to peak concentration (T(max)) (min) of 55 and 48, respectively.",Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088972/),min,55,225861,DB00297,Bupivacaine
,12088972,time to peak concentration (T(max)),"mL(-1)) of 11 and 13, peak concentration (C(max)) (microg/mL) of 1.2 and 1.6, and a time to peak concentration (T(max)) (min) of 55 and 48, respectively.",Levobupivacaine for axillary brachial plexus block: a pharmacokinetic and clinical comparison in patients with normal renal function or renal disease. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/12088972/),min,48,225862,DB00297,Bupivacaine
,17067137,peak bupivacaine concentration,The mean peak bupivacaine concentration during HES 400K infusion was significantly lower than during NS infusion (1488 +/- 302 ng ml(-1) vs 2388 +/- 582 ng ml(-1)).,The effect of hydroxyethylstarch infusion on bupivacaine pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17067137/),[ng] / [ml],1488,226863,DB00297,Bupivacaine
,17067137,peak bupivacaine concentration,The mean peak bupivacaine concentration during HES 400K infusion was significantly lower than during NS infusion (1488 +/- 302 ng ml(-1) vs 2388 +/- 582 ng ml(-1)).,The effect of hydroxyethylstarch infusion on bupivacaine pharmacokinetics in rats. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17067137/),[ng] / [ml],2388,226864,DB00297,Bupivacaine
,17067137,area under curves (AUC),"Mean area under curves (AUC) during HES 200K and HES 400K infusions were significantly lower than during NS infusion (32534 +/- 4180 and 29619 +/- 4431 min ng ml(-1), respectively, vs 39802 +/- 6268 min ng ml(-1)).",The effect of hydroxyethylstarch infusion on bupivacaine pharmacokinetics in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17067137/),[min·ng] / [ml],32534,226865,DB00297,Bupivacaine
,17067137,area under curves (AUC),"Mean area under curves (AUC) during HES 200K and HES 400K infusions were significantly lower than during NS infusion (32534 +/- 4180 and 29619 +/- 4431 min ng ml(-1), respectively, vs 39802 +/- 6268 min ng ml(-1)).",The effect of hydroxyethylstarch infusion on bupivacaine pharmacokinetics in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17067137/),[min·ng] / [ml],29619,226866,DB00297,Bupivacaine
,17067137,area under curves (AUC),"Mean area under curves (AUC) during HES 200K and HES 400K infusions were significantly lower than during NS infusion (32534 +/- 4180 and 29619 +/- 4431 min ng ml(-1), respectively, vs 39802 +/- 6268 min ng ml(-1)).",The effect of hydroxyethylstarch infusion on bupivacaine pharmacokinetics in rats. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17067137/),[min·ng] / [ml],39802,226867,DB00297,Bupivacaine
,17067137,total clearance,"Mean total clearance of bupivacaine during HES 200K and HES 400K infusions was significantly higher than during NS infusion (115 +/- 14 and 132 +/- 15 ml min(-1) kg(-1), respectively, vs 92 +/- 14 ml min(-1) kg(-1)).",The effect of hydroxyethylstarch infusion on bupivacaine pharmacokinetics in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17067137/),[ml] / [kg·min],115,226868,DB00297,Bupivacaine
,17067137,total clearance,"Mean total clearance of bupivacaine during HES 200K and HES 400K infusions was significantly higher than during NS infusion (115 +/- 14 and 132 +/- 15 ml min(-1) kg(-1), respectively, vs 92 +/- 14 ml min(-1) kg(-1)).",The effect of hydroxyethylstarch infusion on bupivacaine pharmacokinetics in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17067137/),[ml] / [kg·min],132,226869,DB00297,Bupivacaine
,17067137,total clearance,"Mean total clearance of bupivacaine during HES 200K and HES 400K infusions was significantly higher than during NS infusion (115 +/- 14 and 132 +/- 15 ml min(-1) kg(-1), respectively, vs 92 +/- 14 ml min(-1) kg(-1)).",The effect of hydroxyethylstarch infusion on bupivacaine pharmacokinetics in rats. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17067137/),[ml] / [kg·min],92,226870,DB00297,Bupivacaine
,15950849,peak concentration,No significant differences were seen between the 2 groups with respect to the mean peak concentration of bupivacaine (single injection 2314 +/- 1385 ng/mL vs multiple injections 2255 +/- 1105 ng/mL) or time to reach the maximal concentration (time to maximum concentration [single injection 12.1 +/- 7.2 minutes vs multiple injections 12.5 +/- 3.9 minutes]).,The number of injections does not influence absorption of bupivacaine after cervical plexus block for carotid endarterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15950849/),[ng] / [ml],2314,227002,DB00297,Bupivacaine
,15950849,peak concentration,No significant differences were seen between the 2 groups with respect to the mean peak concentration of bupivacaine (single injection 2314 +/- 1385 ng/mL vs multiple injections 2255 +/- 1105 ng/mL) or time to reach the maximal concentration (time to maximum concentration [single injection 12.1 +/- 7.2 minutes vs multiple injections 12.5 +/- 3.9 minutes]).,The number of injections does not influence absorption of bupivacaine after cervical plexus block for carotid endarterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15950849/),[ng] / [ml],2255,227003,DB00297,Bupivacaine
,15950849,time to reach the maximal concentration (time to maximum concentration,No significant differences were seen between the 2 groups with respect to the mean peak concentration of bupivacaine (single injection 2314 +/- 1385 ng/mL vs multiple injections 2255 +/- 1105 ng/mL) or time to reach the maximal concentration (time to maximum concentration [single injection 12.1 +/- 7.2 minutes vs multiple injections 12.5 +/- 3.9 minutes]).,The number of injections does not influence absorption of bupivacaine after cervical plexus block for carotid endarterectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15950849/),min,12.1,227004,DB00297,Bupivacaine
,15950849,time to reach the maximal concentration (time to maximum concentration,No significant differences were seen between the 2 groups with respect to the mean peak concentration of bupivacaine (single injection 2314 +/- 1385 ng/mL vs multiple injections 2255 +/- 1105 ng/mL) or time to reach the maximal concentration (time to maximum concentration [single injection 12.1 +/- 7.2 minutes vs multiple injections 12.5 +/- 3.9 minutes]).,The number of injections does not influence absorption of bupivacaine after cervical plexus block for carotid endarterectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/15950849/),min,12.5,227005,DB00297,Bupivacaine
,19574865,maximum serum concentration,"The mean maximum serum concentration and area under the concentration-time curve for morphine and metabolites were not significantly different when EREM was administered alone versus 15, 30, or 60 mins after bupivacaine.",Extended-release epidural morphine (DepoDur) following epidural bupivacaine in patients undergoing lower abdominal surgery: a randomized controlled pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574865/),min,15,227254,DB00297,Bupivacaine
,19574865,maximum serum concentration,"The mean maximum serum concentration and area under the concentration-time curve for morphine and metabolites were not significantly different when EREM was administered alone versus 15, 30, or 60 mins after bupivacaine.",Extended-release epidural morphine (DepoDur) following epidural bupivacaine in patients undergoing lower abdominal surgery: a randomized controlled pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574865/),min,30,227255,DB00297,Bupivacaine
,19574865,maximum serum concentration,"The mean maximum serum concentration and area under the concentration-time curve for morphine and metabolites were not significantly different when EREM was administered alone versus 15, 30, or 60 mins after bupivacaine.",Extended-release epidural morphine (DepoDur) following epidural bupivacaine in patients undergoing lower abdominal surgery: a randomized controlled pharmacokinetic study. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574865/),min,60,227256,DB00297,Bupivacaine
,19574865,area under the concentration-time curve,"The mean maximum serum concentration and area under the concentration-time curve for morphine and metabolites were not significantly different when EREM was administered alone versus 15, 30, or 60 mins after bupivacaine.",Extended-release epidural morphine (DepoDur) following epidural bupivacaine in patients undergoing lower abdominal surgery: a randomized controlled pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574865/),min,30,227257,DB00297,Bupivacaine
,19574865,area under the concentration-time curve,"The mean maximum serum concentration and area under the concentration-time curve for morphine and metabolites were not significantly different when EREM was administered alone versus 15, 30, or 60 mins after bupivacaine.",Extended-release epidural morphine (DepoDur) following epidural bupivacaine in patients undergoing lower abdominal surgery: a randomized controlled pharmacokinetic study. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19574865/),min,60,227258,DB00297,Bupivacaine
,3665324,distribution,"The mean distribution and elimination half-lives were 12 minutes and 100 minutes for lignocaine, and 22 minutes and 143 minutes for bupivacaine.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),min,12,228762,DB00297,Bupivacaine
,3665324,distribution,"The mean distribution and elimination half-lives were 12 minutes and 100 minutes for lignocaine, and 22 minutes and 143 minutes for bupivacaine.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),min,22,228763,DB00297,Bupivacaine
,3665324,elimination half-lives,"The mean distribution and elimination half-lives were 12 minutes and 100 minutes for lignocaine, and 22 minutes and 143 minutes for bupivacaine.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),min,100,228764,DB00297,Bupivacaine
,3665324,elimination half-lives,"The mean distribution and elimination half-lives were 12 minutes and 100 minutes for lignocaine, and 22 minutes and 143 minutes for bupivacaine.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),min,143,228765,DB00297,Bupivacaine
,3665324,volumes of the central compartment,"The mean volumes of the central compartment and the mean steady-state volumes of distribution were: lignocaine, 43L and 99L; bupivacaine, 33L and 68L.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,V1-Q63,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),l,43,228766,DB00297,Bupivacaine
,3665324,steady-state volumes of distribution,"The mean volumes of the central compartment and the mean steady-state volumes of distribution were: lignocaine, 43L and 99L; bupivacaine, 33L and 68L.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,99,228767,DB00297,Bupivacaine
,3665324,steady-state volumes of distribution,"The mean volumes of the central compartment and the mean steady-state volumes of distribution were: lignocaine, 43L and 99L; bupivacaine, 33L and 68L.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),l,33,228768,DB00297,Bupivacaine
,3665324,steady-state volumes of distribution,"The mean volumes of the central compartment and the mean steady-state volumes of distribution were: lignocaine, 43L and 99L; bupivacaine, 33L and 68L.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,Vss-Q65,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,68,228769,DB00297,Bupivacaine
,3665324,Total plasma clearances,Total plasma clearances averaged 0.95 L/min (57 L/h) for lignocaine and 0.52 L/min (31.2 L/h) for bupivacaine.,Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),[l] / [min],0.95,228770,DB00297,Bupivacaine
,3665324,Total plasma clearances,Total plasma clearances averaged 0.95 L/min (57 L/h) for lignocaine and 0.52 L/min (31.2 L/h) for bupivacaine.,Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),[l] / [min],0.52,228771,DB00297,Bupivacaine
,3665324,half-lives,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),min,9.3,228772,DB00297,Bupivacaine
,3665324,half-lives,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),min,82,228773,DB00297,Bupivacaine
,3665324,half-lives,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),min,7.0,228774,DB00297,Bupivacaine
,3665324,half-lives,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),min,362,228775,DB00297,Bupivacaine
,3665324,half-lives,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,0.38,228776,DB00297,Bupivacaine
,3665324,half-lives,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,0.58,228777,DB00297,Bupivacaine
,3665324,half-lives,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,0.28,228778,DB00297,Bupivacaine
,3665324,half-lives,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,0.66,228779,DB00297,Bupivacaine
,3665324,fractions,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,0.38,228780,DB00297,Bupivacaine
,3665324,fractions,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,0.58,228781,DB00297,Bupivacaine
,3665324,fractions,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,0.28,228782,DB00297,Bupivacaine
,3665324,fractions,"The half-lives, characterising the fast and slow absorption processes, were 9.3 and 82 minutes for lignocaine, and 7.0 minutes and 362 minutes for bupivacaine; the fractions of the doses absorbed in the fast and slow processes were lignocaine 0.38 and 0.58, bupivacaine 0.28 and 0.66, respectively.",Pharmacokinetics of lignocaine and bupivacaine in surgical patients following epidural administration. Simultaneous investigation of absorption and disposition kinetics using stable isotopes. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/3665324/),,0.66,228783,DB00297,Bupivacaine
,9567153,maximum dose,A maximum dose of 0.4 mg/kg/h bupivacaine was administered for continuous epidural infusion.,[Plasma concentrations of bupivacaine for continuous peridural anesthesia in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9567153/),[mg] / [h·kg],0.4,228952,DB00297,Bupivacaine
,9567153,maximum levels,At the onset of pain therapy maximum levels of 0.5 microgram/ml were recorded after a loading dose of bupivacaine and levels of up to 2.2 micrograms/ml were achieved following continuous infusion.,[Plasma concentrations of bupivacaine for continuous peridural anesthesia in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9567153/),[μg] / [ml],0.5,228953,DB00297,Bupivacaine
up to,9567153,maximum levels,At the onset of pain therapy maximum levels of 0.5 microgram/ml were recorded after a loading dose of bupivacaine and levels of up to 2.2 micrograms/ml were achieved following continuous infusion.,[Plasma concentrations of bupivacaine for continuous peridural anesthesia in children]. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/9567153/),[μg] / [ml],2.2,228954,DB00297,Bupivacaine
,16490091,volume of distribution (V),The population parameter estimate for volume of distribution (V) was 189 l.70 kg(-1).,Age and size are the major covariates for prediction of levobupivacaine clearance in children. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490091/),[l] / [70·kg],189,229641,DB00297,Bupivacaine
,16490091,Clearance (CL),Clearance (CL) was 5.8 l.h(-1).70 kg(-1) at 1-month PNA and increased with a maturation half-time of 2.3 months to reach 80% of the mature value (22.1 l.h(-1).70 kg(-1)) by 6-month PNA.,Age and size are the major covariates for prediction of levobupivacaine clearance in children. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490091/),[l] / [70·h·kg],5.8,229642,DB00297,Bupivacaine
,16490091,maturation half-time,Clearance (CL) was 5.8 l.h(-1).70 kg(-1) at 1-month PNA and increased with a maturation half-time of 2.3 months to reach 80% of the mature value (22.1 l.h(-1).70 kg(-1)) by 6-month PNA.,Age and size are the major covariates for prediction of levobupivacaine clearance in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490091/),month,2.3,229643,DB00297,Bupivacaine
,16490091,maturation half-time,Clearance (CL) was 5.8 l.h(-1).70 kg(-1) at 1-month PNA and increased with a maturation half-time of 2.3 months to reach 80% of the mature value (22.1 l.h(-1).70 kg(-1)) by 6-month PNA.,Age and size are the major covariates for prediction of levobupivacaine clearance in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490091/),[l] / [70·h·kg],22.1,229644,DB00297,Bupivacaine
,16490091,absorption half-time,The absorption half-time decreased from 0.36 h at 1-month PNA to 0.14 h (CV 48.1%) at 6-month PNA with a maturation half-time of 0.8 months.,Age and size are the major covariates for prediction of levobupivacaine clearance in children. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490091/),h,0.36,229645,DB00297,Bupivacaine
,16490091,absorption half-time,The absorption half-time decreased from 0.36 h at 1-month PNA to 0.14 h (CV 48.1%) at 6-month PNA with a maturation half-time of 0.8 months.,Age and size are the major covariates for prediction of levobupivacaine clearance in children. ,"t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490091/),h,0.14,229646,DB00297,Bupivacaine
,16490091,maturation half-time,The absorption half-time decreased from 0.36 h at 1-month PNA to 0.14 h (CV 48.1%) at 6-month PNA with a maturation half-time of 0.8 months.,Age and size are the major covariates for prediction of levobupivacaine clearance in children. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/16490091/),month,0.8,229647,DB00297,Bupivacaine
,1911009,total body clearance,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),[l] / [min],1.20,230175,DB00297,Bupivacaine
,1911009,total body clearance,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),[l] / [min],0.97,230176,DB00297,Bupivacaine
,1911009,total volume of distribution,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),l,144,230177,DB00297,Bupivacaine
,1911009,total volume of distribution,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),l,80,230178,DB00297,Bupivacaine
,1911009,slow half-life,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),min,120,230179,DB00297,Bupivacaine
,1911009,slow half-life,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),min,84,230180,DB00297,Bupivacaine
,1911009,hepatic extraction ratio,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),,0.50,230181,DB00297,Bupivacaine
,1911009,hepatic extraction ratio,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),,0.52,230182,DB00297,Bupivacaine
,1911009,hepatic clearance,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),[l] / [min],0.75,230183,DB00297,Bupivacaine
,1911009,hepatic clearance,"For R(-)-and S(+)-mepivacaine, respective mean (SEM) values of parameters were: total body clearance 1.20 (0.29) litre min-1 and 0.97 (0.20) litre min-1 (ns); total volume of distribution 144 (39) litre and 80 (21) litre (P less than 0.05); slow half-life 120 (40) min and 84 (22) min (ns); mean hepatic extraction ratio 0.50 (0.14) and 0.52 (0.09) (ns); mean hepatic clearance 0.75 (0.23) litre min-1 and 0.75 (0.18) litre min-1 (ns).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),[l] / [min],0.75,230184,DB00297,Bupivacaine
,1911009,total body clearance,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),[l] / [min],0.77,230185,DB00297,Bupivacaine
,1911009,total body clearance,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,CL-Q22,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),[l] / [min],0.53,230186,DB00297,Bupivacaine
,1911009,total volume of distribution,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),l,40,230187,DB00297,Bupivacaine
,1911009,total volume of distribution,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),l,43,230188,DB00297,Bupivacaine
,1911009,slow half-life,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),min,57,230189,DB00297,Bupivacaine
,1911009,slow half-life,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),min,104,230190,DB00297,Bupivacaine
,1911009,hepatic extraction ratio,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),,0.46,230191,DB00297,Bupivacaine
,1911009,hepatic extraction ratio,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,EH-Q39,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),,0.29,230192,DB00297,Bupivacaine
,1911009,hepatic clearance,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),[l] / [min],0.85,230193,DB00297,Bupivacaine
,1911009,hepatic clearance,"For R(+)- and S(-)-bupivacaine, respective values were: total body clearance 0.77 (0.33) litre min-1 and 0.53 (0.26) litre min-1 (P less than 0.05); total volume of distribution 40 (10) litre and 43 (10) litre (ns); slow half-life 57 (10) min and 104 (21) min (P less than 0.05); mean hepatic extraction ratio 0.46 (0.15) and 0.29 (0.13) (P less than 0.05); mean hepatic clearance 0.85 (0.31) litre min-1 and 0.54 (0.26) litre min-1 (P less than 0.05).",Disposition of mepivacaine and bupivacaine enantiomers in sheep. ,CLH-Q25,[Article Link](https://pubmed.ncbi.nlm.nih.gov/1911009/),[l] / [min],0.54,230194,DB00297,Bupivacaine
,7340377,duration of anal,"The duration of analgesia was significantly longer, on average, with morphine (28 h) than with bupivacaine (4.3 h) when the drugs were given by the lumbar route.",A comparison of epidural morphine and epidural bupivacaine for postoperative pain relief. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7340377/),h,28,230195,DB00297,Bupivacaine
,7340377,duration of anal,"The duration of analgesia was significantly longer, on average, with morphine (28 h) than with bupivacaine (4.3 h) when the drugs were given by the lumbar route.",A comparison of epidural morphine and epidural bupivacaine for postoperative pain relief. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7340377/),h,4.3,230196,DB00297,Bupivacaine
,7340377,duration of pain relief,Thoracic administration of morphine also resulted in a significantly longer duration of pain relief (on average 9.8 h) than that of bupivacaine (3.8 h).,A comparison of epidural morphine and epidural bupivacaine for postoperative pain relief. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7340377/),h,9.8,230197,DB00297,Bupivacaine
,7340377,duration of pain relief,Thoracic administration of morphine also resulted in a significantly longer duration of pain relief (on average 9.8 h) than that of bupivacaine (3.8 h).,A comparison of epidural morphine and epidural bupivacaine for postoperative pain relief. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7340377/),h,3.8,230198,DB00297,Bupivacaine
,17350525,maximum plasma concentration (Cpmax),There was rapid absorption of levobupivacaine after bolus with mean (standard deviation) maximum plasma concentration (Cpmax) of 0.51(0.24) microg/mL in a median time to maximum concentration tCpmax of 15 minutes.,"Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[μg] / [ml],0.51,231928,DB00297,Bupivacaine
,17350525,time to maximum concentration tCpmax,There was rapid absorption of levobupivacaine after bolus with mean (standard deviation) maximum plasma concentration (Cpmax) of 0.51(0.24) microg/mL in a median time to maximum concentration tCpmax of 15 minutes.,"Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),min,15,231929,DB00297,Bupivacaine
,17350525,Cpmax,"Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[ng] / [ml],0.62,231930,DB00297,Bupivacaine
,17350525,Cpmax,"Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[ng] / [ml],0.79,231931,DB00297,Bupivacaine
,17350525,tCpmax,"Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),min,15,231932,DB00297,Bupivacaine
,17350525,tCpmax,"Mean Cpmax fentanyl and clonidine after bolus were 0.62 (0.37) and 0.79 (0.23) ng/mL, in a median tCpmax of 15 and 22.5 minutes, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),min,22.5,231933,DB00297,Bupivacaine
,17350525,Cpmax,Mean Cpmax levobupivacaine after infusion was 0.47 (0.41) microg/mL in a median tCpmax of 24 hours.,"Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[μg] / [ml],0.47,231934,DB00297,Bupivacaine
,17350525,tCpmax,Mean Cpmax levobupivacaine after infusion was 0.47 (0.41) microg/mL in a median tCpmax of 24 hours.,"Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),h,24,231935,DB00297,Bupivacaine
,17350525,Cpmax,"There was progressive accumulation of fentanyl and clonidine at 24 hours with a mean Cpmax of 0.72 (0.33) and 1.74 (0.70) ng/mL, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[ng] / [ml],0.72,231936,DB00297,Bupivacaine
,17350525,Cpmax,"There was progressive accumulation of fentanyl and clonidine at 24 hours with a mean Cpmax of 0.72 (0.33) and 1.74 (0.70) ng/mL, respectively.","Pharmacokinetics of levobupivacaine, fentanyl, and clonidine after administration in thoracic paravertebral analgesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/17350525/),[ng] / [ml],1.74,231937,DB00297,Bupivacaine
,32541292,AUC0-2,Milk/plasma AUC0-t ratios ranged between AUC0-2 of 0.45 (80% CI 0.38-0.52) and AUC0-96 of 0.15 (80% CI 0.14-0.17).,Bupivacaine Pharmacokinetics and Breast Milk Excretion of Liposomal Bupivacaine Administered After Cesarean Birth. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32541292/),,0.45,233178,DB00297,Bupivacaine
,32541292,AUC0-96,Milk/plasma AUC0-t ratios ranged between AUC0-2 of 0.45 (80% CI 0.38-0.52) and AUC0-96 of 0.15 (80% CI 0.14-0.17).,Bupivacaine Pharmacokinetics and Breast Milk Excretion of Liposomal Bupivacaine Administered After Cesarean Birth. ,AUCt-Q19,[Article Link](https://pubmed.ncbi.nlm.nih.gov/32541292/),,0.15,233179,DB00297,Bupivacaine
,952693,Spread of,Spread of sensory analgesia to four segments above and below the site of injection was faster with etidocaine (13 +/- 3 min) (mean +/- SD) than with bupivacaine (22 +/- 8 min).,"Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),min,13,235381,DB00297,Bupivacaine
,952693,Spread of,Spread of sensory analgesia to four segments above and below the site of injection was faster with etidocaine (13 +/- 3 min) (mean +/- SD) than with bupivacaine (22 +/- 8 min).,"Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ",F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),min,22,235382,DB00297,Bupivacaine
,952693,regression of,"The onset of motor blockade tended to be faster with etidocaine (5.8 +/- 3.0 min), than with bupivacaine (10.0 +/- 3.5 min); regression of motor blockade by one unit was longer with etidocaine (306 +/- 103 min) than bupivacaine (238 +/- 75 min).","Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),min,306,235383,DB00297,Bupivacaine
,952693,regression of,"The onset of motor blockade tended to be faster with etidocaine (5.8 +/- 3.0 min), than with bupivacaine (10.0 +/- 3.5 min); regression of motor blockade by one unit was longer with etidocaine (306 +/- 103 min) than bupivacaine (238 +/- 75 min).","Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ",NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),min,238,235384,DB00297,Bupivacaine
,952693,maximum arterial plasma concentration,"The mean maximum arterial plasma concentration of etidocaine was 1.52 +/- 0.64 mug/ml, at 14 +/- 2 min and of bupivacaine was 1.35 +/- 0.63 mug/ml, achieved at 20 +/- 4 min.","Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),[μg] / [ml],1.52,235385,DB00297,Bupivacaine
,952693,maximum arterial plasma concentration,"The mean maximum arterial plasma concentration of etidocaine was 1.52 +/- 0.64 mug/ml, at 14 +/- 2 min and of bupivacaine was 1.35 +/- 0.63 mug/ml, achieved at 20 +/- 4 min.","Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),[μg] / [ml],1.35,235386,DB00297,Bupivacaine
,952693,fast,The systemic absorption of both drugs occurred in a biphasic pattern with a fast and slow half-life of 0.3 and approximately 8 h respectively.,"Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ","t1/2,α-Q59",[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),h,0.3,235387,DB00297,Bupivacaine
,952693,half-life,The systemic absorption of both drugs occurred in a biphasic pattern with a fast and slow half-life of 0.3 and approximately 8 h respectively.,"Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),h,0.3,235388,DB00297,Bupivacaine
,952693,half-life,The systemic absorption of both drugs occurred in a biphasic pattern with a fast and slow half-life of 0.3 and approximately 8 h respectively.,"Effects of extradural block: comparison of the properties, circulatory effects and pharmacokinetics of etidocaine and bupivacaine. ",t1/2-Q57,[Article Link](https://pubmed.ncbi.nlm.nih.gov/952693/),h,8,235389,DB00297,Bupivacaine
,8837190,constant volume,Local anesthetic drugs were administered into the lumbar epidural space in a constant volume of 3.0 mL.,Antinociceptive and motor-blocking efficacy of ropivacaine and bupivacaine after epidural administration in the dog. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8837190/),ml,3,237727,DB00297,Bupivacaine
,30182426,plasma elimination half-life,The bupivacaine plasma elimination half-life was 17.8 ± 5.42 and 11.9 ± 5.17 h for horses from which synovial fluid was collected daily and at 96 h respectively.,Plasma and synovial fluid concentrations and cartilage toxicity of bupivacaine following intra-articular administration of a liposomal formulation to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30182426/),h,17.8,237756,DB00297,Bupivacaine
,30182426,plasma elimination half-life,The bupivacaine plasma elimination half-life was 17.8 ± 5.42 and 11.9 ± 5.17 h for horses from which synovial fluid was collected daily and at 96 h respectively.,Plasma and synovial fluid concentrations and cartilage toxicity of bupivacaine following intra-articular administration of a liposomal formulation to horses. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/30182426/),h,11.9,237757,DB00297,Bupivacaine
,7914736,blood clearance,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,CLb-Q23,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),[ml] / [kg·min],29.8,240059,DB00297,Bupivacaine
,7914736,volume of distribution,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,V-Q61,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),[l] / [kg],3.60,240060,DB00297,Bupivacaine
,7914736,blood elimination half-life,"Propofol blood clearance was 29.8 +/- 6.51 ml/min/kg, and volume of distribution was 3.60 +/- 1.34 L/kg, resulting in a blood elimination half-life of 144 +/- 46 minutes.",Clinical pharmacokinetics of propofol given as a constant-rate infusion and in combination with epidural blockade. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/7914736/),min,144,240061,DB00297,Bupivacaine
,10215682,unbound CSF fraction,"The CSF binding of BUP and LID was linear in a range from 50 to 500 micrograms/ml, and the mean unbound CSF fraction at a concentration of 100 micrograms/ml was 39.",Cerebrospinal fluid bioavailability and pharmacokinetics of bupivacaine and lidocaine after intrathecal and epidural administrations in rabbits using microdialysis. ,fu-Q46,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215682/),,39,243919,DB00297,Bupivacaine
,10215682,bioavailability,"Although the absorption rate of BUP appeared higher than that of LID, the mean CSF bioavailability of epidural BUP and LID was 5.5 and 17.7%, respectively.",Cerebrospinal fluid bioavailability and pharmacokinetics of bupivacaine and lidocaine after intrathecal and epidural administrations in rabbits using microdialysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215682/),%,5.5,243920,DB00297,Bupivacaine
,10215682,bioavailability,"Although the absorption rate of BUP appeared higher than that of LID, the mean CSF bioavailability of epidural BUP and LID was 5.5 and 17.7%, respectively.",Cerebrospinal fluid bioavailability and pharmacokinetics of bupivacaine and lidocaine after intrathecal and epidural administrations in rabbits using microdialysis. ,F-Q40,[Article Link](https://pubmed.ncbi.nlm.nih.gov/10215682/),%,17.7,243921,DB00297,Bupivacaine
,19282712,basal rate,"The PCEA regimen was prepared as 0.15% ropivacaine and fentanyl 2 microg/mL (basal rate, 6 mL/h; demand dose, 4 mL/20 min).",Excretion of ropivacaine in breast milk during patient-controlled epidural analgesia after cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19282712/),[ml] / [h],6,244767,DB00297,Bupivacaine
,19282712,demand dose,"The PCEA regimen was prepared as 0.15% ropivacaine and fentanyl 2 microg/mL (basal rate, 6 mL/h; demand dose, 4 mL/20 min).",Excretion of ropivacaine in breast milk during patient-controlled epidural analgesia after cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19282712/),-1·ml,4,244768,DB00297,Bupivacaine
,19282712,milk-plasma ratios,"Ropivacaine excretion into the breast milk produced concentrations that significantly correlated with those in the plasma 18 and 24 hrs after administration, achieving milk-plasma ratios (mean +/- SD) of 0.25 +/- 0.08 and 0.23 +/- 0.07, respectively.",Excretion of ropivacaine in breast milk during patient-controlled epidural analgesia after cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19282712/),,0.25,244769,DB00297,Bupivacaine
,19282712,milk-plasma ratios,"Ropivacaine excretion into the breast milk produced concentrations that significantly correlated with those in the plasma 18 and 24 hrs after administration, achieving milk-plasma ratios (mean +/- SD) of 0.25 +/- 0.08 and 0.23 +/- 0.07, respectively.",Excretion of ropivacaine in breast milk during patient-controlled epidural analgesia after cesarean delivery. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/19282712/),,0.23,244770,DB00297,Bupivacaine
,8462537,half-lives of elimination,"The half-lives of elimination are respectively 3 min for nicomorphine, 3 and 15 min for 6-nicotinoylmorphine, and 135-190 min for morphine.",Pharmacokinetics of intravenously administered nicomorphine and its metabolites in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462537/),min,3,247956,DB00297,Bupivacaine
,8462537,half-lives of elimination,"The half-lives of elimination are respectively 3 min for nicomorphine, 3 and 15 min for 6-nicotinoylmorphine, and 135-190 min for morphine.",Pharmacokinetics of intravenously administered nicomorphine and its metabolites in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462537/),min,15,247957,DB00297,Bupivacaine
,8462537,half-lives of elimination,"The half-lives of elimination are respectively 3 min for nicomorphine, 3 and 15 min for 6-nicotinoylmorphine, and 135-190 min for morphine.",Pharmacokinetics of intravenously administered nicomorphine and its metabolites in man. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/8462537/),min,135-190,247958,DB00297,Bupivacaine
,31124839,peak plasma concentrations,The range of peak plasma concentrations was 0.39-2.44 µg/mL for the manual bolus atomization versus 0.25-1.07 μg/mL for the micropump nebulization.,Population Pharmacokinetics of Intraperitoneal Bupivacaine Using Manual Bolus Atomization Versus Micropump Nebulization and Morphine Requirements in Young Children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31124839/),[μg] / [ml],0.39-2.44,247993,DB00297,Bupivacaine
,31124839,peak plasma concentrations,The range of peak plasma concentrations was 0.39-2.44 µg/mL for the manual bolus atomization versus 0.25-1.07 μg/mL for the micropump nebulization.,Population Pharmacokinetics of Intraperitoneal Bupivacaine Using Manual Bolus Atomization Versus Micropump Nebulization and Morphine Requirements in Young Children. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/31124839/),[μg] / [ml],0.25-1.07,247994,DB00297,Bupivacaine
,14756696,log Poct,"3. Ropivacaine, with a log Poct of 2.9, exhibited a tmax of 61.6 min.",Lipophilicity affects the pharmacokinetics and toxicity of local anaesthetic agents administered by caudal block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756696/),,2.9,249667,DB00297,Bupivacaine
,14756696,tmax,"3. Ropivacaine, with a log Poct of 2.9, exhibited a tmax of 61.6 min.",Lipophilicity affects the pharmacokinetics and toxicity of local anaesthetic agents administered by caudal block. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756696/),min,61.6,249668,DB00297,Bupivacaine
,14756696,log Poct,"At log Poct of approximately 3.0, the toxicity of these local anaesthetic agents was substantially increased.",Lipophilicity affects the pharmacokinetics and toxicity of local anaesthetic agents administered by caudal block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756696/),,3.0,249669,DB00297,Bupivacaine
higher,14756696,log Poct,"Toxicity, due to plasma availability of these local anaesthetic agents, seems to be increased at log Poct equal or higher than 3.0 secondary to the highest transfer from plasma into the central nervous system.",Lipophilicity affects the pharmacokinetics and toxicity of local anaesthetic agents administered by caudal block. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/14756696/),,3.0,249670,DB00297,Bupivacaine
,11812681,area under the plasma concentration curve,The peak plasma concentration (mean +/- SD) (R = 0.67 +/- 0.16 and B = 0.73 +/- 0.23 microg/mL) and the area under the plasma concentration curve (R = 61.9 +/- 20.6 and B = 62.7 +/- 18.2 microg x mL(-1) x min(-1)) were comparable between the two study groups.,Ropivacaine undergoes slower systemic absorption from the caudal epidural space in children than bupivacaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11812681/),[μg] / [min·ml],61.9,249840,DB00297,Bupivacaine
,11812681,area under the plasma concentration curve,The peak plasma concentration (mean +/- SD) (R = 0.67 +/- 0.16 and B = 0.73 +/- 0.23 microg/mL) and the area under the plasma concentration curve (R = 61.9 +/- 20.6 and B = 62.7 +/- 18.2 microg x mL(-1) x min(-1)) were comparable between the two study groups.,Ropivacaine undergoes slower systemic absorption from the caudal epidural space in children than bupivacaine. ,AUCinf-Q17,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11812681/),[μg] / [min·ml],62.7,249841,DB00297,Bupivacaine
,11812681,time to attain peak plasma concentration,"The median (range) time to attain peak plasma concentration was significantly slower in children who received ropivacaine (R = 65 [10-120] min and B = 20 [15-50] min, P < 0.05).",Ropivacaine undergoes slower systemic absorption from the caudal epidural space in children than bupivacaine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11812681/),min,65,249842,DB00297,Bupivacaine
,11812681,time to attain peak plasma concentration,"The median (range) time to attain peak plasma concentration was significantly slower in children who received ropivacaine (R = 65 [10-120] min and B = 20 [15-50] min, P < 0.05).",Ropivacaine undergoes slower systemic absorption from the caudal epidural space in children than bupivacaine. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11812681/),min,20,249843,DB00297,Bupivacaine
,7605757,duration of,"The duration of labor after epidural administration was prolonged in group B + C patients compared to group B (282 +/- 43 minutes and 169 +/- 26 minutes, respectively, P < .05).",Epidural clonidine combined with bupivacaine for analgesia in labor. Effects on mother and neonate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605757/),min,282,250891,DB00297,Bupivacaine
,7605757,duration of,"The duration of labor after epidural administration was prolonged in group B + C patients compared to group B (282 +/- 43 minutes and 169 +/- 26 minutes, respectively, P < .05).",Epidural clonidine combined with bupivacaine for analgesia in labor. Effects on mother and neonate. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605757/),min,169,250892,DB00297,Bupivacaine
,7605757,concentrations,"Plasma clonidine concentrations were, respectively, 0.31 +/- 0.16 ng/mL 60 minutes after the first injection and 0.62 +/- 0.13 ng/mL at birth in mothers while plasma umbilical cord concentrations were 0.56 +/- 0.12 ng/mL.",Epidural clonidine combined with bupivacaine for analgesia in labor. Effects on mother and neonate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605757/),[ng] / [ml],0.31,250893,DB00297,Bupivacaine
,7605757,concentrations,"Plasma clonidine concentrations were, respectively, 0.31 +/- 0.16 ng/mL 60 minutes after the first injection and 0.62 +/- 0.13 ng/mL at birth in mothers while plasma umbilical cord concentrations were 0.56 +/- 0.12 ng/mL.",Epidural clonidine combined with bupivacaine for analgesia in labor. Effects on mother and neonate. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/7605757/),[ng] / [ml],0.56,250894,DB00297,Bupivacaine
,11152032,total bupivacaine,"The total bupivacaine concentration at t=360 min was significantly higher in the ""adrenaline"" group compared to the ""plain"" group, i.e. a median (range) 742 ng/ml (372-1423 ng/ml) vs. 400.5 ng/ml (114-446 ng/ml), P=0.0080.",Plasma concentrations and pharmacokinetics of bupivacaine with and without adrenaline following caudal anaesthesia in infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11152032/),[ng] / [ml],742,251947,DB00297,Bupivacaine
,11152032,total bupivacaine,"The total bupivacaine concentration at t=360 min was significantly higher in the ""adrenaline"" group compared to the ""plain"" group, i.e. a median (range) 742 ng/ml (372-1423 ng/ml) vs. 400.5 ng/ml (114-446 ng/ml), P=0.0080.",Plasma concentrations and pharmacokinetics of bupivacaine with and without adrenaline following caudal anaesthesia in infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11152032/),[ng] / [ml],400.5,251948,DB00297,Bupivacaine
,11152032,concentration,"The total bupivacaine concentration at t=360 min was significantly higher in the ""adrenaline"" group compared to the ""plain"" group, i.e. a median (range) 742 ng/ml (372-1423 ng/ml) vs. 400.5 ng/ml (114-446 ng/ml), P=0.0080.",Plasma concentrations and pharmacokinetics of bupivacaine with and without adrenaline following caudal anaesthesia in infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11152032/),[ng] / [ml],742,251949,DB00297,Bupivacaine
,11152032,concentration,"The total bupivacaine concentration at t=360 min was significantly higher in the ""adrenaline"" group compared to the ""plain"" group, i.e. a median (range) 742 ng/ml (372-1423 ng/ml) vs. 400.5 ng/ml (114-446 ng/ml), P=0.0080.",Plasma concentrations and pharmacokinetics of bupivacaine with and without adrenaline following caudal anaesthesia in infants. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/11152032/),[ng] / [ml],400.5,251950,DB00297,Bupivacaine
,11152032,apparent,"The median ""apparent"" terminal half-life (t1/2) was significantly longer in the ""adrenaline"" group (363 min; range 238-537 min) compared to the ""plain"" group (n=6) (165 min; range 104-264 min), P=0.0087.",Plasma concentrations and pharmacokinetics of bupivacaine with and without adrenaline following caudal anaesthesia in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11152032/),min,363,251951,DB00297,Bupivacaine
,11152032,apparent,"The median ""apparent"" terminal half-life (t1/2) was significantly longer in the ""adrenaline"" group (363 min; range 238-537 min) compared to the ""plain"" group (n=6) (165 min; range 104-264 min), P=0.0087.",Plasma concentrations and pharmacokinetics of bupivacaine with and without adrenaline following caudal anaesthesia in infants. ,"t1/2,β-Q60",[Article Link](https://pubmed.ncbi.nlm.nih.gov/11152032/),min,165,251952,DB00297,Bupivacaine
,8150879,extraction yield,"The extraction yield of bupivacaine from plasma was 73.5 +/- 5.1% (mean +/- S.D., n = 10).",High-performance liquid chromatographic determination of bupivacaine in plasma samples for biopharmaceutical studies and application to seven other local anaesthetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150879/),%,73.5,253252,DB00297,Bupivacaine
,8150879,signal-to-noise ratio,"The limit of detection, defined by a signal-to-noise ratio of 3:1, was 2 ng/ml.",High-performance liquid chromatographic determination of bupivacaine in plasma samples for biopharmaceutical studies and application to seven other local anaesthetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150879/),[ng] / [ml],3:1,253253,DB00297,Bupivacaine
,8150879,signal-to-noise ratio,"The limit of detection, defined by a signal-to-noise ratio of 3:1, was 2 ng/ml.",High-performance liquid chromatographic determination of bupivacaine in plasma samples for biopharmaceutical studies and application to seven other local anaesthetics. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8150879/),[ng] / [ml],2,253254,DB00297,Bupivacaine
,8610868,Tmax,The Tmax of lidocaine was shorter in the presence of hyaluronidase (17.1 +/- 2.6 min vs 32.7 +/- 6.0 min) as well as the Tmax of bupivacaine (16.8 +/- 3.0 min vs 26.5 +/- 4.4 min).,The role of hyaluronidase on lidocaine and bupivacaine pharmacokinetics after peribulbar blockade. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610868/),min,17.1,253407,DB00297,Bupivacaine
,8610868,Tmax,The Tmax of lidocaine was shorter in the presence of hyaluronidase (17.1 +/- 2.6 min vs 32.7 +/- 6.0 min) as well as the Tmax of bupivacaine (16.8 +/- 3.0 min vs 26.5 +/- 4.4 min).,The role of hyaluronidase on lidocaine and bupivacaine pharmacokinetics after peribulbar blockade. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610868/),min,32.7,253408,DB00297,Bupivacaine
,8610868,Tmax,The Tmax of lidocaine was shorter in the presence of hyaluronidase (17.1 +/- 2.6 min vs 32.7 +/- 6.0 min) as well as the Tmax of bupivacaine (16.8 +/- 3.0 min vs 26.5 +/- 4.4 min).,The role of hyaluronidase on lidocaine and bupivacaine pharmacokinetics after peribulbar blockade. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610868/),min,16.8,253409,DB00297,Bupivacaine
,8610868,Tmax,The Tmax of lidocaine was shorter in the presence of hyaluronidase (17.1 +/- 2.6 min vs 32.7 +/- 6.0 min) as well as the Tmax of bupivacaine (16.8 +/- 3.0 min vs 26.5 +/- 4.4 min).,The role of hyaluronidase on lidocaine and bupivacaine pharmacokinetics after peribulbar blockade. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/8610868/),min,26.5,253410,DB00297,Bupivacaine
,23503706,time to maximum concentration (tmax),The time to maximum concentration (tmax) varied from 0.5 to 24 hours (median 12 hours) according to which peak predominated.,The pharmacokinetics and safety of an intraoperative bupivacaine-collagen implant (XaraColl(®)) for postoperative analgesia in women following total abdominal hysterectomy. ,tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503706/),h,12,254654,DB00297,Bupivacaine
,23503706,maximum concentration (Cmax),"The mean maximum concentration (Cmax) was 0.22 μg/mL and the maximum individual Cmax was 0.44 μg/mL, which are well below the established systemic toxicity threshold.",The pharmacokinetics and safety of an intraoperative bupivacaine-collagen implant (XaraColl(®)) for postoperative analgesia in women following total abdominal hysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503706/),[μg] / [ml],0.22,254655,DB00297,Bupivacaine
,23503706,maximum individual Cmax,"The mean maximum concentration (Cmax) was 0.22 μg/mL and the maximum individual Cmax was 0.44 μg/mL, which are well below the established systemic toxicity threshold.",The pharmacokinetics and safety of an intraoperative bupivacaine-collagen implant (XaraColl(®)) for postoperative analgesia in women following total abdominal hysterectomy. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23503706/),[μg] / [ml],0.44,254656,DB00297,Bupivacaine
,23539934,peak plasma concentration,"The median of peak plasma concentration was 538.35 ng/mL (min = 176.30, max = 1,383.99) at 60 minutes after femoral nerve block, while the maximal plasma concentration of bupivacaine was 1,883.39 ng/mL at 10 minutes.",Plasma concentrations of bupivacaine after spinal anesthesia with single shot femoral nerve block in total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23539934/),[ng] / [ml],538.35,263532,DB00297,Bupivacaine
,23539934,max,"The median of peak plasma concentration was 538.35 ng/mL (min = 176.30, max = 1,383.99) at 60 minutes after femoral nerve block, while the maximal plasma concentration of bupivacaine was 1,883.39 ng/mL at 10 minutes.",Plasma concentrations of bupivacaine after spinal anesthesia with single shot femoral nerve block in total knee arthroplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23539934/),,"1,383.99",263533,DB00297,Bupivacaine
,23539934,maximal plasma concentration,"The median of peak plasma concentration was 538.35 ng/mL (min = 176.30, max = 1,383.99) at 60 minutes after femoral nerve block, while the maximal plasma concentration of bupivacaine was 1,883.39 ng/mL at 10 minutes.",Plasma concentrations of bupivacaine after spinal anesthesia with single shot femoral nerve block in total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/23539934/),[ng] / [ml],"1,883.39",263534,DB00297,Bupivacaine
,25265771,median plasma concentration,"The highest median plasma concentration was 586.22 ng/ml (min = 245.39, max = 1,614.36) at 45 minutes after periarticular injection.",Plasma concentrations of bupivacaine after spinal anesthesia with single shot femoral nerve block and periarticular injection in total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25265771/),[ng] / [ml],586.22,264906,DB00297,Bupivacaine
,25265771,max,"The highest median plasma concentration was 586.22 ng/ml (min = 245.39, max = 1,614.36) at 45 minutes after periarticular injection.",Plasma concentrations of bupivacaine after spinal anesthesia with single shot femoral nerve block and periarticular injection in total knee arthroplasty. ,NIL-Q100,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25265771/),,"1,614.36",264907,DB00297,Bupivacaine
,25265771,maximum plasma bupivacaine concentration,"The maximum plasma bupivacaine concentration was 1,709.71 ng/ml at 60 minutes after periarticular injection.",Plasma concentrations of bupivacaine after spinal anesthesia with single shot femoral nerve block and periarticular injection in total knee arthroplasty. ,Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/25265771/),[ng] / [ml],"1,709.71",264908,DB00297,Bupivacaine
,26275090,peak plasma NeoSTX concentration,"Mean peak plasma NeoSTX concentration for NeoSTX-Bup-Epi was reduced at least two-fold compared with NeoSTX-Saline and NeoSTX-Bup (67 ± 14, 134 ± 63, and 164 ± 81 pg/ml, respectively; P = 0.016).","A Phase 1, Dose-escalation, Double-blind, Block-randomized, Controlled Trial of Safety and Efficacy of Neosaxitoxin Alone and in Combination with 0.2% Bupivacaine, with and without Epinephrine, for Cutaneous Anesthesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26275090/),[pg] / [ml],67,267497,DB00297,Bupivacaine
,26275090,peak plasma NeoSTX concentration,"Mean peak plasma NeoSTX concentration for NeoSTX-Bup-Epi was reduced at least two-fold compared with NeoSTX-Saline and NeoSTX-Bup (67 ± 14, 134 ± 63, and 164 ± 81 pg/ml, respectively; P = 0.016).","A Phase 1, Dose-escalation, Double-blind, Block-randomized, Controlled Trial of Safety and Efficacy of Neosaxitoxin Alone and in Combination with 0.2% Bupivacaine, with and without Epinephrine, for Cutaneous Anesthesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26275090/),[pg] / [ml],134,267498,DB00297,Bupivacaine
,26275090,peak plasma NeoSTX concentration,"Mean peak plasma NeoSTX concentration for NeoSTX-Bup-Epi was reduced at least two-fold compared with NeoSTX-Saline and NeoSTX-Bup (67 ± 14, 134 ± 63, and 164 ± 81 pg/ml, respectively; P = 0.016).","A Phase 1, Dose-escalation, Double-blind, Block-randomized, Controlled Trial of Safety and Efficacy of Neosaxitoxin Alone and in Combination with 0.2% Bupivacaine, with and without Epinephrine, for Cutaneous Anesthesia. ",Cmax-Q32,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26275090/),[pg] / [ml],164,267499,DB00297,Bupivacaine
,26275090,time to near-complete recovery,"Median time to near-complete recovery for 10 μg NeoSTX-Bup-Epi was almost five-fold longer compared with Bup (50 vs. 10 h, P = 0.007).","A Phase 1, Dose-escalation, Double-blind, Block-randomized, Controlled Trial of Safety and Efficacy of Neosaxitoxin Alone and in Combination with 0.2% Bupivacaine, with and without Epinephrine, for Cutaneous Anesthesia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26275090/),h,50,267500,DB00297,Bupivacaine
,26275090,time to near-complete recovery,"Median time to near-complete recovery for 10 μg NeoSTX-Bup-Epi was almost five-fold longer compared with Bup (50 vs. 10 h, P = 0.007).","A Phase 1, Dose-escalation, Double-blind, Block-randomized, Controlled Trial of Safety and Efficacy of Neosaxitoxin Alone and in Combination with 0.2% Bupivacaine, with and without Epinephrine, for Cutaneous Anesthesia. ",tmax-Q56,[Article Link](https://pubmed.ncbi.nlm.nih.gov/26275090/),h,10,267501,DB00297,Bupivacaine
